Nutritional regulation of adiponectin and the effect of genetic variations in the adiponectin gene on bone density in the Newfoundland population by Khalili, Sammy




NUTRITIONAL REGULATION OF ADIPONECTIN AND THE EFFECT 
OF GENETIC VARIATIONS IN THE ADIPONECTIN GENE ON BONE 
DENSITY IN THE NEWFOUNDLAND POPULATION 
By 
© Sammy Khalili 
A Thesis submitted to the 
School ofGraduate Studies 
in partia l fulfillment of the requirements for the degree of 
Master of Science in Medicine 
Faculty of Medicine 
Memorial University ofNewfound land 
July 201 2 
St. John 's, Newfoundland 
Page 2 of167 
Table of Contents 
Summary........ .. ... .... ... . . .... .. . ............ .... ........ .. ...... . .. .... .. ... . .. . ..... ... . . . .... 5 
Acknowledgernents... .... .... .. . ... .. . .. . . ....... ... .. .. . .. . ...... . ....... .. ....... .. . ... ... . . . .. 7 
List of Figures.. .. . ... .. .. .. .... . .. .. .. . . ....... . ... .. ........ .. . .. .. . .. .. . .. ... .. .. ... ... .... . . . . 8 
List of Tables . ..... .. .. . .. .. ........ .. .. . ..... .. . .. .. ...... .... ...... ... . . .. ... ........... .. ... . .. . 9 
List of Abbreviations.... . .. ... .... .... . .. . ...... .. . ...... .. ...... . . . . .. .. . ... . ...... . . .... .. . .. .. 15 
Chapter I 
1.0 Introduction....... ... ... . .. .. ..... .... .. . .... .... ...... . .. .... . . ... ....... . .. . . ... .. . .. . . 17 
1.0.1 Obesity and Society... .. .. . . . ... . ...... .. ... .... .... .... . .. ..... ... ......... ... 17 
1.0.2 Obesity and Prevalence.... . . . .. ... .. ..... .. . ........ . ...... . . ... .. .. .. .. . .. . ... 18 
1.0.3 Definition of Obesity . .. . . . . ... .. . . .... .. ...... ... . . ....... .. . . .. . . . . . . . ..... .. .. 20 
1.0.4 Identifying obesity Candidate genes.. . .. . ...... . .. ... . . .. .... . . ... . .. ..... . . . 23 
1.0.5 Newfoundland as a good study popu lation for multifactorial conditions 24 
1.1 Adiponectin as a Candidate Gene... .. .. .... .. . . ... . .. .... ....... . . . .. . . . . . . ... . . ... . .. 25 
1.1.1 Discovery of adiponectin. . .. .... ... ... .. .. . .... ... ..... ....... ... .... . . .. ..... 25 
1.1.2 Structure and genetic location of adiponectin. ..... .... ... . .... . . ..... . ... . 27 
1.1.3 Adiponectin and body fat composition.. . . .. .... . .. . .... .. ...... .. .. .... .. ... 27 
1.1.4 Pathophysiology of adiponectin . . . ... .. ... ... .. . .... .. . . . . ... . . . . ... . . ... .. ... 30 
1.1 .5 Adiponectin and coronary artery disease.... .... . . .. . .. .. .. . ... ...... ..... . . 36 
1.1.6 Genetic association of adiponectin....... . ..... . .. .. .. ........ . . . .. ......... 39 
1.2 Adiponectin and Osteoporosis .. . ... . . .. . .. . . ..... . .... . . . . ... ... ............ .. . ...... 42 
1.2. 1 Definition and diagnosis of osteoporosis.. . . ... .. . ... ...... ...... ... . ... . .. . 42 
1.2.2 Prevalence of osteoporosis ... . . .. .. ..... ... .. . ......... . ..... . . ... . . . ... ..... . 46 
Page 3 of167 
1.2.3 Adiponectin and bone mineral density.......... .. ... . ....................... 50 
Chapter 2 
2.0 Material and Methods. . ........ .. . .. .. ....... ... ...... . ...... ......... ....... .. ...... .. 54 
2.1 Association study.. . ....... .. ........ .. . ................. ..... ... .. . . . .. . . ... .... ... . ... 54 
2.1.1 Recruitment of volunteers.... ... . ... ...... ......... .. .... .. ... . . . . ... ........ 54 
2.1.2 Plasma and serum extraction.................. ...... ...... .. .. .... ........ .. 55 
2.1.3 Body composition measurements .. ............ ........ ..... . . . . . . . . ........ 55 
2.1.4 Serum biochemical measurements .......... ....... ........... . .......... .. . 
2.1.5 DNA extraction and genotyping ........ .... ........ .. .. .. ...... .......... .. 
2.1.5 .1 Genomic DNA extraction ... .. ..... .................. ... .. .. .. ... . .. 
2.1 .5.2 Genotypic . .... .. . .................. . ....... . .. ... .......... .. ....... .. 
2.1.6 Statistical Analysis .... ......... .. ......... . ...... . .... .... ....... . ....... .... . 
2.2 Overfeeding study . ..... .. . ... ....... . .. .. ........ .. . .... ... . . . .. .......... . . .... . .... . 
2.2.1 Recruitment of Volunteers .... . ...... ...... .. . ......... ... ............ ...... .. 
2.2.2 Plasma and serum extraction ..... ..... ..... ...... .. ........ .. . .. . . .... . . .. . .. . 
2.2.3 Body composition measurements .. ... .. .... .. ........ .... . .. .... .... ....... . 
56 
56 
56 
57 
59 
6 1 
61 
61 
62 
2.2.4 Overfeeding protocol.. ........ ...... .. ..... ... ..... ..... .... ........... ..... .. 62 
2.2.5 Serum biochemical measurements .... .... ..... ... . . .. . .... . . . ....... .. . ..... 64 
2.2.6 Genomic extraction and genotyping , ....... .. .. .. .. .. .. .. .. .. . ... . . ... ... . . 66 
2.2.7 Statistical Analysis . . . ... . ........ .... .. . .... .......... .. . ... .. .. .... .. .... ..... 66 
Chapter 3 
3.0 Results.......... . ..... . ................. . .................... . .................... .. ...... 68 
3.0.1 Association study results .. . ....... ... ....... .... .................. . ....... . .. . 68 
Page 4 of167 
3.0.2 Overfeeding study results.... . .. . ..... .... . ...... .......... .. . .. . .... . . . . ..... 136 
Chapter 4 
4.0 Discussion ................. ... . . .. . ............. .. . ... .. .......... .. . .. .. .. .... .. .......... 141 
4.0.1 Adiponectin and bone mineral density... . . .. .. . ..... . . ..... . .... . .. .. . . . .... 141 
4.0.2 Adiponectin and its response to positive-energy challenge. . . . .... .. . .. . .. 144 
4.0.3 Study limitations.. ......... . . .. . .. .... .... .... . ............. .... . . ... .. . . ........ 147 
4.0.4 Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ... 148 
Chapter 5 
5.0 References................... ... . .. . . ......... . . ..... . .. .. . .. . ........... . ... . ... .... .. . . .. 149 
Page 5 of 167 
Summary 
Adiponectin, as an adipokine, has been shown to be involved in insulin sensitivity and 
obesity. Recently data mainly from animal models, have suggested that adiponectin may have a 
role in bone metabolism. This project addresses the association of adiponectin with insulin 
sensitivity and obesity status, the regulation of positive energy challenge on adiponectin, and the 
association of DNA sequence variation in adiponectin gene with bone mineral density in the 
Newfoundland population. This project comprises two studies: I) a Newfoundland-population-
based-genetic-association cohort study and 2) an overfeeding study. 
1) Genetic Association Study of adiponectin with bone density 
A total of 1811 third-generation Newfoundlanders, 403 males and 1408 females, ages 19-
73, were recruited to take part in the study. To participate, each subject completed a screening 
questionnaire, a physical activ ity fonn, a dietary form, a menstrual cycle form (females only) and 
a consent form. Plasma and serum samples were collected. Bone mineral density and 
percentage body fat were measured by Dual energy X-ray absorptiometry (DEXA). Blood 
samples were assayed for lipid profile, electrolyte levels, and insulin levels. DNA was extracted 
from white blood cells. Five s ing le nuc leotide polymorphisms (SNPs) in the adiponectin gene 
(tagging SNPs) were selected and genotyped with the TaqMan SNP genotyping kits performed 
on an ABI 7000 instrument. Multiple regression analysis was conducted through regression at 
the SNP markers against gender, age, smoking, and medication status as covariates. Significance 
of this regression was assessed via a bootstrap with I 00,000 resamples. Contrary to previous 
studies, no association between adiponectin genotypes and bone mineral density was found. 
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Regulation of circulating adiponectin by a short-term positive energy challenge 
The response of serum adiponectin in young males aged 19-29 to a 7-day overfeeding 
course was observed. Subjects were overfed 70% above their baseline with a macronutrient 
mixture of 50% carbohydrates, 35% fat, and 15% protein. Blood serum and plasma samples 
were taken prior to the start of the overfeeding, as well as the morning after the last day of the 
overfeeding period, both after a 12 hour fast. Serum electrolytes, lipid profiles, insulin levels 
and adiponectin levels were measured . Percentage body fat and bone mineral density values 
were obtained by DEXA pre- and post-overfeeding. Serum adiponectin levels increased 
significantly from baseline after a positive-energy challenge in all adiposity categories (11.60 ± 
6.3 to 13.96 ± 4.5 in underweight/ lean individuals ; 12.84 ± 4.6 to 14.81 ± 4.05 in overweight 
individuals; 10.69 ± 6.3 to 12.82 ± 6.1 in obese individuals, p<0.05 as measured by 2- Way 
mixed model ANOVA). This finding contradicts previous studies, which used longer-term 
overfeeding protocols (Ukkola eta/., 2008). This study also shows that baseline adiponectin 
level is not directly associated with adiposity in response to short-term overfeeding. 1t also 
provides evidence that the protective response of adiponectin may be preserved when challenged 
by a short-term energy balance, irrespective of obesity status. 
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1.0 Introduction 
1.0.1 Obesity and Society 
Obesity has become a big healthcare problem in today's society. According to the World 
Health Organization (WHO), more than one billion adults in the world are overweight, with 300 
million women and 200 million men being considered clinically obese (WHO, 2008). In some 
societies, the epidemic is much more rampant than in others (e.g. less than 5% in China and 
Japan, more than 75% in urban Samoa; WHO, 2006). The obesity epidemic not only affects 
adults of specific countries, but also has become a great concern in children as well. The WHO 
and the International Obesity Task Force report 22 million children under age five are estimated 
to be overweight or obese worldwide (WHO, 2006; Malecka-Tendera & Mazur, 2006). 
Although prevalence rates in certain subpopulations of differing socioeconomic backgrounds 
may be slightly higher than others, it is still considered a large problem affecting all peoples and 
societies (WHO, 2006). Furthermore, in almost all populations and subpopulations, the epidemic 
is growing. In the United States, it has been reported that in children aged 6-17, obesity and 
obesity-associated hospital discharge rates have tripled (Dietz, 2004; Rubenstein, 2005). The 
rate in adults has increased 50% per decade during the 1980s and 1990s (Behn & Ur, 2006). A 
study of South Australians showed that obesity increased significantly from 8. 7% in 1991 to 
14.1% in 2003 , while the prevalence of severely obese individuals increased significantly from 
2.6% to 5.3% (Dal Grande, Gill , Taylor, Chittleborough & Carter, 2005). Moreover, the 
prevalence of obesity in Canada has more than doubled in Canada between 1985 and 1998 
(Vanasse, Demers, Hemiari, & Courteau, 2006). 
Obesity often results in numerous chronic and debilitating conditions, including type 2 
diabetes, hypertension, cardiovascular problems, insulin resistance, and cancer (Rubenstein, 
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2005). It is associated with many other debilitating conditions as well , including respiratory 
di fficulties, dyslipidemia, chronic musculoskeletal problems, skin problems and even infertility 
(WHO, 2006). As a result of these complications, the cost of obesity and obesity-related 
problem on healthcare systems is substantial. The WHO reports 2-6% of tota l healthcare costs in 
several developed countries is attributed to obesity (WHO, 2006). In Canada, it has been 
estimated that obesity-re lated illness accounts for $4.3 billion, representing 2.2% of the total 
healthcare costs in Canada (Katzmarzyk, Janssen, & Ardern., 2003; Vanasse et al., 2005). 
1.0.2 Obesity and Prevalence 
As previously stated, approximately I bill ion people worldwide are considered to be 
overweight. Although a serious healthcare issue worldwide, prevalence rates vary in different 
populations. In the United States, Rubenstein (2005) reported that 35% of U.S. adults are 
overweight, while 30% are obese. Those that are considered extremely or morbidly obese 
accounted for 4.7% of U.S. adults, which was an increase from 0.8% in I 960 (Rubenstein, 2005). 
Similar figures have been reported in later studies (Wyatt, Winters, & Dubbert, 2006). As well , 
evidence has also shown in the U.S. that obesity rates among non-Hispanic blacks as compared 
with non-Hispanic whites are considerably higher (Boardman, Saint Onge, Rogers, & Denny, 
2005). In Canada in 2003, one-third of Canadian individuals aged 20 years and o lder were 
overweight and 15.2% were considered obese (Vanasse eta!. , 2006). This significantly varied 
between different regions of the country as well, with Vancouver showing a rate of 6.2%, while 
some aboriginal populations showed prevalence rates of 47.5% (Vanasse et al. , 2006). Some of 
the highest rates of obesity were found in Newfoundland and Labrador, which showed the 
greatest relative increase in the number of overweight and obesity-related deaths over I 5 years 
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(Vanasse eta!., 2006). 
A number of potential causes have been suggested for the increase in obesity prevalence. 
Lowering in many populations of physical activity has been suggested as a factor (Katzymarzyk 
et a!., 2003; Vanasse et a/., 2006). Others attribute the increase to types of foods being eaten, 
specifically those foods that are high in simple sugars, fats and low in proteins, and a decrease in 
the amount of vegetables and fresh fruits (Vanasse et al., 2006). Other studies noted 
relationships between geography and obesity rates, such as industrialization of rural areas in 
Africa, Latin America and Haiti (Wang & Brownell, 2005), or the increase in likeliness of 
obesity of African-Americans living in an obese African-American community (Boardman eta!. , 
2005). Socioeconomic factors have also been suggested (Wyatt eta/., 2006; Boardman eta/. , 
2005). 
However, the role of genetics in human obesity has become of particular interest. 
Although all experts agree it is not the only factor affecting obese phenotypes, it is agreed that 
how people respond biologically to their environment and socioeconomic factors directly results 
from their genes. Since the discovery of the leptin gene in 1995 and its role in obese phenotypes, 
there is marked increase in the search for potential players in the genetic story of obesity. Many 
monogenic conditions were identified that lead to obesity, including Prader-Willi Syndrome, 
Bardet-Biedl syndrome and Cohen syndrome (Clement, 2006). However, aside from these low 
frequency conditions that lead to severely obese phenotypes, obesity in the general population is 
a multi-factorial or polygenic disease. Several genes are believed to play a role in the 
development of obesity, such as the genes of leptin, retinal-binding protein-4, visfatin, 
adiponectin, TNF-a, IL-6 and adiponectin. Adiponectin, a novel hormone believed to be 
involved in adiposity, is the focus ofthis thesis. 
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1.0.3 Definition of Obesity 
Obesity and obesity prevalence are defined by body mass index (BMI; kg/m2) , which is 
an individual's weight in kilograms, divided by their height in meters squared. The WHO 
divides an individual 's BMI in six main categories in an effort to define those individuals who 
are obese: underweight (BMI< I8.5), normal (18.5:S;BM1<25), overweight (25 :S;BM1<30), Class I 
obese (30:S;BMI<35), Class II obese (35:S;BMI<40) and Class III obese (40:S;BMI); (WHO, 2006). 
For economic reasons many studies, when assessing prevalence of obesity, often use self-
reported data to calculate BMI. However, other studies examined the accuracy of the self-
reported approach (Niedhammer, Bugel, Bonenfant, Goldberg, & Leclerc, (2000); Hill & 
Roberts, ( 1998); Alvarez-To rices, Franch-Nadal, Alvarez-Guisaola, Hernandez-Mejia, & Cueto-
Espinar, ( 1993)). In addition, using BMI has been found to be inaccurate in many cases, 
particularly in individuals with di ffering body sizes (e.g. body builders) because BMI does not 
indicate an accurate fat distribution throughout the body. 
Other techniques exist for examining obesity more accurately in order to assess adiposity. 
The newer form of evaluating obesity is the use of body fat composition or percentage body fat, 
which more accurately assesses body fat distribution and obesity. It was orig ina lly measured by 
hydrodensitometry, which determined a person's percentage body fat by submerging the 
individual completely in water and calculating the water displacement based on the principle that 
fat components float and non-fat components sink (Bray, 2003). However, the procedure was 
cumbersome for people and its accuracy was affected by pulmonary residual volume of air in 
one' s lungs. An alternative for measurement of body composition is Dual X-Ray 
Absorptiometry (DXA) which measures percentage body fat as well as bone mineral 
composition by using very low energy x-ray beams that are absorbed at different rates in 
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different tissues (Bray, 2003). 
According to Bray (2003), obesity as defined by percentage body fat varies among races, 
ages, and genders. Obesity is thus classified by Bray (2003), which is shown in Table I . 
Page 22 of 167 
Table I. Body fat for men and women of di fferent ethnic groups according to BMI cut points (adapted from Bray, 2003). 
Females (% Body Fat) Males (% Body Fat) 
BMI Blacks Asians Whites Blacks Asians Whites 
Age 20-39 
18.5 20 25 21 8 13 8 
25 32 35 33 20 23 21 
30 38 40 39 26 28 26 
Age 40-59 
18.5 21 25 23 9 13 II 
25 34 36 35 22 24 23 
30 38 41 41 27 29 29 
Age 60- 79 
18.5 23 26 25 II 14 13 
25 35 36 38 23 24 25 
30 4 1 41 43 29 29 31 
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1.0.4 Identifying obesity candidate genes 
Various techniques exist for identifying potential novel candidate genes that may be 
linked to different multifactorial diseases. One of these methods is the genetic association study 
which is designed to determine associations between one or more genetic variants and a specific 
trait that is normally linked with a disease. The Human Genome Project facilitated this type of 
study and the generation of over 1.4 million single nucleotide polymorph isms (Lewis, 2002); 
International SNP MAP Working Group, 200 I). These polymorph isms occur throughout the 
genome in all regions ofthe DNA (i.e. coding, promoters, introns, splice-sites, etc). 
Genetic association studies attempt to identify candidate genes, and often more 
specifically, single nucleotide polymorphism (SNP) alleles that may potentially co-occur with a 
diseased state (Lewis, 2002). Such investigations have become a central focus of research aimed 
at uncovering the underlying etiologies of many multifactorial diseases, such as obesity, 
cardiovascular disease and asthma (Cordell & Clayton, 2005; Lewis, 2002). However, 
association studies have sometimes been questioned as not being potentially worthwhile because 
of the high costs needed in genotyping and sample collection, in addition to the large number of 
samples needed to conduct an effective analysis (Howson, Barratt, Todd, & Cordell, 2005). 
Moreover, some researchers claim skepticism because of their lack of reproducibility (Cardon & 
Bell, 200 I), while others have argued cost-benefit of association studies is reasonable with the 
falling costs of genotyping (Cordell & Clayton, 2005). 
Regardless, association studies have been shown to be successful in identifying candidate 
genes in multifactorial conditions. Reuter, Markett, Melchers and Montag (2012), in an effort to 
assess the genetic basis for depression, genotyped 800 individuals for the BCL 1 rs4142324 7 and 
the CHRNA4 rs I 044396 single-nucleotide polymorphism alleles. Individuals with the CC 
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genotype at the BCL I locus who were also homozygous for the T allele at the CHRNA4 locus 
had the highest depression scores on Beck's Depression Inventory (Reuter, Markett, Melchers, & 
Montag, 2012). Other researchers noted that the 373 A9TII allele gene involved in the 
production of Interleukin-6 (IL-6), was linked with a reduced susceptibility of chronic 
periodontitis, a chronic inflammatory disease caused by the interaction between host immune 
and periodontal bacteria (Komatsu et al., 2005). Association studies were successful in showing 
connections between CD209 promoter polymorph isms, an immune system surface molecule 
involved in pathogen recognition and immune activation, and HLA-DQ2 negative celiac disease 
in a Spanish population (Nunez et al., 2006). 
1.0.5 Newfoundland as a study population for multi-factorial conditions 
Founder populations are always useful for studying genetic conditions. They have 
become of particular value in the study of multi-factorial conditions such as obesity, 
hypertension and immunological disorders, mainly due to clustering of genes resulting from the 
population being established by a relatively small number of individuals. Some conditions in 
many founder populations often can occur with an increased frequency which suggests that from 
a genetic perspective, the extent of linkage disequilibrium in Newfoundland reflects the fact that 
the ancestry of any given child may only be separated by a few meiotic events. It is reasonable 
to believe that the probability for finding candidate genes in such populations is much higher. 
Particularly, the population of Newfoundland is considered to be of significant use for 
study, even when compared with other isolated populations (Rahman eta!., 2003). It is a very 
young founder population, where even smaller pockets of genetic isolates exist in the outports of 
the province. In addition, extended linkage disequilibrium in the Newfoundland population have 
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been noted. This may reflect complex disease alleles that are relatively high in frequency. Since 
they have a higher frequency, they tend to persist for a long time (Rahman eta!., 2003). 
1.1 Adiponectin as a Candidate Gene 
1.1.1 Discovery of Adiponecticn 
Adiponectin (i.e. AdipoQ, Adipose Most Abundant Gene Transcript I, Acrp 30) is a 
hormone discovered by four different groups at very close periods of time independently. The 
first group to identify the hormone, Scherer, Williams, Fogliano, Baldini and Lodish ( 1995), 
discovered it by creating a full-length eDNA library template by mRNA from 3T3-L I adipocytes 
at day 8 of differentiation and screening the library with a digoxyegenin-labeled eDNA fragment. 
The group found a novel protein, Acrp30, that was exclusively made in adipose tissue and 
secreted in the serum, and like previously discovered adipocytokines, its secretion was enhanced 
several fold by insulin (Scherer, Williams, Fogliano,Baldini, & Lodish, 1995). 
Several months later in May 1996, Hu, Liang and Spiegelman. ( 1996), using an mRNA 
differential display technique, discovered a novel protein expressed exclusively by mature 
adipose cells AdipoQ. eDNA for the molecule encodes a 247 amino acid polypeptide with a 
signal sequence at the amino terminus, a collagenous region (Gly-XY repeats), and a globular 
domain that shares sequence homology with subunits of complement factor C I q, collagen 
VI (X), and brain-specific factor cerebellin (Hu eta!. , 1996). A third group isolated adiponectin 
independently from human plasma as gelatin-binding protein 28 (Nakano,Tobe, Choi-Miura, 
Mazda, & Tomita., 1996). 
A fourth group also discovered the molecule at around the same time. Maeda eta!. 
( 1996) constructed a 3'-directed eDNA library from abdomina! subcutaneous and visceral fat 
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from two female patients, and transfected them into Escherichia coli. A partial eDNA sequence, 
GS31 09 was the most abundant transcript in expression profiles of adipose tissue. The group 
isolated a 4517 BP long clone with a 244-amino acid open reading frame, fl owed by a long 3'-
untranslated region. As with Hu et al. ( 1996), sequencing exposed a putative signal sequence at 
the amino-terminus with no transmembrane domains. In addition, short collagen-like motif 
GXY repeats were located immediately downstream of a short N-terminal non-collagenous 
sequence. In concordance with the other groups, BLAST database searches showed a cysteine 
residue within the short non-collagenous segment preceding the collagen-like domain that bears 
significant sequence sim ilarity with collagen X, VIII and complement protein C lq. However, 
this domain was a little shorter than other collagen-like domains. Maeda et al. ( 1996) further 
detected a 4.5kb apM I mRNA in the adipose tissue, but not in any other tissue (i.e. skeletal 
muscle, small intestine, placenta, uterus, ovary, kidney, liver, lung brain or heart). A fourth 
group isolated adiponectin independently from human plasma as gelatin-binding protein 28 
(Nakano, Tobe, Choi-Miura, Mazda, & Tomita, 1996). 
All four groups found similar results for the novel protein which was later labelled 
adiponectin. Expression of adiponectin is highly regulated during adipose cell maturation and 
differentiation and is restricted to adipose tissue in vivo (Scherer et al. , 1995; Hu et al., 1996; 
Maeda et al. , 1996). Hu et al. ( 1996) showed expression of both 3T3-F442A and 3T3-L I 
pread ipocytes but not in fibroblastic 3T3-C2 cells. Furthermore, expression of Ad iponectin 
mRNA was found to be significantly reduced in ad ipose tissue from obese mice and humans (Hu 
et al. 1996). 
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1.1.2 Structure and Genetic Location of Adiponectin 
Adiponectin is encoded on chromosome 3q27, a Type 2 diabetes and metabolic syndrome 
susceptibil ity locus. The gene consists of3 exons and 2 introns occupying a 17-kb region on 
chromosome 3 (Stumvoll et al., 2002). The protein contains 244 amino acids, a signal peptide, a 
collagen-like domain at its N-terminus and a globular domain at its C-terminus. The globular 
domain shares sequence similarities with collagens X, VIII and C I q (Okamoto, Kihara, 
Funahashi, Matsuzawa, & Libby, 2006; Hu et al., 1996). In plasma, the adipocytokine exists in 
very high levels (i.e. 3-30:g/ml). In addition, Adiponectin exists in three main different forms: I) 
trimers, 2) hexamers, and 3) high-molecular-mass form . Some research also identified a smaller 
form of adiponectin with globular domain which exists in smaller amounts that cleaves 
proteolytically from the full-length adiponectin (Fruebis et al., 2001). 
1.1.3 Adiponectin and Body Fat composition 
Many animal studies have been conducted to delineate the relationship between 
adiponectin and body fat composition. Among the first groups to identi fy a relationship between 
adiponectin and body fat composition was A rita et al. ( 1999). Adiponectin levels were measured 
in 87 non-obese subjects and 57 obese subjects and found to be significantly lower in obese 
subjects as compared with non-obese individuals (Arita et al. , 1999). A strong negative 
correlation was noted with ad iponectin and body mass indices in both genders (Arita et al., 
1999). 
Berk eta/. , (2005), measured changes in adiponectin levels, along with insulin, leptin and 
glucose, in response to high-fat and low-fat eucaloric diets in 11 obese and I 0 lean subjects. 
Although leptin, insulin and glucose levels were found to be significantly higher in obese groups 
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when compared with the lean subjects, adiponectin levels were found to be lower (Berk et al. , 
2005). Insulin-resistant subjects in the obese group were found to have significantly higher 
adiponectin levels than did the insulin-resistant lean subjects (Berk eta/., 2005). 
A cohort study of202 Japanese workers participating in an annual health check revealed 
subjects with plasma adiponectin levels below 4.0ug/ml had significantly lower HDL-cholesterol 
levels, higher levels of BMI, systolic and diastolic blood pressure, fasting blood glucose, 
platelets and total cholesterol as compared with subjects with higher adiponectin levels 
(Tsukinoki, Morimoto, & Nakayama 2005). The same low-adiponectin levels were also found to 
be associated with smoking status, a daily diet rich in deep yellow vegetables, eating out, and 
physical exercise two or more times per week (Tsukinoki et a/., 2005). 
The relationship between adiponectin concentrations and insulin resistance and body fat 
composition was assessed in I 02 Korean type-2 diabetic subjects and compared with 50 controls 
(Kim eta/., 2005). Post a 12-hour fast, adiponectin levels were found to be significantly lower 
in men as compared with women. They were also found to be negatively correlated with hip 
circumference, BMI, HOMA-lR and fasting glucose concentrations, but positively correlated 
with systolic blood pressure and HDL-Ievel (Kim eta!., 2005). Adiponectin was found to be 
significantly lower in diabetics as compared with non-diabetics, except in obese males (Kim et 
a!. , 2005). Similar findings were noted in a study involving 150 South Asians, where subjects 
were divided into 60 non-diabetic subjects, 60 subjects with impaired glucose tolerance and 30 
with diabetes (Wasim eta/. , 2006). Adiponectin levels were found to be highest in non-diabetic 
subjects as compared with the other groups, and lowest in those with diabetes (Wasim et al., 
2006). An inverse relationship was noted between log adiponectin and resistin levels (Wasim et 
al., 2006). 
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Further support for the inverse relationship of adiponectin with insulin, as well as its 
relationships with adiposity, is provided in a study of316 men and 353 Yup' ik Inuit of southwest 
Alaska (Goropashnaya et al., 2008). Adiponectin again was found to be negatively correlated 
with percentage body fat, sum of skin folds, waist circumference, triglycerides, insulin 
resistance, fasting insulin and leptin in both groups of men and women, whereas it was positively 
correlated with HDL-C levels in both sexes, and LDL-c levels in women (Goropashnaya et al. , 
2008). In addition, insulin sensitive individuals had higher plasma adiponectin concentrations 
than insulin resistant individuals (Goropashnaya et al. , 2008). However, no difference was noted 
between the Inuit and Caucasian groups (Goropashnaya eta/., 2008). 
The relationship ofadiponectin and insulin has also been noted in children. Nishimura et 
al. (2009) conducted a 3-year prospective cohort study of268 Japanese boys and 251 Japanese 
girls aged 9-10 followed over a 3-year period. A significant strong correlation was noted with 
adiponectin and BMI in both boys and girls before and after the 3-year period of follow-up 
(Nishimura et al., 2009). More specifically, adiponectin levels decreased in subjects whose BMI 
increased during the period in which they were followed (Nishimura et al. , 2009). 
Supportive findings also arose when studying adiponectin levels in pubertal ballet 
dancers (Donoso et al., 20 I 0). In a prospective follow-up study, 22 female Caucasian ballet 
dancers ofTanner stage II development were followed throughout puberty. Energy intake in 
these individuals was deficient according to the physical exercise exerted. These girls were 
found to have elevated levels of adiponectin throughout puberty, while their percentage body fat 
and mass was decreased overall (Donoso eta!., 20 I 0). 
Elevated adiponectin levels associated with increased risk of total and cardiovascular 
mortality in subjects greater than 69 years of age (Poehls et al. , 2008). 3,075 well-functioning 
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adults aged between 69 and 79 were assessed at baseline and followed for an approximate 6-
year period (Poehls eta/. , 2008). After adjusting for age, sex, hypertension, diabetes, prevalent 
heart disease, smoking, weight-loss and race, adiponectin remained associated with an increased 
risk of both total and cardiovascular mortality (Poehls eta/. , 2008). 
Other subject groups were noted to have associated elevated adiponectin levels. Serum 
adiponectin levels were found to be significantly lower in individuals with hepatocellular 
carcinoma and liver cirrhosis as compared with healthy controls, whereas patients with chronic 
hepatitis B Virus infection were found to have similar levels (Liu eta!., 2008). 
The exact role that adiponectin plays in fat metabolism and metabolic syndrome is still 
not completely understood. However, its inverse relationship with insulin and with body fat 
composition has been clearly demonstrated in many studies which seems to add further support 
to that role. 
1.1.4 Pathophysiology of Adiponectin 
The complete actions of adiponectin have not been completely described, but much was 
discovered in terms of potential roles it plays in the body. Given its structure resembles that of 
other fibrillar collagen molecules, it is believed it may interact with other matrix component 
proteins, particularly in arteries since the molecule was shown to be associated with many 
cardiovascular conditions that are often major outcomes in the pathology of the metabolic 
syndrome (Okamoto eta!. , 2006). Among these conditions, the role of adiponectin in 
atherosclerosis was examined. During the early stages of atherosclerosis development, injured 
endothelial cells release factors that induce circulating monocytes chemotactically to infiltrate 
the subendothelial space, leading to their differentiation into macrophages (Ouchi eta!., 2001 ). 
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These macrophages phagocytose modified LDL-c molecules in the injured area and transformed 
their appearance to foam cells. This scavenging process is aided by the use of two main 
receptors: the class A and 8 macrophage scavenging receptors (MSR). Ouchi eta!. (200 I) 
studied the effects of adiponectin on both the macrophages involved in atherosclerosis and the 
expression of MSR. Treatment of macro phages with adiponectin for three days significantly 
reduced their cholesteryl-ester contents by - 50% as compared with the untreated sample. In 
addition, adiponectin reduced the macrophage to foam cell transition in vitro. Furthermore, two 
days of adiponectin treatment markedly reduced class A MSR protein expression in a dose-
dependent manner (Ouchi et al. 200 I) . In a previous study, adiponectin was found to inhibit 
specifically the 168- a -NF-68 pathway which is normally stimulated by TNF- a. It was 
specifically shown to prevent 168- a from being phosphorylated (Ouchi eta!. , 2000). 
Continued immunostaining investigations showed in addition to the suppressed expression of 
MSR protein, adiponectin was abundant in the endothelium and subendothelial space, but it was 
not detected in the subendothelial space of atherosclerotic lesions with an intact endothelium 
(Ouchi eta!. , 200 I). 
In the development of atherosclerosis, vascular smooth muscle cell proliferation is a key 
step. This can often lead to hypertonicity and a resulting decreased arteriole lumen size. In 
culture, the migration and proliferation ofthese cells have been shown to be suppressed with the 
addition of adiponectin through an effect on the direct binding to platelet-derived-growth-factor-
88 (Arita eta!. , 2002). Specifically, plasma adiponectin suppressed PDGF-88- induced ERK 
phosphorylation (Arita eta!. , 2002). It also inhibits growth-factor-stimulated extra-cellular-
signal-regulated kinase, further suggesting that adiponectin is a modulator of atherosclerosis 
through anti-inflammatory and anti-proliferative means (Arita eta!. , 2002). 
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Adiponectin is also believed to interact with other key molecules such as interleukin-1 0 
(IL-l 0). Manigrasso eta/. (2005) conducted a short-term weight loss program and monitored its 
effect on circulating adiponectin and IL-l 0 levels in 15 android obese women. They observed 
that baseline IL-l 0 levels were significantly correlated with adiponectin concentrations in 
android, but not gyenoid in obese women. The effects of short-term weight loss resulted 
however in no significant change in either adiponectin or IL-l 0 (Manigrasso eta!., 2005). 
Kobayahsi eta!. (2004) assessed the three isoforms of adiponectin found in human blood to 
determine if any changes in distribution occurred in subjects with significant weight reduction, or 
in subjects that were determined to be obese, non-obese and with coronary artery disease. The 
high molecular weight form of adiponectin was significantly increased by those who had 
significant weight reduction, whereas the trimer and hexamer forms significantly declined 
(Kobayahsi eta!. , 2004). However, HMW form was decreased in CAD patients, while the trimer 
isoform increased and the hexamer isoform showed no change. Moreover, after examining the 
effects ofunfractionated, recombinant adiponectin on Human Umbilical Vein endothelial cells 
that were death induced by mitogen-deprivation, they found that adiponectin decreased the 
mitogen-induced apoptosis in a dose dependent manner (Kobayashi eta!., 2004). Furthermore, 
the HMW isoform was found to be mainly responsible for the apoptotic effect. 
Adiponectin has been shown to be a key regulator of vascular vasomotor function 
(Okamoto eta!., 2006). After analyzing the endothelial function in 202 hypertensive patients, 
including those 58 not taking medication, Ouchi eta!. (2003) noted that plasma adiponectin 
levels significantly correlated with the endothelium-dependent vasodilatation as a result of 
forearm vasodilatory response to reactive hyperemia. This was found in both the entire group 
and in the non-medication group. Furthermore, in adiponectin-KO mice which were fed high-
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fat/high-sucrose/high-salt diets for four weeks, Ach-induced vasorelaxation was significantly 
reduced compared with wildtype mice (Ouchi eta!., 2003). 
Other research suggested close links between hypoadiponectinemia and endothelial 
dysfunction in men. Forearm blood flow was measured during reactive hyperemia using stain-
gauge plethysmography to assess resistant vessel endothelial function physiologically 
(Shimabukuro eta!. 2003). Peak forearm blood flow was used as a combination marker of shear 
stress and local metabolic factors at an early phase of reactive hyperemia, while flow debt 
repayment marked NO-dependant levels at mid-to-late phase of reactive hyperemia 
(Shimabukuro et al. 2003). Impaired forearm blood flow response and flow debt repayment 
were correlated with low levels of serum adiponectin (Shimabukuro eta!. 2003). 
Hypoadiponectemia being associated with impaired endothelium-dependent 
vasodilatation was further confirmed by Tan et al. (2004). In a similar study for 73 patients with 
type 2 diabetes mellitus assessed for endothelium-dependant vasodilatation by high resolution 
ultrasound, plasma adiponectin levels correlated significantly with endothelium-dependent 
vasodilatation in both type 2 diabetics and controls, whereas no link showed endothelium-
independent vasodilatation (Tan eta!. 2004). Furthermore, general linear model univariate 
analysis demonstrated that brachial artery diameter, plasma HDL and adiponectin levels were the 
main independent determinants of endothelial function . 
Another study showed in a similar fashion how circulating adiponectin concentration was 
significantly associated with insulin sensitivity and fasting serum TG in healthy individuals. 
This suggested that serum adiponectin concentration is significantly associated with vascu lar 
function in healthy people (Fernandez-Real et al., 2004). 
In another cross-sectional study, Shetty, Economides, Horton, Mantzoros, & Veves, 
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(2004) conducted an investigation on the associations between adiponectin and resistin with 
inflammatory markers, hyperlipidemia and vascular reactivity. They recruited seventy-seven 
individuals with Type 2 diabetes, who were without any major complications, or who were 
believed to be at high risk for developing Type 2 diabetes. Adiponectin negatively correlated 
with tPA, CRP, TG and BMI, but positively correlated with HDL-c, as in previous studies 
(Shetty et al., 2004). These findings were independent of sex. As a supplemental interventional 
study, the group was given in a randomized fashion 20mg of atorvastatin or placebo over a 12 
week period. However, no association was found between atorvastatin treatment and adiponectin 
(Shetty et al., 2004). 
In almost all studies adiponectin in adults showed it was a predictor of insulin resistance, 
endothelial function, coronary artery disease, and Type 2 diabetes. Singhal et al., (2005) 
conducted a similar analysis of insulin resistance, cardiovascular risk factors and endothelial 
function in young, healthy adolescents. They studied 294 non-smoking adolescents from ages 
13-16. Consistent with previous research, adiponectin was significantly associated with HOL-e 
concentration, but not CRP or blood pressure (Singhal et al., 2005). Insulin resistance was 
inversely related to adiponectin concentration, but endothelial function was not found to be 
associated with adiponectin distribution as had been previously demonstrated in adults (Singhal 
et al. , 2005). However, Matsubara et al. (2003) took 384 blood samples from a previous cross-
sectional study of women residing in Hokkaido, Japan to compare both plasma ad iponectin and 
CRP. Unlike Singhal eta!. (2004), they found plasma adiponectin and CRP levels in their 
female subjects to be significantly inversely correlated. 
In terms of actual weight reduction and changes in physical appearance, ad iponectin has 
been shown to be significantly associated with changes in BMI, waist and hip circumference 
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(Yang eta!., 2002). Yang eta!. (2002) observed the plasma adiponectin level changes in 22 
individuals that underwent gastric partition surgery. They noted a significant increase of 46% in 
levels of plasma adiponectin when compared with a 21% drop in BMI. They further noted that 
changes in plasma adiponectin levels were significantly correlated with changes in plasma 
adiponectin levels. 
Animal models demonstrated other roles for adiponectin. In a study using adiponectin-
KO mice, it was found that cardiac hypertrophy resulting from pressure overload increased when 
adiponectin was deficient. However, when adiponectin was injected via adenovirus, the degree 
of cardiac hypertrophy lessened (Shibata eta!., 2004), which suggests that it may have a role in 
treatment of conditions leading to hypertrophic cardiomyopathy. 
In obese KK-Ay mice, the effects of soy protein diet on body fat composition, plasma 
glucose, lipid and adiponectin levels and gene expression of those involved in glucose and fatty 
acid metabolism was assessed (Nagasawa eta!. , 2002). They found a significant difference in 
adiponectin gene expression between rats on a soy protein diet and those on a casein-restricted 
diet (Nagasawa eta!. , 2002). Adipose adiponectin mRNA expression and plasma adiponectin 
levels were significantly higher in those rats that were calorie-restricted than controls (Nagasawa 
eta!. , 2002). Similarly, adiponectin has been shown to stimulate glucose utilization, fatty acid 
production, and lactose production in myocytes through the activation of 5'-AMP-activated 
protein kinase (Yamauchi eta/. , 2002). Furthermore, blocking AMPK inhibited these effects, 
suggesting that adiponectin conducted these actions through AMPK (Yamauchi et al. , 2006). 
Another study also has shown that diet may affect plasma levels of adiponectin. Serum 
concentrations of adiponectin increased significantly in sixty obese women aged 20-46 years 
without diabetes, hypertension and hyperlipidemia after two years on a Mediterranean-style diet 
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and increased physical activity, (Esposito et al., 2006). 
1.1.5 Adiponectin and Coronary Artery Disease 
Although the initial discovery of adiponectin was about I 0 years ago, its role in the 
metabolic syndrome was recently explored. A rita et al. , ( 1999) was among one of the first 
groups to assess the plasma levels of adiponectin in obese individuals. Adiponectin was 
significantly lower in 57 obese subjects than in 87 non-obese individuals. This was contrary to 
the initial hypothesis since adiponectin is exclusively released by adipose cells. Plasma 
adiponectin levels and body mass indices in both men and women had a strong negative 
correlation between them. In addition, plasma adiponectin levels in men were sign ificantly 
lower than in women among non-obese and obese subjects. However, plasma adiponectin 
showed no correlation with age when adjusted for BMI. 
Adiponectin has been further studied in atherosclerotic cardiovascular diseases. 
Hotta et al. , (2000), analyzed the plasma adiponectin levels in 183 age and BMI matched Type 2 
diabetics (with and without coronary artery disease) and non-diabetic subjects. Patients with 
defined diabetes were shown to have significantly lower plasma adiponectin levels than 
controlled non-diabetic women and men when adjusted for age and BMI. The diabetics were 
further subd ivided into two groups: subjects with CAD, and subjects without CAD (Hotta et al. , 
2000). Diabetic women without CAD had significantly lower adiponect in levels than non-
diabetic women without CAD. Plasma adiponectin concentrations were even lower in women 
with CAD. Adiponectin levels were significantly lower in fema le and male patients with both 
CAD and Type 2 diabetes than in those with diabetes alone (Hotta et al., 2000). Furthermore, a 
reduction in BMI in 13 non-diabetic subjects and 9 diabetics showed plasma adiponectin levels 
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were significantly increased in both groups. However, Hotta et al. , (2000) found no significant 
changes when assessing the adiponectin levels when comparing men or women factoring for age, 
BMI status, value of haemoglobin A I c, and other parameters including triglycerides and plasma 
insulin levels. 
Similarly, Kumada et al., (2003) determined whether hypoadiponectinemia was 
independently associated with CAD. 225 Japanese male patients undergoing coronary 
angiography age 40 to 69 years with a greater than 75% stenosis of at least one coronary artery 
(confirmed by angiogram), who had developed Ml or who had a previous percutaneous 
transluminal coronary angioplasty or CABG, had venous blood drawn and analyzed by ELISA 
for plasma adiponectin levels. Males with hypoadiponectinemia had an increased two-fold 
prevalence of coronary artery disease shown through multiple logistic regression analysis, 
independent of diabetes mellitus, dyslipidemia, hypertension, smoking and BMI (Kumada eta!. , 
2003). In addition, as was previously shown, plasma adiponectin levels in CAD patients were 
significantly lower as compared with controlled subjects. 
Other studies have linked plasma adiponectin concentration with cardiovascular events. 
Mallamaci eta!. (2002) researched the relationship of plasma adiponectin with BMI, fat mass, 
and renal function in 36 hypertensive patients as compared with 31 normotensive individuals. 
The group showed plasma adiponectin levels were higher in hypertensive patients (not enough to 
reach significance) when compared with normotensive subjects. However, when separated by 
sex, hypertensive males showed significantly higher levels of plasma adiponectin than 
normotensive males; women demonstrated no significance (Mallamaci et a!., 2002). In terms of 
kidney function, plasma ad iponectin was inversely related to creatinine clearance, and was 
further confirmed by multiple regression analysis where creatin ine clearance was the principle 
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predictor of plasma adiponectin. Healthy subjects showed a direct relationship with serum HDL 
and plasma adiponectin, while it was inversely related to serum TG. 
Connections between adiponectin and Ml have also been made. Pischon et al., (2004) 
assessed the risk ofMI with plasma adiponectin concentrations. In the Nested control case-study 
containing 18,225 participants, 266 individuals were identified as having an incident of a 
nonfatal Ml or fatal coronary heart disease. While adjusting for age, they noted that adiponectin 
levels were positively correlated with HOL-e, and physical activity. However, it was negatively 
correlated with TG, CRP (c-reactive protein; acute-phase reactant and a powerful marker for 
systemic inflammation), HbA I c and BMI (Pischon eta/., 2004). Furthermore, their data 
showed that high plasma adiponectin concentration was associated with lower risk of myocardial 
infarct in healthy men after a six year follow up (Pischon eta/., 2004). Some case controlled 
studies examined plasma adiponectin levels in patients with an acute Ml and acute coronary 
syndrome. Thirty-four patients with acute MI were compared with 35 individuals with atypical 
chest pain at rest or with exercise but with no significant artery stenosis (Kojima eta/., 2003). 
Patients presenting with an acute Ml were found to have higher adiponectin levels as compared 
with controls. In addition, sequential analysis after from 24 hours, three days, seven days, and 
four weeks after the event showed adiponectin levels dropped significantly 24 hours and three 
days after the acute MI when compared with admission day levels. However, levels returned to 
admission day levels on day seven and four weeks later (Kojima eta/., 2003). A similar study 
supported the finds and further noticed that individuals with unstable angina showed 
significantly lower plasma concentrations of adiponectin (Nakamura et a/. , 2004). The study 
additionally showed that adiponectin concentrations in plasma were significantly lower than 
those in patients with stable angina. 
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Negative associations in other populations have been shown when comparing plasma 
adiponectin levels and the future risk of coronary heart disease. Using cases and controls from 
the case-controlled selected subjects in the strong heart study on American Indians (population at 
high risk of obesity and Type 2 diabetes and high risk of CHD), plasma adiponectin levels 
showed no significant association with coronary heart disease (Lindsay eta!. , 2006). Similarly, 
70 Pima Indians who developed Type 2 diabetes were examined and were shown to have 
significantly lowered plasma adiponectin levels as compared with 70 controls from the same 
population (Lindsay eta!. , 2006). These low concentrations of plasma adiponectin correlated 
strongly with lowered insulin sensitivity, and those with higher adiponectin levels were less 
likely to develop Type 2 diabetes (Lindsay et al. , 2006). 
Hypertension has also been linked with variations in adiponectin plasma concentrations. 
In a study by Adamczak et al., (2003), 33 essential hypertension patients (2 1 men, 12 women) 
were compared with 33 normotensive BMI-matched healthy subjects (20 men, 13 women). 
Essential hypertensive subjects had significantly lower plasma adiponectin levels than 
normotensive individuals, regardless of gender. Furthermore, plasma adiponectin concentrations 
were negatively correlated with Mean arterial pressure, systolic pressure, and diastolic pressure 
(Adamczak eta/. , 2003). 
1.1.6 Genetic Associations of Adiponectin 
Much research showed an association between adiponectin and various genetic 
polymorphisms. In Japanese population, Kondo eta!. (2002) compared 2 18 Type 2 diabetics or 
coronary artery disease patients with 452 age- and BMI-matched non-diabetic control subjects 
for mutations in the adiponectin gene. The group assessed five mis-sense mutations in the 
-------------------------------------- - - -- - --
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adiponectin gene: a R 112C mis-sense mutation, a G/T polymorphism at position 94, a T-C 
substitution at nucleotide 517 leading to an amino acid substitution from isoleucine to threonine 
at position 164, a C-A substitution at nucleotide 687 leading to an arginine-serine substitution at 
position 221 , and an A-C substitution at nucleotide 748 causing a histidine to proline substitution 
at position 241 . No mutations were found in intronic sequences, which suggest there was no 
mutation to produce alternative splicing for the adiponectin gene (Kondo eta!., 2002). Patients 
carrying the 1164T mutation had markedly low plasma adiponectin concentrations as compared 
with those with other mis-sense mutations. In addition, plasma adiponectin levels in volunteers 
with the 1164T mutation were significantly lower compared to those of the 209 diabetics without 
mutations. This suggested hypoadiponectinemia was associated with an 1164T mutation and not 
as a consequence of Type 2 diabetes or insulin resistance (Kondo eta!., 2002). Previous studies 
have reported subjects with the R 112C mutation as having low plasma adiponectin 
concentrations, wh ich was further confirmed by Kondo eta!. , (2002); Takahashi eta!. , 2000). 
The current study showed even heterozygotes for the 1164T and R 112C mutations had 
significantly lowered plasma concentrations (Kondo et a!. , 2002). It was later shown that the 
1164T variant displayed impaired adiponectin secretion from adipose tissue (Okamoto, Kihara, 
Funahashi, Matsuzawa, & Libby, 2006). The T/G polymorphism at nucleotide 94 is believed to 
affect plasma adiponectin levels (Stumvoll eta!. , 2002). Even though studies have shown no 
statistical significance associated between the polymorph ism and plasma adiponectin levels, the 
G allele has been shown in a Japanese population to decrease adiponectin concentrations in a 
dose dependent manner (Takahashi eta!., 2000). More SNPs were discovered to be associated 
with Type 2 diabetes, including SNPs at position 45 and 276 (Hara eta!. , 2006). Some 
mutations are associated with reduced formation of adiponectin trimers or high-molecular mass 
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or high-molecular mass multimers, which may affect the action of adiponectin (Waki et al., 
2003). 
The frequency of the 1164T mutation in coronary artery disease patients was significantly 
higher than in non-CAD patients (Ohashi et al., 2004). In addition, all subjects found to date 
with the mutation are heterozygotes. Plasma adiponectin levels were low in both coronary artery 
disease patients and non-CAD patients with the mutation. Ohashi et al., (2004) looked at other 
single nucleotide polymorphisms in the adiponectin gene, including GIG, GIT and TIT alleles at 
SNP94 and GIG, GIT and TIT alleles at SNP276; no significant changes were observed. 
However, polymorphisms ofSNP94 in subjects ofthe Tubingen Family study did show 
an association between TIG polymorphisms in Exon 2 (Stumvoll et al., 2002). Unlike the 
polymorphisms encountered resulting in mis-sense mutations, the TIG exchange in nucleotide 94 
shows a much higher prevalence (-25%). Overall, Exon 2 seems to be more polymorphic than 
Exon 3. 371 non-diabetic subjects (with no family history oftype 2 diabetes) that underwent 
oral glucose tolerance tests showed large BMis and percentage body fat levels associated with 
the GG + GT genotypes as opposed to the TT genotype (Stumvoll eta!, 2002). Furthermore, 
insulin sensitivity was significantly lower in the GG + GT genotypes as compared with TT. This 
suggests that the TIG polymorphism in non-type 2 diabetes individuals may mildly increase 
obesity risk and insulin-resistance (Stumvoll eta/. , 2002). 
Similarly, SNPs 45 and 276 of the adiponectin gene have also been linked with Type 2 
diabetes and the metabolic syndrome. Hara et al. (2002) detected ten relatively frequent SNPs in 
the adiponectin gene in both a population of French and Japanese subjects. Of these SNPs, the 
GIG genotype at position 276 was shown to have an increased risk of type 2 diabetes compared 
with the TIT genotype. Those with the GIT or GIG genotype at position 45 also showed a 
Page 42 of 167 
significantly increased risk of type 2 diabetes (Hara et a/. 2002). In addition, SNPs at position 
4034, 3964, and 276 were found to be significantly associated with HOMA-IR. Furthermore, 
plasma ad iponectin levels tended to be lower in subjects with the G allele (Hara eta!., 2002). 
The same two SNPs were also assessed by Gonzalez-Sanchez et al., (2005) in 747 
unrelated Spanish subjects with associated symptoms ofthe metabolic syndrome. They noted 
carriers of the G allele at nucleotide 45 had higher odds ratios for impaired glucose tolerance as 
compared with non-carriers. Similarly, the GIG genotype at position 276 also showed a higher 
odds ratio for impaired glucose tolerance as compared with the T allele (TIT + GIT; Gonzalez-
Sanchez et al. , 2005). The group also noted both SNPs are in linkage disequilibrium. In 
add ition, after measuring the serum adiponectin levels in 721 subjects oftheir cohort, 
adiponectin levels were higher in women than in men, lower in homozygous carriers ofthe G 
allele than in carriers of the GIT or TIT genotypes, and significantly lower in obese subjects 
carrying the GIG genotype as compared with both heterozygous and TIT homozygotes 
(Gonzalez-Sanchez et a/., 2005). Overall, in both SNPs, the GG haplotype was associated with 
lower serum adiponectin levels as compared with TI haplotypes. 
1.2 Adiponectin and Osteoporosis 
1.2.1 Definition and Diagnosis of Osteoporosis 
Osteoporosis is defined as a skeletal disorder characterized by compromised bone 
strength predisposing to an individual to an increased risk of fracture (Glaser & Kaplan, 1997). 
The current definition of osteoporosis, although still criticised and debated, is still the same 
definition which the World Health Organization proposed in 1994. Since then osteoporosis and 
osteopenia have been defined in terms ofthe patient' s bone mineral density in specific bone sites 
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around the body at a given age and gender as compared with the general population (Knapp, 
Blake, Spector & Fogelman, 2004). Specifically, osteoporosis and osteopenia were expressed as 
standard deviation units called T-scores, with T-score thresholds equal to or less than -2.5 SO 
and -1.0 SO for osteoporosis and osteopenia respectively. These scores would be calculated by 
comparing one individual's bone mineral density, usually calculated by dual-X-Ray-
absorptiometry (DEXA), with that of a similar population data set. These scans would be taken 
typically from the highest ri sk fracture areas in the body and compared with the general 
population. Specifically, the spine, the hip or the radius are usual measurement areas, with the 
spine or the hip being most frequently measured (Knapp, Blake, spector, & Fogelman, 2003). 
This current definition of osteoporosis requires no previous history of fragility fractures for an 
individual to be diagnosed with the disease. It only serves to identify individuals at high risk for 
fracture from low-energy-impacts. 
In classifying an individual with osteoporosis, variations can occur based on the 
standards at each center, the methods used, and differences in equipment and population. 
Goemaere, Zmierczak, Van Pottelberg, and Kaufman (2002) noted that the current working 
definition for osteoporosis has only been validated in white postmenopausal women. There has 
been criticism of the current definition of osteoporosis because of its lack of specificity for 
diagnosing males. Multiple studies note that there is little consensus of using BMD threshold to 
be applied clinically for identifying men at high risk of fracture, particularly when using DEXA 
(Goemaere eta!. , 2002; Seeman, 1999). DEXA use in men has shown low sensitivity, with 80% 
of men with fractures occurring at BMD-T scores greater than -2 .5 (Szulc, Munoz, Duboeuf, 
Marchand, & Delmas, 2005). As a result, although the T -score approach has shown strong 
sensitivity and specificity in postmenopausal women, it has been suggested that the diagnosis of 
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osteoporosis in men should be an integration of clinical history and BMD measurement 
(Kaufman & Goemaere, 2008). The risk factors of importance on clinical history include 
previous fracture prior to age 50, elder age, incidence of falls, history of endogenous or 
exogenous glucocorticoids, hypergonadism, alcoholism, liver disease and family history 
(Kaufman & Goemaere, 2008). The defined measures for bone mineral density can be found in 
Table 2. 
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Table 2. Defining measurements for bone mineral density as defined by WHO. 
Normal bone density T score greater than -I 
Osteopenia T score between -I and -2.5 
Osteoporosis T score less than -2.5 
Severe (Established) osteoporosis T score less than -2.5 with an established fracture 
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1.2.2 Prevalence of Osteoporosis 
The prevalence of osteoporosis varies in each race and with the methods of calculation. 
In the United States, one article quotes the rate at approximately 24 million, with 15-20 million 
of them being women above age 45 (Iqbal, 2000). The rate has been quoted between I 0-20% 
overall. In Denmark, a recent study aiming to assess the number of individuals diagnosed with 
osteoporosis and osteoporotic fractures found that the estimated prevalence of osteoporosis was 
40.8% of women aged greater than or equal to 50 years and 17.7% among men greater than or 
equal to 50 years old (Vestergaard, Rejnmark, & Mosekilde, 2005). A study from the 
Netherlands assessing time trends of change for the incidence of osteoporosis in the country, 
noted the initial increase of incidence in osteoporosis observed in the mid-nineties has been 
levelling off (Goettsch, delong, Kramarz, & Herings, 2007). Interestingly, in a paper hosted by 
the Canadian Association of Orthopaedic Surgeons, the worldwide prevalence of osteoporosis in 
individuals over 40 was 1-in-3 for women and 1-in-5 for men, with the incidence increasing with 
age (Guy, 2007; Kanis & Kanis, 1994; Kanis, Melton, Christiansen, Johnston, & Khaltaev, 
1994). This increasing incidence has been reported by WHO working group on osteoporosis 
(Figure I). 
Currently, the gold standard for the diagnosis of low bone mineral density is made by 
using Dual-X-ray Absorptiometry (DXA; Figure 2). It can be made by radiograph when 
fractures or structural abnormalities are present (Chun, 20 II). However, this is not effective in 
detecting low-bone mineral density prior to the presentation of c linica l findings. In addition, 
unlike DXA, radiographs fail to take into account demographic factors such as age and gender 
that influence overall bone minera l density (Chun, 2011). DXA incorporates data obtained from 
the NHANES Ill study (National Health and Nutrition Examination Survey), for comparison of 
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bone-mineral density, to calculated individuals of same age, gender and ethnicity, whose bone 
mineral density is two-standard deviations below the mean (Chun, 20 II). 
DXA evolved from the development of single-photon and dual photon absorptiometry. 
However, unlike the its predecessors, DXA uses a low-energy X-ray beam, high-photon flux that 
permits faster scanning, improved reso lution and image quality (Chun, 20 II). As explained in a 
review by Chun (20 II), DXA uses highly collimated beams that pass through soft ti ssue and 
bone and are absorbed by a detector on the opposite side of the emitter. Bone-mineral density is 
calculated by comparison of the intensity of a beam of an excited body part with the intensity of 
photons of known density. A schematic diagram of how DXA works is displayed in Figure 2, 
adapted from Chun, 20 I I. 
There is still considerable debate as to the areas scanned that are best assessed to 
determine osteoporosis. As a result, most centers evaluate at risk sites to determine long-term 
fracture risk. These sites mainly include hip and the posterior-anterior spine. 
The main criticism of DXA is that it only provides an individual with an estimate of 
bone-mineral density from a 2-dimensional view, such that it may over or under estimate a 
person 's osteoporosis ri sk and subsequent fracture risk based on the thickness or width ofthe 
person 's bone in the plane measured. However, as compared with other methods that have been 
suggested such as MRI, it is more cost-effective, effectively predictive, and still w idely used. 
Page 48 of 167 
• 
80+ 
70-79 
,-, 
rl1 
:.. 
c:: 
~ 
b 60-69 ~ 
tw 
< 
50-59 
50 
-6 -5 -4 -3 -2 - 1 0 1 2 3 
BlVID (SD units) 
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prevalence w ith increasing age. This graph specifically represents the bone mineral density change in women. 
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Figure 2. This image was adapted from Chun (20 II ) . This is a schematic diagram of the princ iples of DXA technology. 
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1.2.3 Adiponectin and Bone Mineral Density 
Adiponectin has been shown to be associated with fat mass, atherosclerosis and anti-
inflammatory molecules; however, there has been debate as to whether circulating adiponectin 
levels show any correlation with bone mineral density. It is uncertain if any correlations that do 
exist with bone mineral density and fat composition are true direct correlations or are 
confounded by the direct role that fat mass plays on bone mineral density. The clinically most 
relevant areas in terms of bone mineral density- specifically, lumbar spine, hip and femoral 
neck- have been inconsistent in showing a correlation with adiponectin when controlling for 
other variables. 
In a study of25 premenopausal and 55 postmenopausal women, adiponectin showed no 
significant correlation with total body bone mineral composition, with an initially negative 
correlation with L2-L4 bone-mineral density (BMD) (Kontogianni et al., 2004). However, the 
negative correlation was lost after adjustment for menopausal status (Kontogianni, Dafini, 
Roustsias, Skopouli, 2004). In a study of 42 men and 38 women in North Carolina, where most 
of the women were postmenopausal, there was an inverse correlation noted between adiponectin 
and bone-mineral density at all skeletal sites measured including Areal BMD, L 1-L4 spine, total 
hip, lumbar and thoracic spine, and volumetric BMD (Lenchik et al., 2003). These associations 
held after adjusting for fat mass, age, menopausal status and other covariates (Lenchik et al., 
2003). Another study by Jtirimae, Rembel, Jtirimae, and Rehand, (2005) involved 21 
premenopausal and 17 postmenopausal women matched for daily energy expenditure and BMI. 
Adiponectin showed a significant negative association with total BMD, lumbar spine BMD, 
independent of body composition, hormonal and physical performance factors exerted on BMD. 
In a follow-up study by Jtirimae and Jtirimae (2007) with 88 postmenopausal women from 
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Estonia, adiponectin was found to be significantly related to total bone mineral composition, 
lumbar spine BMD, and femoral neck BMD. The relationships remained significant when 
adjusting for body composition, hormonal and insulin resistance values; however, they showed 
no correlation when adjusted for fat-free mass (Jtirimae and Jtirimae, 2007). 
Fat and body mass have been shown to be strong predictors of bone mineral density, 
particularly in postmenopausal women (Douchi eta/., 2000). In a study looking at 296 
premenopausal women with regular menses and 230 postmenopausal females, Douchi and 
colleagues determined that the number of years since menopause, fat mass, total lean body mass 
and height were significant determinants of bone mineral density in post-menopausal women, 
whereas only lean body mass and age of menarche were determinants for premenopausal women 
(Douchi et al. , 2000). Subsequently, the group concluded that adiposity status plays a more 
significant role in bone mineral density in postmenopausal women than it does in premenopausal 
women. 
Other studies have noted correlations between adiponectin levels and other measured 
areas of bone mineral density. There was a study which assessed adiponectin and leptin levels in 
40 Japanese patients with Type 2 diabetes, looking specifically at the distal radius, lumbar spine 
and femoral neck measurements from DEXA. Tamura eta!., (2006) noted no correlations were 
found with adiponectin and lumbar spine or the femoral neck. However, there was a significant 
positive correlation found between adiponectin and leptin with the BMD of the distal radius 
(Tamura eta!., 2006). They found no significant correlation between adiponectin and 
osteocalcin or urine deoxypyridinoline, and other determinants of bone mineral density which 
were measured in the study (Tamura eta!. , 2006). 
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In a large scale cohort study from the United Kingdom involving I ,735 nondiabetic 
women, increasing serum adiponectin levels were found to be significantly correlated with 
decreasing bone mineral density, even after controlling for BMI, serum leptin levels, central fat 
mass, hormone replacement therapy, smoking and exercise (Richards, Valdes, Burling, Perks, & 
Spector, 2007). In addition, as has been similarly shown by other groups (Douchi eta!. , 2000), 
this correlation was strengthened in postmenopausal women, but was lost in premenopausal 
females (Richards eta!. , 2007). 
Several studies in rodents and human cell lines have attempted to aid in the role 
adiponectin may play in bone mineral density. Receptors of adiponectin have been identified on 
both osteoblasts and osteoclasts, further suggesting a potential role in bone mineral density 
regulation (Shinoda eta!. , 2006; Bernera eta/., 2004). Williams eta!. (2009), in a series of 
experiments on rodent and human cell lines and rodent adiponectin-knockout mice, noted an 
increase in mitogenic activity and proliferation in osteoblastic cell lines treated with adiponectin 
concentrates, whereas osteoclastic cell lines were significantly inhibited. 
However, they noted that adiponectin had no affect on isolated mature osteoclastic cells, 
suggesting that the inhibitory process may be mediated by an intermediated cell line, possibly a 
stromal cell (Wi lliams eta!., 2009). In addition, in the ad iponectin-knockout mice, bone strength 
increased at all measures of testing- displacement to fracture, work to fracture and displacement 
to peak load (Williams et a/., 2009). Similar findings were previously noted by Oshima et a!., 
(2005). In an experiment involving adiponectin-adenovirus treated mice, an increase in 
trabecular bone growth was noted and a decrease in plasma osteoclasts were detected (Oshima et 
a/. , 2005). In vitro studies showed that adiponectin treated cell lines inhibited macrophage and 
monocyte differentiation into osteoclasts, while mRNA expression of alkaline phosphatase 
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enhanced the mineralization activity of the osteoblastic cell line (Oshima eta!., 2005). In 
another study from the same group, adiponectin-deficient mice were found to have an increased 
bone volume at nine months of age, with normal values at three months of age (Nampei eta!., 
2004). 
These findings ofthe inhibitory effect ofadiponectin on osteoclasts and the proliferative 
and increased activity on osteoblasts have been similarly replicated . Using the D clone of 
RA W264 (a highly osteoclastic clone cell line), Yamaguchi eta!. , (2007) demonstrated that 
adiponectin inhibited osteoclastic cell formation stimulated by a specific lipopolysaccride the 
microbe Actinobacillus actinomycetemcomitans. Specifically, they showed that adiponectin 
inhibited the TLR4-mediated NF-kappaB activity in RA W264 cells (Yamaguchi eta!., 2007). 
Lee eta!. (2009) demonstrated that adiponectin increased osteoblast differentiation in 
mesenchymal progenitor cells, showing that expression of cyclooxygenase-2 (COX-2) was 
potently increased by adiponectin, whereas inhibition ofCOX2 activity completely negated the 
effect adiponectin had on osteogenesis. Adiponectin has been shown to stimulate osteoblastic 
activity through the mitogen-activated-protein-kinase pathway and c-jun N-terminal kinase 
pathway, where inhibition of either of these two pathways completely abolishes the effect of 
adiponectin on osteoblastic proliferation (Luo eta/., 2005). 
2.0 Materials and Methods 
2.1 Association study 
2.1.1 Recruitment of Volunteers 
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The Canadian province ofNewfoundland and Labrador recruited 1811 volunteers using 
several different means including poster distribution, personal contact, television media, and the 
use of bone density scans as an incentive. Interested volunteers who wished to participate in the 
study were allowed to do so based on the following criteria: I) They were between the ages of 
19-73; 2) each person is at least a third generation Newfoundland resident with at least one 
grandparent being born in Newfoundland; 3) no one was pregnant at the time of the study. If the 
criteria were met, each person was provided with a list of four questionnaires to be answered and 
returned either prior to or on the day of arrival to the laboratory. These questionnaires included a 
screening questionnaire, a physical activity form, a dietary form, a menstrual cycle form , and a 
consent form. All forms were approved by the Human Investigation Committee of Memorial 
University ofNewfoundland, and the physical activity and dietary forms were received from the 
Heritage Study (Bouchard et al., 1995). The screening questionnaire contained information 
pertaining to background, volunteer heritage, age, reported height and weight, smoking status, 
medication status, medical conditions, and family history. The menstrual cycle form was only 
given to women, which addressed the menopausal status of individuals, as well as period 
regularity. The overall study design was approved by the Human Ethics Committee. 
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2.1.2 Plasma and Serum Samples extraction 
Plasma and serum blood samples were taken upon arrival to the laboratory after a 
complete 12 hour fast. To isolate blood plasma, blood was collected in evacuated tubes 
containing K3EDTA, preventing the blood from coagulating. The plasma samples were 
immediately centrifuged for 15 minutes at 1300g or stored at 4 ·c unti l they could be centrifuged. 
The plasma (supernatant) was then stored at -so·c until it was necessary for further analysis, 
while the remaining pellet of blood cells was stored at -2o·c. 
Serum samples were isolated in tubes containing a clot activator. After collection, the 
tubes were left to sit at 22·c (room temperature) for 20 minutes to allow the blood adequate time 
to fully clot. The tubes were then centrifuged at 2s•c for I 0 minutes at 3500rpm. The serum 
samples were then stored at -so·c until further analysis, with the remaining pellet being stored at 
-2o·c. 
2.1.3 Body composition measurements 
Each volunteer was asked to remove all articles of clothing, particularly all metallic 
objects, with exception of bottom underwear that contained no metal substances, and was asked 
to put on a medical gown. Individuals were then weighted and measured for their height using a 
standard medical scale and ruler (Health-a-meter Inc., Brydgirow, IL USA). Waist and hip 
measurements were taken using a centimetre measuring tape, with waist being measured around 
the navel, and hip being measured around the individual 's greater trochanter. Body composition 
measurements, bone mineral composition and density measurements, and muscle and fat weight 
and percentage measurements for arms, legs, trunk and whole body were conducted using a dual-
energy X-ray absorptiometry (DEXA) Lunar prodigy system (GE Medical Systems, Madison, 
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WI, USA). In addition to total bone density measurements, spine and left hip measurements 
were conducted. During scans, subjects lay still in a supine position. Analysis of the resu lts was 
conducted using Lunar prodigy software version 4.0. The classification for lean, normal, 
overweight and obese followed the Bray 2003 body composition classification for Caucasians. It 
is displayed in Table 1. 
2.1.4 Serum biochemical measurements 
Glucose, total cholesterol, high-density lipoprotein (HDL-c), triglycerides (TGs), 
calcium, magnesium and albumin serum concentrations were measured using Synchron reagents 
performed on an Lx20 (Beckman Coulter, Inc., CA, USA). Serum insulin levels were obtained 
using an lmmulite immunoassay analyzer (DPC, CA, USA). Low-density lipoprotein-
cholesterol (LDL-c) was determined using the following equation Total cholesterol- HDL-c. -
0.45 (triglycerides). 
2.1.5 DNA Extraction and genotyping 
2.1.5.1 Genomic DNA Extraction 
Extraction of DNA was completed using the Wizard® Genomic DNA purification Kits 
(Promega, Madision, WI, USA) as per the company's protocol. The DNA was extracted from 
white blood cells. The isolation protocol involved 3 main steps: I) Red blood cell lysis, 2) WBC 
Nuclei lysis and protein precipitation, and 3) DNA precipitation and rehydration. During the 
first step, red blood cells were lysed by mixing lysis solution obtained from the kit with blood 
samples of subjects. After mixing, the mixture was incubated for I 0 minutes, then centrifuged 
for I 0 minutes at 2000g, discarding the supernatant. As part of the WBC Nuclei lysis and 
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protein precipitation step, nuclei lysis solution was added, followed by the protein precipitation 
solution. After vortexing, the mixture was centrifuged again at 2000g for I 0 minutes. Finally, as 
part of the DNA precipitation and rehydration step, the supernatant was retrieved into a new tube 
containing isopropanol and again centrifuged for 10 minutes at 2000g. The supernatant was 
discarded and 70% ethanol was added to the pellet for cleaning. The ethanol was aspirated and 
air dried for I 0-15 minutes. Using rehydration solution, the DNA was rehydrated for I hour at 
65EC. 
2.1.5.2 Genotyping 
Five single nucleotide polymorph isms (SNPs) in the gene coding for adiponectin were 
chosen for investigation. These SNPs were chosen to cover the entire length of the gene. The 
first was an intronic SNP (public ID, dbSNP: rs 182052 chromosome 3q27) which was an A/G 
SNP at the 5' end of the gene. The second was an A/G SNP chosen within the 3'UTR region of 
the gene (public ID, dbSNP: rs3774262). The third was a CIT SNP chosen downstream ofthe 
gene in the 3' Untranslated region (public ID, dbSNP: rs I 063537), as according to 
SNPbrowserTM 2.0 designed by Applied Biosystems (ABI). The fourth SNP (public ID: 
rs6773957) was an A/G SNP in the 3'Untranslated region, while the fifth SNP (public TD: 
rs I 063539) was a C/G SNP chosen further downstream in the 3 'Untranslated region. D' values 
for each of the SNPs were also calculated, noting that rsl 063537 is in almost perfect linkage 
with rs377426, while both are weakly linked with rs182052. Descriptions are located in Table 
45. 
Genotyping for each sample was completed using Taqman® validated SNP Genotyping 
assays from Applied Biosystems, foll owing the company's mandated protocol. For each 96 well 
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plate completed, a SNP assay mixture was created using 0.25j..Jl ofSNP assay solution combined 
with 2.5j..Jl of DNA Master solution. Sufficient amounts of assay were created to allow for 
2.75 j..Jl assay to be placed in each 96 wel l plate. In 91 ofthe 96 wel ls, 2.25 j..JL of DNA samples 
were added to the SNP assay mixture, with two non-translated controls (NTC) and three positive 
controls, one for each genotype (i.e . homozygous for SNPl , heterozygous, homozygous for SNP 
2). Each NTC only had 2.25 j..Jl of DNAase, RNAase free distilled water added into each well 
containing the assay mixture. The remaining concentrated SNP assay mixtures were stored at -
20EC. The p lates were then sealed with optical caps, vortexed and centrifuged briefly to ensure 
all the liquid was at the bottom. Plates were then pre-read on an AB I Prism 7000® sequence 
detection system (SDS). The plates were then placed in Eppendorf Mastercycler to undergo real-
time PCR. Settings were set for the reaction to undergo 4 1 cycles. The first cycle contained four 
main steps: I) 2 minutes at 50°C, 2) I 0 minutes at 95°C, 3) 15 seconds at 95 °C, and 4) I minute 
at 60°C. Steps three and four were repeated for the remaining 40 cycles. The total length for 
DNA amplification time would be 2 hours and 15 minutes. Once amplification was completed, 
the plates were post-read in the ABI prism 7000. 
Each SNP assay mixture consisted of2 probes: VIC and FAM. The probe for allele I is 
labelled at its 5' end with VIC dye, while the 5' end of a lle le 2 was labelled with the FAM dye. 
At the 3' end of both probes is a non-fluorescent quencher which allows the reporter dyes (VIC 
and F AM) to be detected more accurately. Each Taqman probe binds to its complementary 
sequence on the forward and reverse primer sites. For intact probes, reporter dye proximity to 
the quencher dye results in suppression of the reporter fluorescence primarily by Forster-type 
energy transfer (Forster, 1948). Once bound, AmpliTaq Gold® DNA polymerase cleaves only 
to probes that are hybridized to the target, separating the reporter dye from the quencher dye and 
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resulting in a fluorescent signal. However, this is only increased ifthe amplified DNA sequence 
is complementary to the probe. Through PCR amplification, the generated fluorescence signal is 
sufficient to determine the a llele(s) present. The process is presented diagrammatically in Figure 
3 (Obtained from AB I, Adapted from Livak, Flood, Marmara, Giusti , & Deetz, 1995). 
2.1.6 Statistical Analysis 
All statistical analysis was conducted using either R statistical software or SPSS 19.0 
(SPSS Inc., Chicago, IL, USA). Chi-square analysis with one degree of freedom was used to test 
for Hardy-Weinberg proportions. Multiple regression analysis using an allele dosage or additive 
model (i.e. 2 copies of a minor allele doubles the protective effect compared to having just one 
copy) was used to assess the association between adiponectin SNP variants and body 
composition and bone mineral density. Smoking status, medication usage, menopausal status, 
sex, and age were all used as covariates in the regression. The association analysi s was 
conducted through regression at the markers with gender, age, smoking, and medication status as 
covariates. Significance was assessed via bootstrap with I 00,000 resamples. Prior to any 
analysis, triglycerides, insulin, HOMA-IR and HOMA-B were log transformed to reach a normal 
distribution. Hypotheses regarding the effect of adiponectin genotypic variants on the 
parameters measured were two-sided and a P-value of0.05 was used as the threshold for 
significance. A power calculation for the data and disequilibrium coefficients was also 
calculated. 
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Figure 3. A diagrammatic repr_esentation ofthe TaqMan probe system from ABI (adapted from Livak eta!., 1995). 
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2.2 Overfeeding study 
2.2.1 Recruitment of Volunteers 
Similar to the association study recruitment, volunteers were recruited from the St. John' s 
area in the province of Newfoundland and Labrador, Canada. Young males were recruited for the 
study through solicitation, word-of-mouth, poster distribution and the incentive of free meals for 
one week. Volunteers who were interested in participating in the study were al lowed to do so 
provided they followed the criteria: I) subjects were male; 2) their ages ranged between 19-29; 
3) they are at least third generation Newfoundlanders with at least one grandparent born in 
Newfoundland; 4) they are healthy, without any serious metabolic, cardiovascular and/or 
endocrine conditions; 5) they are not on any medication for lipid metabolism; and 6) they have 
reported a stable weight (\7'5 pounds) within the previous six months. Only healthy young men 
were recruited for the study because literature showed that the potential risk of injury due to 
overfeeding in younger individuals is small (Tremblay, Despres, Theriault, Fournier, & 
Bouchard, 1992; Robertson, Henderson, Yist, & Rumsey, 2004). As in the association study, 
each volunteer completed a screening questionnaire, a physical activity form, and a dietary 
questionnaire prior to beginning overfeeding. These forms, in addition to the study design, were 
approved by the Human Investigation Committee of Memorial University ofNewfoundland and 
Labrador. 
2.2.2 Plasma and Serum Samples extraction 
The same method was applied for the plasma and serum samples extraction as in the 
association study. Pre-overfeeding samples were obtained the morning prior to beginning the 7-
day overfeeding regime after a 12 hour fast, and post-overfeeding samples were obtained 
typically on the morning ofthe eighth day, after a 12 hour fast from their last meal. 
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2.2.3 Body Composition measurements 
A similar protocol was followed as was conducted with the association study. Prior to 
the 7-day overfeeding regimen, subjects would arrive after a 12 hour fast the morning prior to 
beginning overfeeding. Pre-overfeeding measurements were obtained in the same manner as the 
association study, with the same measurements being taken. A second set of post-overfeeding 
measurements was taken on the eight day, the morning after the final day of overfeeding. 
2.2.4 Overfeeding protocol 
Multiple studies have employed either long-term or short-term overfeeding intervention 
methods in an effort to investigate the metabolic and biochemical responses of individuals 
(Bouchard et al, 1990; Jebb eta!. , 1996; Katezeff & Danforth., 1989; Chin-Chance, Polonsky, & 
Schoeller, 2000). Although many short-term overfeeding strategies have been implemented, 
there is limited consistency between studies as to what length of time is standard for short-term 
overfeeding, with study lengths often ranging between 12 hours to 22 days (Chin-Chance et al. , 
2000; Jebb et al, 1996; Kashiwagi eta!., 1985). However, some have argued that overfeeding 
periods should be long enough to expect an increase in body weight in excess of changes due to 
bowel contents and edema (Joosen & Westerterp, 2006). In this instance, a 7-day overfeeding 
intervention was chosen as an adequate length of time to induce changes in adipose tissue gene 
expression levels, in addition to overall body composition. 
The degree of macronutrient intake has also varied greatly. Previous studies have 
overfed subjects between 30% and I 00% above baseline energy intake levels for a given 
individual (Bouchard et al., 1990; Kashiwagi et al. , 1985). As similarly stated by Joosen and 
Westerterp (2006), pertaining to the length of short-term overfeeding, the same argument can be 
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made for a degree of overfeeding above baseline. Adequate levels should be achieved to ensure 
increased adipose tissue gene expression level changes, as well as changes in overall body 
composition. However, they should be enough to limit the risk to the individuals undergoing the 
study and for this reason, 70% overfeeding was chosen for this study. 
Many types of diet have also been used in overfeeding interventions. Some studies have 
used high fat diets, others have used high carbohydrate and protein diets, while others have 
chosen a mixed diet. In an effort to mimic the common North American diet, a mixed diet was 
chosen for this study. 
In terms of overfeeding intervention design, the study can be conducted in an inpatient or 
outpatient form. Previous studies have argued that the most ideal and reliable studies are those 
conducted in a controlled environment (i.e. a research institute) during the entire study (Joosen 
& Westerterp, 2006). However, it is agreed that those types of studies are disadvantaged in that 
results cannot be effectively extrapolated to other real world situations (Joosen & Westerterp, 
2006). Since this study aimed to model North American style eating as frequently as possible, it 
was decided to undergo the protocol in an outpatient form. 
Baseline energy intake measurements were collected in three forms: I) three 24-hour diet 
recall questionnaires, 2) completion of a 30-day dietary inventory, and 3) estimation of total 
energy expenditure by an Actical™ physical activity level monitor (Mini Mitter Co., Inc. Bend, 
OR, USA). The monitor was placed for the week prior to overfeeding to obtain the energy 
expenditure measurements. The baseline energy intake measurements were calculated by 
averaging the three 24 hour recalls, the 30-day dietary inventory and the energy expenditure 
value obtained by the Actical. Individuals then started on a 7-day regimen of overfeeding (1-7 
days, with the 8111 day subjects arriving for their fasted post-overfeeding measurements). The 
macronutrient compositions of the diets were kept stable at 50% carbohydrates, 35% fat, and 
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15% protein. Meals were purchased from restaurants including McDonald ' s, Extreme Pita, Tim 
Horton's, Swiss Chalet, Wendy's, A&W, Dairy Queen, Kentucky Fried Chicken, Subway, and 
Pizza Hut for which nutritional information of the food was available. Calorie intakes for 
protein, carbohydrates, fiber, total fat, saturated fat and cholesterol were as follows: 2969 kcal, 
I 06g, 394g, 19g, I 05g, 38g, and 304mg per day at baseline and 5471 kcal, 178g, 713g, 33g, 
221 g, 71 g and 735 mg per day during overfeeding. Subjects received their food everyday for 
breakfast at 9:00a.m., lunch at 12:00 p.m., and supper at 5:00p.m. During each meal, someone 
was present to ensure that all the food was consumed. In addition, physical activity levels were 
monitored during the week of overfeeding using the Acticat™, to ensure the same pattern of 
physical activity as with the week pre-overfeeding was maintained. The variation in physical 
activity between baseline measurements and the overfeeding period was controlled below 15%. 
During overfeeding, subjects were asked to abstain from any alcoholic or additional calorie-
containing beverages (outside those provided). The energy values and macronutrient content of 
the intakes ofthe volunteers were computed using the Food Processor SQL version 9.5.0.0 
(ESHA Research, Salem, OR, USA). 
2.2.5 Serum biochemical measurements 
Glucose, total cholesterol, high-density lipoprotein (HDL-c), triglycerides (TGs), 
calcium, magnesium, albumin and insulin serum concentrations were measured in the same 
manner as the association study. Serum adiponectin levels were measured in duplicate with 
human adiponectin enzyme immunometric assay (ELISA; Phoenix Pharmaceuticals, Belmont, 
CA, USA) performed on an Alisei Quality System (SEAC Radim Group, Pomezia, Italy). Each 
96 well-immunoplate was pre-coated with Anti-human Adiponectin Capture antibody and had 
the non-specific binding sites blocked. Reagent preparation involved fifty milliliters of 
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concentrated assay buffer being diluted 20x with 950 ml of distilled water and then stored at 
4EC. The biotinylated anti-human adiponectin detection antibody was then rehydrated with 
I OO<DI of I x Assay buffer (tubes were centrifuged to dislodge powder from the cap or the tube 
walls) . This was then further diluted to I :250. 30 IJL ofStreptavidin-horseradish peroxidase 
was centrifuged at 4,000 rpm for 5 seconds and further diluted with lx assay buffer to I :2000 
before use. 
Human adiponectin standard preparation was then prepared. Recombinant human 
adiponectin standard was rehydrated with 1 ml of I x Assay buffer, and the solution was allowed 
to sit for at least 10 minutes at 22 ·c (room temperature) to ensure the IOOng/vial of standard was 
completely dissolved. Serial dilutions were prepared from the stock solution in the following 
concentrations: I OOng/ml, I Ong/ml, 5ng/ml, 2.5ng/ml, 1.25ng/ml, 0.625ng/ml, 0.312ng/ml and 
0.156ng/ml. These were used to make a standard curve for comparison. I OOIJL of prepared 
human adiponectin standard was then added in reverse order of serial dilution, and these were 
used in duplicate. Diluted I 001-JL samples obtained from study subjects were then added in their 
designated wells. The immuoplate was then sealed with an acetate plate sealer and incubated for 
2 hours at 22·c (room temperature) on a plate shaker at 350 rpm. The acetate seal was removed 
and the liquid was discarded from the wells. Each well was washed with 300-3501-JL of Assay 
buffer four times. I OOIJL of biotinylated anti-human adiponectin detection antibody was added 
into each well and resealed into the immunoplate with the acetate plate sealer and incubated for 2 
hours at 22EC on an acetate plate shaker at 350 rpm. A second four time wash was performed 
with I x Assay buffer as previously described. Following the second wash, I OOIJL of 
streptadivin-hoarseradish peroxidase solution was added into each well and resealed and 
incubated for 30minutes on a plate shaker at 350rpm. I 00 IJL of light sensitive substrate 
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solution was added to each well and incubated from the light at room temperature of20-30 
minutes on the plate shaker. Finally, 100 j.JL of2N HCl was added to stop the reaction, inducing 
a color change from blue to yellow. The intensity of the color is directly proportional to the 
amount of human adiponectin with known concentration. The plate was allowed to sit for 20 
minutes, and finally, the optical density absorbency readings were measured at 450nm on the 
Alisei Quality System (SEAC Radim Group, Pomezia, Italy). 
Human adiponectin in the samples binds to the captured antibody immobilized in the 
wells. The biotinylated anti-human adiponectin detection antibody then binds to the adiponectin 
bond to the anti-adiponectin in order to capture antibodies at the bottom of the plate. The 
Streptavidin-horseradish peroxidase catalyzes and binds to biotin bound to the Fe portion ofthe 
anti-adiponectin antibody, inducing the color change from blue to yellow. 
2.2.6 Genomic Extraction and Genotyping 
The genomic extraction and genotyping followed the same method as the association 
study. 
2.2. 7 Statistical Analysis 
Data that was obtained that was not normally distributed was logarithmically transformed 
to approximate a normal distribution for subsequent analysis. These variables included 
concentrations of triglycerides, insulin, and HOMA-IR and HOMA-~ changes at baseline and 
overfeeding. The Homeostasis model assessment (HOMA) was used as a measure of insulin 
resistance (HOMA-IR = insulin (j.JU/ml) x glucose (mmol/L)/22.5)) and 13-cell function 
(HOMA- 13 = 20* insulin (j..JU/ml)/(glucose-3 .5) (Matthews eta/. , 1985). To evaluate the effect 
adipocity had on ad iponectin concentrations, subjects were classified according to their adiposity 
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status. The analysis was conducted using on ly percentage body fat instead of body mass index 
(kg/m2). This was done because of increasing inaccuracy with the use of BMI. The men aged 
20-39 were c lassified as normal, overweight and obese as per Bray (2003) classification. The 
analysis conducted involved comparing physical and biochemical characteristics between the 
three different body fat categories. The comparisons were completed using a one-factor analysis 
of variance with a bonferroni correction. The before and after overfeeding changes were tested 
using a general linear model. The differences among the three groups were conducted using a 
general linear model by including the baseline covariates in the same model. Multiple 
comparison adjustments were performed w ith a post hoc Tukey test. Pearson correlation 
analysis was performed to screen for potential factors related to fasting serum concentrations of 
adiponectin. A multiple regression analysis was used to assess factors in prediction fasting 
serum ad iponectin concentrations. These variables in the model specifically included percentage 
body fat, glucose level, insulin level, triglyceride level, HOMA-IR and HOMA- j3. Baseline 
data and the change in variables after the 7 day overfeeding were also assessed. Statistical 
analysis was conducted using SPSSS vers ion I 9.0 (SPSS Inc., Chicago, IL USA) for all analysis . 
Statistical analysis was two-sided and a p-value of <0.05 was used to determine statistical 
s ignificance. 
Page 68 of 167 
3.0 Results 
3.0.1 Association Study Results 
The general descriptive statistic results for the entire cohort used in this analysis are 
shown in Tables 1-3. A total of I ,811 subjects enrolled in this study, with 403 males and I ,408 
female subjects (Table 3). The mean ages for all male and female subjects in the study were 41 
and 44 respectively (Table 3). The average height and weight for male subjects were 175.47cm 
and 84.64 kg respectively, whereas for female subjects they were 162.1cm and 69.65 kg 
respectively (Table 3). The average male total percentage body fat was 25.7% for all males 
whereas in females the total percentage body fat was 37.68%. This was significantly different 
(p<O.OO I). Total bone mineral density, lumbar spine density (L2-L4) and left femoral neck/hip 
BMD are reported in Table I. Total BMD, Spine BMD and Left Hip BMD were significantly 
greater in males when compared with females (p<O.OO I, Table 3). Body-mass index (BM I) was 
also found to be significantly higher in males than in females (p<O.OO I, Table 3). Waist-Hip 
ratio were also recorded and were found to be significantly higher in males as compared with 
females (p<O.OO I). 
Baseline laboratory data are also reported in Tab le 4. Phosphate levels, cholesterol and 
HDL levels were significantly elevated in females, while glucose, calcium, albumin, GGT, 
logarithmic-transform for triglycerides, insulin, and HOMA-insulin resistance were more 
elevated in males. Triglyceride/HDL ratio was also found to be significantly higher in males 
than in females. The comparison data of bone mineral density and body mass composition 
between males and females is reported in Table 5. Women displayed significantly higher 
percentage trunk fat as compared with men. Men however displayed significantly higher arm 
BMD, lumber BMD and total BMD. 
Tables 6-8 compare premenopausal and postmenopausal women. Premenopausal 
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women had significantly higher total, arm, leg, rib, pelvis, lumbar and left hip BMD, as well as 
being taller. Premenopausal women had significantly higher logarithmic transform HOMA-~ 
function (Table 7). Postmenopausal women had significantly higher total arm, leg and trunk 
percentage body fat, weight, waist and hip length. Glucose, phosphate, calcium, cholesterol, 
triglyceride, GGT, LDL, logarithmic insulin, HOMA-IR and triglyceride levels, and 
triglyceride/HDL ratio were significantly higher in postmenopausal women. 
When separating the cohort into individuals that were taking any medication versus those 
who were not taking medication, non-medication users were significantly older, with 
significantly increased total percentage body fat, arm fat, leg fat, trunk fat and BMI (Table 9). 
However, total arm, leg, trunk, spine, pelvis and left hip BMD were significantly elevated in 
medication users (Table 9 and II). Albumin and magnesium levels were significantly elevated 
in medication users, while glucose and the logarithmic transform of insulin and triglyceride 
levels, HOMA-IR, and HOMA-~ were significantly elevated in non-medication users (Table I 0). 
The cohort was further divided by gender into those individuals taking medication (Table 12-17). 
In both males and females, the majority of the same relationships held for those individuals 
taking medications and for those not taking medications (Table I 0-1 2). 
The cohort was then divided into subjects who smoked versus those who were non-
smokers. A total of 222 smokers were in the cohort versus 1573 non-smokers (Table 18). Non-
smokers were found to be significantly older and to have significantly elevated total , spine and 
left hip BMD, as well as significantly elevated HDL levels (Table 18-20). Smokers, however, 
were found to have significantly elevated triglyceride, risk factor, and triglyceride/HDL ratio 
(Table 19). The cohort was further subdivided by gender and smoking status (Table 21-26). 
Smoking males had significantly elevated total BMD, arm BMC and leg BMC when compared 
with non-smoking males (p<0.05, Table 21 and Table 23). However, non-smoking females were 
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found to be significantly older and taller with significantly elevated total, spine, leg and left hip 
BMD (Table 24). They had significantly elevated leg percentage body fat and gynecoid fat, 
glucose and HDL level (Table 26). Smoking females were found to have significantly elevated 
triglyceride levels and elevated triglyceride/HDL level (Table 25). 
A one-way ANOV A analysis was conducted factoring for Bray percentage body fat 
categories of lean, overweight and obese for the entire cohort, then factoring for gender (Table 
27-35). The normal/ underweight group was significantly younger when compared to the 
overweight and obese groups (Table 27). Total body, spine, rib, pelvis and left hip BMD were 
significantly elevated in obese subjects as compared with overweight and normal/underweight 
individuals (Table 27 and 29). Glucose, insulin, HOMA-IR and HOMA-~ showed a significant 
steady increase among the three groups of underweight/normal, overweight and obese 
individuals (Table 28). Cholesterol, LDL and triglyceride levels were significantly lower in 
normal/underweight subjects. HDL levels showed a significant steady decrease as individuals 
increased in percentage body fat (Table 28). When factoring for gender, normal/underweight 
males had significantly elevated arm, pelvis and total bone mineral density. They also had 
significantly decreased glucose, cholesterol, triglyceride, and magnesium levels. Insulin, 
HOMA-IR and HOMA-~ showed a significantly steady increase from normal/underweight to 
overweight to obese males (Table 31 ). Obese females were found to have significantly elevated 
total arm, leg, trunk, spine, pelvis, and left hip BMD (Table 33 and 35). Similar laboratory 
results were shown among female subjects as with male subjects. Glucose, insulin, HOMA-IR 
and HOMA-~ and triglycerides showed a significant steady elevation from normal/underweight 
to obese females (Table 34). HDL levels showed a significant steady decrease in the three 
groups (Table 34). 
A similar one-way AN OVA analysis was conducted to see if similar findings could be 
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found when factoring for WHO BMI categories and gender (Table 36-44). Total arm, leg, trunk, 
pelvis and left hip BMD significantly increased between each group from no rmal/underweight 
individuals, overweight, to obese (Table 36 and Table 38). Glucose, insulin, HO MA-IR, 
HOMA-~ and trig lycerides showed a significant steady elevation among a ll three groups (Table 
37). HDL levels aga in showed a steady decrease among the groups (Table 37). The same 
re lationships he ld when the analys is factored for gender in both females and males (Tables 39-
44). 
Figure 4 shows the overall sample-size power calculation for the data set, showing that 
this sample size was adequately powered. It illustrates the power profi les as a function of 
varying coefficients of determ ination for a range of heri tabili ty estimates. Tab le 45 shows a 
summary of the single nuc leotide polymorphisms, a lle lic frequencies and whether if the re are 
any SNPs in Hardy-Weinberg equilibrium . Table 46 shows the linkage disequil ibrium (LD) 
analys is as an estimate of the variants. 
Multiple regression analysis for the fi ve SNPs analyzed was conducted . Each SNP 
frequency was analyzed for bone minera l density and for percentage body fat with and without 
factoring for specific confounding variables inc luding gender, smoking, age, medication status 
and smoking. These results have been displayed in Tables 47-5 1. Significance was noted in 
total bone mineral density for SNP rs6773957 when factored fo r age. However, no significance 
was found in any SNP when assess ing for spine or left hip bone minera l density. 
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Table 3. The descriEtive statistics for the entire cohort, male and female subjects. 
Entire Cohort Male Female 
n Mean SD n Mean SD n" Mean SD p 
Age 18 11 43.68 ± 11.87 403 41.00 ± 14.1 1408 44.47 ± 11.0 0 .000 Female 
Weight (kg) 1808 73.00 ± 15.45 401 84.64 ± 14.0 1407 69.65 ± 14.2 0.000 Male 
Height (em) 1808 165.07 ± 8. 14 401 175 .47 ± 6.4 1407 162.10 ± 5.8 0.000 Male 
Waist (em) 1785 92.44 ± 14.23 389 97.86 ± 12.2 1396 90.93 ± 14.4 0.000 Male 
Hip (em) 1783 102.25 ± 11.1 7 388 101.31 ± 9 .1 1395 102.49 ± 11.7 NS 
Percentage Body Fat 1805 34 .97 ± 9.03 400 84.42 ± 13.9 1405 68.76 ± 14.0 0 .000 Male 
Percentage Trunk Fat 1805 36.93 ± 9.39 400 25 .37 ± 7.6 1405 37.68 ± 7.4 0 .000 Female 
Total Bone minera l density (BMD) 1803 1.18 ± 0. 10 400 30.1 5 ± 8.9 1403 38.84 ± 8 .6 0.000 Female 
Spine BMD 1806 1.2 1 ± 0.1 6 400 1.26 ± 0.1 1406 1.1 6 ± 0. 1 0.000 Male 
Left Hip BMD 1709 0.97 ± 0. 13 360 1.26 ± 0.2 1349 1.20 ± 0.2 0 .000 Male 
BMI 12 12 26.74 ± 5.09 282 5.78 ± 0.9 930 4.60 ± 0.7 0 .000 Male 
Waist-HiE Ratio 1793 0.90 ± 0.08 400 0.09 ± 0 .3 1393 0.00 ± 0.2 0.000 Male 
P-values at the end of table indicate if there is a significant difference between both the male and female genders. The last column indicates wh ich gender is greater for that 
measurement (e.g. average age of the female cohort is significantly higher than that of males). n, n' and n" refer to the total number of individuals, males and females in the 
cohort for a specitic measurement respectively. NS- Not significant ifp-value is less than 0.5. 
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Table 4. The baseline laboratory values, HOMA-IR, and HOMA-P for the entire cohort, male and female subjects. 
Entire Cohort Male Fema le 
N Mean SD n' M ean SD n" Mean SD p 
Glucose 267 5. 13 ± 0.95 72 0.0 1 ± 0.1 195 0.0 1 ± 0. 1 NS 
Phosphate 1793 1.19 ± 0.18 400 5.30 ± 1.1 1393 5.08 ± 0.9 0.000 M ale 
Calcium 1713 2.35 ± 0.1 2 369 1.1 3 ± 0.2 1344 1.20 ± 0.2 0.000 Fema le 
A lbumin 1717 4 1.30 ± 3.85 374 2.36 ± 0. 1 1343 2.34 ± 0. 1 0.002 Male 
C ho les tero l 17 12 5. 17 ± 1.05 369 42.71 ± 4.0 1343 40.92 ± 3.7 0.000 M ale 
T rig lycerides 1793 1.23 ± 0.79 400 5.05 ± 1.1 1393 5.2 1 ± 1.0 0.007 Female 
M agnesium 1793 0.88 ± 0.09 400 1.49 ± 1.0 1393 1. 15 ± 0.7 0.000 M ale 
HDL 1713 1.49 ± 0.38 369 0.89 ± 0.1 1344 0.88 ± 0. 1 N S 
GGT 1794 19.93 ± 24.1 I 400 1.24 ± 0.3 1394 1.56 ± 0.4 0.000 Fema le 
LDL 1207 3.12 ± 0.90 29 1 25.77 ± 21.0 916 18.07 ± 24.7 0.000 M ale 
Risk Factor 1793 3.63 ± 1.03 400 3.10 ± 0.9 1393 3. 12 ± 0.9 NS 
Buc he 1793 9229.50 ± 2710.56 400 4 .20 ± 1.1 1393 3.47 ± 0.9 0.000 M ale 
Corrected BUCH E (SI Units) 1339 5613.57 ± 5422.55 296 10134.87 ± 2557.4 1043 8973.55 ± 2704.8 0.000 M ale 
Insulin 296 72.09 ± 66.48 46 5609.56 ± 6195.4 250 5636.73 ± 528 1.2 NS 
HOMA-~ 1808 139.81 ± 236.64 40 1 27.50 ± 4.4 1407 26.52 ± 5.3 0.00 1 M ale 
HOM A-IR 1668 2.48 ± 3. 15 362 139.39 ± 142.9 1306 139.87 ± 257. 1 NS 
T riglyceride!HDL ra tio 1670 0.93 ± 0.77 363 2.82 ± 3.6 1307 2.39 ± 3 .0 0.022 M ale 
Log Insulin 1793 1.78 ± 0.25 400 1.32 ± 1.0 1393 0.82 ± 0.6 0.000 Male 
Log HOMA-IR 167 1 0.29 ± 0.28 363 1.81 ± 0.3 1308 1.77 ± 0.2 0.00 1 Male 
Log HOMA-~ 1670 2.06 ± 0.26 363 0.34 ± 0.3 1307 0.27 ± 0.3 0.000 Male 
Log Triglycer ide 1666 0.02 ± 0.24 362 2.05 ± 0.3 1304 2.07 ± 0.3 NS 
Waist-Hi~ Ratio 1793 0.90 ± 0.08 400 0.09 ± 0.3 1393 0.00 ± 0.2 0.000 Male 
P-values at the end of table indicate if there is a significant difference between both the male and female genders. The last column indicates which gender is greater for that 
measurement (e.g. average blood glucose of the female cohort is signi ficantly higher than that of males). n, n' and n" refer to the total number of individuals. males and females in 
the cohort for a specific measurement respectively. NS- Not s ignificant ifp-value is less than 0.5. 
Table 5. Baseline cohort bone density and Body composition data for the entire cohort. 
Total Arm BMO 
Total Leg BMO 
Trunk BMO 
Total Rib BMO 
Total Pelvis BMO 
Total BMO 
Arm %Fat 
Arm tissue 
Arm Fat weight(g) 
Arm Lean muscle mass (g) 
Arm Bone M ineral Composit ion 
Leg% Fat 
Leg Tissue weight(g) 
Leg Fat weight (g) 
Leg lean muscle mass(g) 
Leg bone minera l composition 
T runk %Fat 
Trunk T issue weight (g) 
Trunk Fat weight (g) 
Trunk lean m uscle mass (g) 
Trunk bone mineral composition 
Android % fat mass 
Android tissue mass (g) 
Android Fat mass (g) 
Android lean musc le mass (g) 
Android BMC 
Gynecoid% Fat 
Gynecoid t issue mass (g) 
Gynecoid fat mass (g) 
Gynecoid lean muscle mass (g) 
Gynecoid BMC 
n 
167 1 
1804 
1805 
1805 
661 
66 1 
1802 
1803 
1804 
1804 
1804 
1803 
1805 
1805 
1805 
1804 
1804 
1804 
1805 
1805 
1805 
1805 
1799 
1800 
1800 
1800 
1800 
1800 
1800 
1800 
1800 
Enti re Cohort 
Mean so 
0.92 ± 0. 14 
1.28 ± 0. 14 
0.94 ± 0.09 
0.68 ± 0.08 
1. 16 ± 0. 13 
1.1 8 ± 0.10 
34.95 ± 12.22 
8000. 14 ± 2830.77 
2998.27 ± 1872.65 
5004.7 1 ± 1762.54 
343 .59 ± 89.57 
34.86 ± 9.85 
22479.56 ± 4557.82 
824 1.9 1 ± 3203.21 
14235 .58 ± 3480.80 
975.53 ± 20 I. 78 
36.97 ± 9.36 
35 189.55 ± 9039.9 1 
13654.22 ± 5777.29 
21555.96 ± 5344.13 
792.99 ± 187.17 
42.36 ± 11 .00 
5432.4 1 ± 1715.68 
2436.3 1 ± 1230.20 
2998.08 ± 730.59 
53.23 ± 11.80 
41.35 ± 9.46 
1133 1.66 ± 22 17.02 
4841.3 I ± 164 1 .42 
6489.78 ± 1527.99 
276.69 ± 6 1.98 
n' 
363 
400 
400 
400 
176 
176 
400 
400 
400 
400 
400 
399 
400 
400 
400 
400 
400 
400 
400 
400 
400 
400 
397 
398 
398 
398 
398 
398 
398 
398 
398 
Male 
Mean so 
78.23 ± 58.5 
1.07 ± 0. 1 
1.43 ± 0. 1 
1.00 ± 0.1 
0.75 ± 0. 1 
1.24 ± 0. 1 
1.26 ± 0. 1 
20.04 ± 8.9 
9739.40 ± 2572.8 
2 163 .7 1 ± 1558.2 
7573.47 ± 1446.2 
468.2 1 ± 73.7 
21.8 1 ± 6.9 
25385.6 1 ± 4440.0 
5987.16 ± 2711.5 
1937 1.78 ± 2792.2 
1232.89 ± 179.2 
30.2 1 ± 8.9 
4 1465.82 ± 8842.4 
13264.46 ± 5601.8 
28 193 .8 1 ± 4994.1 
960.76 ± 208.3 
36.90 ± 
6451.95 ± 
2546.94 ± 
I 1.1 
1758.2 
1285.7 
3907.50 ± 686.3 
59.10 ± 13.1 
29.11 ± 7.9 
12518.3 1 ± 2 130.5 
3849.54 ± 15 11. 1 
8674.35 ± 1249.5 
n" 
1308 
1404 
1405 
1405 
485 
485 
1402 
1403 
1404 
1404 
1404 
1404 
1405 
1405 
1405 
1404 
1404 
1404 
1405 
1405 
1405 
1405 
1402 
1402 
1402 
1402 
1402 
1402 
1402 
1402 
1402 
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Female 
Mean so 
70.34 ± 68.6 
0.88 ± 0.1 
1.24 ± 0. 1 
0.92 ± 0.1 
0.65 ± 0.1 
1. 13 ± 0.1 
1. 16 ± 0.1 
39.18 ± 9.4 
7499.98 ± 2704.7 
3232.40 ± 1887.9 
4271.87 ± 991.7 
308.03 ± 55.5 
38.55 ± 7.0 
2 1638. 13 ± 4229.4 
8872.59 ± 3024.8 
12769.43 ± 1917.0 
90 1.81 ± 137.1 
38.87 ± 8.6 
33396.58 ± 8278.6 
13756.06 ± 5827.7 
19669.24 ± 3676.0 
744.53 ± 148.9 
43 .88 ± 10.5 
5141.47 ± 1590.9 
2403.00 ± 1213 .8 
2740.32 ± 500.7 
5 1.47 ± 10.7 
44.80 ± 6.5 
10989.31 ± 2 123.5 
5117.45 ± 156 1.9 
5869.53 ± 903 .0 
p 
0.046 
0.000 
0.000 
0.000 
0.000 
0.000 
0.000 
0.000 
0.000 
0.000 
0.000 
0.000 
0.000 
0.000 
0.000 
0.000 
0.000 
0.000 
0.000 
NS 
0.000 
0.000 
0.000 
0.000 
0.039 
0.000 
0.000 
0.000 
0.000 
0.000 
0.000 
Male 
Male 
Male 
Male 
Male 
Male 
Male 
Female 
Male 
Female 
Male 
Male 
Female 
Male 
Female 
Male 
Male 
Female 
Male 
Male 
Male 
Female 
Male 
Male 
Male 
Male 
Female 
Male 
Female 
Male 
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Tota l % body fat 1800 34.97 ± 9.0 1 398 346.94 ± 59.0 1402 256.52 ± 46.1 0.000 
Total ti ssue mass (g) 1805 69974.20 ± 185 12.45 399 25 .39 ± 7.5 1406 37.67 ± 7.4 0.000 
Tota l fat mass (g) 1805 25675.62 ± I 0044.0 1 399 8 13 17.38 ± 13714.4 1406 6673 1.1 2 ± 18450.4 0.000 
Total lean muscle mass (g) 1805 44048.60 ± 10152.68 399 22095.04 ± 9 144.0 1406 26667.48 ± 10055 .3 0.000 
Total Bone Minera l Composition 1805 2588 .08 ± 459.69 399 59222.43 ± 7546.6 1406 39741.99 ± 5686.2 0.000 
L2-L4 (Z-Score) 1804 0 .22 ± 1.26 399 84.45 ± 13.9 1405 68.79 ± 14.2 0.000 
L2-L4 BMC 1226 53 .64 ± 11.04 280 0. 15 ± 1.3 946 0.24 ± 1.2 NS 
Femoral Neck (Z-Score) 1238 0. 10 ± 0.93 287 62 .88 ± I 1.2 95 1 50.86 ± 9.3 0.000 
Neck BMC 11 93 4.87 ± 0.89 270 0 .00 ± 0.9 923 0. 13 ± 0.9 0.04 1 
P-values at the end of table indicate if there is a significant difference between both the male and female genders. The last column indicates which gender is greater for that 
measurement (e.g. average %body fat of the female cohort is significantly higher than that of males). n, n' and n" refer to the total number of individuals, males and females in 
the cohort for a specific measurement respectively. NS- Not significant if p-value is less than 0.5. 
Male 
Female 
Male 
Female 
Male 
Male 
Male 
Female 
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Table 6. The baseline descriptive characteristics for Pre- and Post-menopausal females. 
Pre-Menopausal Post-Postmenopausal 
n Mean SD n' Mean SD p 
Age 790 38.88 ± 9.0 548 52.75 ± 8.1 0.000 Post 
Weight (kg) 790 68.73 ± 13.4 547 70.61 ± 14.7 0.0 15 Post 
Height (em) 790 162.78 ± 5.6 547 160.87 ± 5.8 0.000 Pre 
Waist (em) 785 88.60 ± 13.4 545 94.18 ± 15.1 0.000 Post 
Hip (em) 785 I 01.08 ± 11.3 544 104.50 ± 11.8 0.000 Post 
Total %Body Fat 790 36.48 ± 7.5 546 39.5 1 ± 6.9 0.000 Post 
Total %Trunk Fat 790 37.23 ± 8.7 544 41 .26 ± 7.9 0.000 Post 
Total BMD (g/em2) 790 1.17 ± 0. 1 546 1.14 ± 0.1 0.000 Pre 
Spine BMD 755 1.24 ± 0. 1 526 1.1 6 ± 0.2 0.000 Pre 
Left Hip BMD 756 0.98 ± 0. 1 525 0.91 ± 0.1 0.000 Pre 
P-values at the end of table indicate if there is a significant difference between both the premenopausal and postmenopausal females. The last column indicates which gender is 
greater for that measurement (e.g. age of post-menopausal females is significantly higher than that of premenopausal females). Pre- refers to premenopausal subjects, whereas post-
re fers to post-menopausal subjects. n and n ' re fer to the total premenopausal and postmenopausal females for a specific measurement respectively. NS- Not significant if p-value 
is less than 0.5. 
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Table 7. Baseline labo ratory values, HOMA-IR, and HOMA-P for pre-menopausal and post-menopausal female subjects. 
n 
Glucose 783 
Phosphate 755 
Calcium 754 
Albumin 755 
Cholesterol 784 
Triglycerides 784 
Magnesium 755 
HOL 784 
GGT 489 
LOL 784 
Risk Factor 784 
Buche 6 16 
Corrected Buche (S1 Units) 159 
Insulin 736 
HOMA-~ 734 
HOMA-IR 735 
Triglyceride!HOL ratio 784 
Log Insulin 736 
Log HOMA-IR 735 
Log HOMA-~ 733 
Pre-Menopausal 
Mean so 
4.93 ± 0.7 
I. I 8 ± 0.2 
2.32 ± 0.1 
40.89 ± 3.8 
4.97 ± 0.9 
1.04 ± 0.7 
0.88 ± 0.1 
1.58 ± 0.4 
14.55 ± 9. 1 
2.91 ± 0.8 
3.27 ± 0.8 
8487.06 ± 2572.4 
5750.26 ± 5030.0 
65. 19 ± 44.7 
146.15 ± 180.9 
Post-Postmenopausal 
n' Mean SO 
543 5.29 ± 1. 1 
524 1.23 ± 0.2 
524 2.36 ± 0. 1 
523 
542 
542 
524 
543 
40.79 ± 3.5 
5.53 ± 1. 1 
1.30 ± 0.7 
0.88 ± 0.1 
1.55 ± 0.4 
394 2 1.86 ± 34.9 
542 3.39 ± 0.9 
542 3.73 ± 1.0 
370 
71 
507 
507 
9726.06 ± 2714.2 
5383 .12 ± 5832.2 
76.77 ± 93.5 
130.08 ± 349.2 
2. 13 ± 1.7 507 2.74 ± 4.3 
0.73 ± 0.6 542 0.93 ± 0.7 
1.75 ± 0.2 507 1.79 ± 0.3 
0.24 ± 0.3 507 0.3 1 ± 0.3 
p 
0.000 Post 
0.000 Post 
0.000 Post 
NS 
0.000 Post 
0.000 Post 
NS 
NS 
0.000 Post 
0.000 Post 
0.000 Post 
0.000 Post 
NS 
0.004 Post 
NS 
0.00 1 Post 
0.000 Post 
0.002 Post 
0.000 Post 
2.08 ± 0.2 506 2.04 ± 0.3 0.0 I I Pre 
Log Triglyceride 784 -0.04 ± 0.2 542 0.05 ± 0.2 0.000 Post 
P-values at the end o f table indicate i f there is a significant difference bet\veen both the premenopausal and postmenopausal females. The last column indicates which gender is 
greater for that measurement (e.g. average blood glucose in post-menopausal females is signi ficantly higher than that of premenopausal females). Pre- refers to premenopausal 
subjects, whereas post- re fers to post-menopausal subj ects. n and n' re fer to the total premenopausal and postmenopausal females for a specific measurement respectively. NS- Not 
significant ifp-value is less than 0.5. 
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Table 8. The baseline cohort bone density and body composition data for pre-menopausal and post-menopausal females. 
Pre-menopausal Post-menopausal 
n Mean SD n' Mean SD p 
Total Arm BMD 790 0.89 ± 0. 1 545 0.86 ± 0. 1 0.000 Pre 
Total Leg BMD 790 1.26 ± 0. 1 545 1.20 ± 0. 1 0.000 Pre 
Trunk BMD 790 0.93 ± 0. 1 545 0.90 ± 0. 1 0.000 Pre 
Total Rib BMD 235 0.66 ± 0.1 235 0.64 ± 0. 1 0.000 Pre 
Tota l Pelv is BMD 235 1. 15 ± 0. 1 235 l.ll ± 0.1 0.000 Pre 
Tota l BMD 789 1. 17 ± 0. 1 544 1.1 4 ± 0.1 0.000 Pre 
Arm %Fat 789 37.80 ± 9.7 545 41.32 ± 8.2 0.000 Post 
Arm tissue 790 7375. 11 ± 2690.8 545 7635.51 ± 2660.6 NS 
Arm Fat weight(g) 790 3095.54 ± 1928.7 545 342 1.61 ± 1763.8 0.002 Post 
Arm Lean muscle mass (g) 790 4283.4 1 ± 899.9 545 42 19.37 ± 1062.4 NS 
Arm Bone M ineral Composition 790 3 13.11 ± 50.3 545 298.73 ± 59.6 0.000 Pre 
Leg% Fat 790 37.97 ± 6.8 545 39.49 ± 6.9 0.000 Post 
Leg Tissue weight(g) 790 2 19 16.04 ± 4 148.5 545 2 1126.30 ± 4159.6 0.00 1 Pre 
Leg Fat weight (g) 790 8860.92 ± 3020.3 545 8864.12 ± 2957.1 NS 
Leg lean muscle mass(g) 790 13062.83 ± 1782.1 545 12262. 16 ± 1867.8 0.000 Pre 
Leg bone minera l composition 789 9 19.39 ± 133 .1 545 871.94 ± 132.0 0.000 Pre 
T runk %Fat 789 37.28 ± 8.7 545 4 1.25 ± 7.9 0.000 Post 
Trunk Tissue weight (g) 790 32368. 15 ± 7368.6 545 34675 .34 ± 9064.4 0.000 Post 
Trunk Fat weight (g) 790 12828.2 1 ± 5462.2 545 15045.63 ± 604 1.1 0.000 Post 
Trunk lean muscle mass (g) 790 19603.65 ± 3369.3 545 196 11.39 ± 3944.1 NS 
Trunk bone mine ral composition 790 768.54 ± 140.2 545 708.49 ± 151.7 0.000 Pre 
Andro id% fat mass 788 42.18 ± 11 .0 54 1 46.42 ± 9.1 0.000 Post 
Android tissue mass (g) 788 4941.46 ± 1533.3 541 5396. 13 ± 1585.2 0.000 Post 
Android Fat mass (g) 788 2234.88 ± 11 89.9 54 1 2632.75 ± 11 77.3 0.000 Post 
Android lean muscle mass (g) 788 2707.6 1 ± 467.7 54 1 2766.65 ± 526.4 0.032 Post 
Android BMC 788 52.97 ± 10.8 54 1 49.38 ± 10.6 0.000 Pre 
Gynecoid % Fat 788 44.48 ± 6.6 541 45.37 ± 6.2 0.0 13 Post 
Gynecoid tissue mass (g) 788 11 046.59 ± 2085.9 541 1084 1.27 ± 205 1.6 NS 
Gynecoid fat mass (g) 788 5 114.33 ± 1573.0 54 1 5100.66 ± 14 7 1.5 NS 
Gynecoid lean muscle mass (g) 788 593 1.97 ± 84 1.3 541 5735 .19 ± 9 15.5 0.000 Pre 
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Gynecoid BMC 788 259 .72 ± 45 .4 541 2 5 1.28 ± 46.5 0 .00 1 Pre 
Total % body fat 790 36.47 ± 7 .5 546 39.49 ± 6.9 0 .000 Post 
Total ti ssue mass (g) 790 65459.74 ± 13317.1 546 68247.68 ± 240 14.5 0 .007 Post 
Total fat mass (g) 790 25520.13 ± 9772.1 546 28241.68 ± 10064.0 0 .000 Post 
Total lean muscle mass (g) 790 39939.21 ± 506 1.7 546 39 178.27 ± 6065.9 0.0 13 Pre 
Total Bone Mineral Compositio n 790 2486.84 ± 3 12.5 546 2341.51 ± 322.4 0.000 Pre 
L2-L4 (Z-Score) 502 0.3 1 ± 1.2 403 0.18 ± 1.3 NS 
L2-L4 BMC 506 52.64 ± 9. 1 404 4 8.42 ± 9. 1 0 .000 Pre 
Femoral Neck (Z-Score) 488 0 .16 ± 0 .9 398 0.09 ± 0.9 NS 
Femoral Neck BMC 494 4.73 ± 0 .7 399 4.41 ± 0 .6 0 .000 Pre 
P-values at the end of table indicate if there is a significant difference between both the premenopausal and postmenopausal females. The last column indicates which gender is 
greater for that measurement (e.g. average blood glucose in post-menopausal females is significantly higher than that of premenopausal females). Pre- refers to premenopausal 
subjects, whereas post- refers to post-menopausal subjects. nand n' reter to the total premenopausal and postmenopausal females for a specific measurement respectively. NS-
Not significant ifp-value is less than 0.5. 
----~------------------ ------------
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Table 9. The baseline descriptive characteristics for the entire cohort of subjects on medication versus those who were not taking any 
medication. 
No Medicatio n Taking Medication 
n Mean SD n' Mean SD p 
Age 966 45.66 ± 12 .2 8 12 41.54 ± 10.8 0.000 Non-Med 
Weight (kg) 966 73.44 ± 16.1 809 72.29 ± 14.6 NS 
Height (em) 966 164.04 ± 7.4 809 166.11 ± 8 .5 0.000 Med 
Waist (em) 960 93 .97 ± 15.4 802 90.59 ± 12.3 0.000 Non-Med 
Hip (em) 959 103.41 ± 12.0 802 100.76 ± 10.0 0 .000 Non-Med 
Total %Body Fat 966 36.56 ± 8.3 807 33.21 ± 9.3 0 .000 Non-Med 
Total %Trunk Fat 965 38.56 ± 8.7 806 35. 16 ± 9.6 0.000 Non-Med 
Total BMD (g/cm2) 966 1.17 ± 0.1 807 1.19 ± 0 .1 0.000 Med 
Spine BMD 927 1.21 ± 0.2 764 1.22 ± 0.2 0.0 17 Med 
Left Hip BMD 926 0.95 ± 0. 1 765 0.99 ± 0.1 0.000 Med 
BMI 966 27.25 ± 5.4 809 26. 13 ± 4.5 0.000 Non-Med 
Waist-Hi E Ratio 959 0.9 1 ± 0.1 802 0.90 ± 0. 1 NS 
P-values at the end of table indicate if there is a significant difference between all individuals in the cohort who were taking medications and all those that were not on any 
medications. The last column indicates which group is greater in value for that measurement (e.g. average age of individuals not on any medications is signi ticantly higher than 
that individuals taking medication). No-Med refers to subjects who were not taking any medications, whereas Med re fers to subjects taking any type of medication. nand n' refer 
to the total number subjects not taking medication and taking medication respectively. NS- Not significant ifp-value is less than 0.5. 
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Table 10. The baseline laboratory values, HOMA-IR, and HOMA-~ for the entire cohort comparing those on medications versus 
those not taking any medications. 
No Medication Taking Medication 
n Mean SD n' Mean SD p 
G lucose 959 5.22 ± 1.1 803 5.02 ± 0.7 0.000 Non-Med 
Phosphate 919 1.18 ± 0 .2 774 1.19 ± 0 .2 NS 
Calc ium 9 18 2.34 ± 0 .1 778 2.35 ± 0.1 NS 
A lbumin 9 18 40.73 ± 3.9 774 4 1.93 ± 3.7 0.000 Med 
Cholesterol 959 5 .1 9 ± 1.0 803 5. 16 ± 1.1 NS 
Triglycerides 959 1.30 ± 0.8 803 1.1 4 ± 0.8 0 .000 Non-Med 
Magnesium 9 19 0.88 ± 0. 1 774 0 .89 ± 0.1 0 .00 1 Med 
HDL 960 1.49 ± 0.4 803 1.50 ± 0.4 NS 
GGT 665 20.39 ± 23.2 528 19.26 ± 25.5 NS 
LDL 959 3.11 ± 0.9 803 3.14 ± 0.9 NS 
Risk Factor 959 3.64 ± 1.0 803 3.62 ± 1.1 NS 
Buche 695 94 14.03 ± 26 15 .2 622 8993 .1 9 ± 2787.7 0 .005 Non-Med 
Corrected Buche (S1 U ni ts) 134 6044. 15 ± 556 1.5 157 5350.06 ± 5310.2 NS 
Insulin 902 79.06 ± 82.0 748 63 .93 ± 40.8 0.000 Non-Med 
HOMA-p 90 1 147.24 ± 298. 1 746 131.78 ± 134.5 NS 
HOMA-IR 90 1 2.80 ± 4.0 748 2. 11 ± 1.6 0.000 Non-Med 
Triglyceride/HDL ratio 959 0.98 ± 0.7 803 0.87 ± 0 .8 0.003 Non-Med 
Log Insulin 902 1.8 1 ± 0 .3 748 1.74 ± 0 .2 0 .000 Non-Med 
Log HOMA-IR 901 0.33 ± 0.3 748 0.24 ± 0 .3 0 .000 Non-Med 
Log HOMA-p 900 2.08 ± 0.3 745 2.04 ± 0.2 0 .001 Non-Med 
Log Triglz:ceride 959 0.05 ± 0 .2 803 -0.02 ± 0 .2 0 .000 Non-Med 
P-values at the end of table indicate if there is a significant difference between all individuals in the cohort who were taking medications and all those that were not on any 
medications. The last column indicates which group is greater in value for that measurement (e.g. average glucose level for individuals not on any medications is signi ficantly 
higher than that of individuals taking medications). No-Med refers to subjects who were not taking any medications, whereas Med refers to subjects taking any type of medication. 
nand n' refer to the total number subjects not taking medication and taking medication respectively. NS- Not significant ifp-value is less than 0.5. 
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Table II . The baseline cohort bone density and body composition data comparing individuals who were on medications against those 
that were not taking any medications. 
No Medications Taking Medication 
n Mean SD n' Mean SD p 
Total Arm BMD 965 0.9 1 ± 0. 1 807 0.94 ± 0.1 0.000 Med 
Total Leg BMD 965 1.26 ± 0. 1 807 1.30 ± 0. 1 0.000 Med 
Total Trunk BMD 965 0.93 ± 0. 1 807 0.94 ± 0. 1 0.043 Med 
Total Rib BMD 350 0.67 ± 0.1 289 0.69 ± 0.1 0.024 Med 
Total Pelvis BMD 350 1. 15 ± 0.1 289 1. 17 ± 0. 1 0.0 17 Med 
Total BMD 963 1. 17 ± 0. 1 806 1. 19 ± 0. 1 0.000 Med 
Arm% Fat 964 37. 11 ± 11.3 807 32.58 ± 12.7 0.000 Non-Med 
Arm ti ssue 965 8030.76 ± 2942.9 807 7937.68 ± 2729.6 NS 
Arm Fat weight(g) 965 32 14.02 ± 19 10.4 807 2755 .22 ± 1813.4 0.000 Non-Med 
Arm Lean muscle mass (g) 965 4822.06 ± 1641.6 807 5 182.48 ± 1863.0 0 .000 Med 
Arm Bone Mineral Composition 964 330.02 ± 84.2 807 357.64 ± 92. 1 0.000 Med 
Leg% Fat 965 36.22 ± 9 .3 807 33 .35 ± 10. 1 0 .000 Non-Med 
Leg Ti ssue weight(g) 965 22329.96 ± 4625 .7 807 22585.39 ± 4455.9 NS 
Leg Fat weight (g) 965 8554.68 ± 3298.0 807 7875.93 ± 3028.5 0.000 Non-Med 
Leg lean muscle mass(g) 964 13767.73 ± 3 11 0. 1 807 14713.25 ± 3757.6 0.000 Med 
Leg bone mineral composition 965 945.84 ± 18 1.8 806 1007.95 ± 2 14.1 0.000 Med 
Trunk % Fat 965 38.57 ± 8.7 806 35.17 ± 9.6 0.000 Non-Med 
Trunk Tissue weight (g) 965 35774.39 ± 9899.6 807 34397.38 ± 7792.3 0.001 Non-Med 
Trunk Fat weight (g) 965 14484.52 ± 6067.9 807 12675 .8 1 ± 5209.2 0.000 Non-Med 
Trunk lean muscle mass (g) 965 21338.93 ± 5709.5 807 2 1709.15 ± 4792.3 NS 
Trunk bone mineral composition 965 765.83 ± 176.9 807 822.32 ± 190.8 0.000 Med 
Android % fat mass 958 44.02 ± 10.3 806 40.56 ± 11.3 0.000 Non-Med 
Android tissue mass (g) 958 5573 .OS ± 18 13.9 807 5258. 10 ± 1568.1 0.000 Non-Med 
Andro id Fat mass (g) 958 2593.80 ± 1270.4 807 2253.46 ± 1139.8 0 .000 Non-Med 
Android lean muscle mass (g) 958 2978.9 1 ± 742.3 807 3005.77 ± 7 12.5 NS 
Android BMC 958 52.41 ± 11.5 807 54.05 ± 11.9 0 .003 Med 
G~necoid % Fat 958 42.60 ± 8.7 807 40.02 ± 10.0 0 .000 Non-Med 
Page 83 of 167 
Gynecoid tissue mass (g) 958 11 322.70 ± 2228.6 807 11 3 11.72 ± 220 1.4 NS 
Gynecoid fa t mass (g) 958 4987 .10 ± 1640.3 807 4676.02 ± 162 1.2 0.000 Non-Med 
Gy necoid lean muscle mass (g) 958 6332.86 ± 1406.8 807 6637.66 ± 1622.9 0.000 Med 
Gy necoid BMC 958 270 .6 1 ± 58.4 807 282 .82 ± 64.7 0.000 Med 
Total % body fa t 966 36.53 ± 8.3 807 33.20 ± 9 .3 0.000 Non-Med 
Total ti ssue mass (g) 966 7066 1.93 ± 2 141 0. 1 807 68969.43 ± 1442 1.8 NS 
To tal fat mass (g) 966 27066.64 ± 10378 .2 807 24029.29 ± 9332.7 0 .000 Non-Med 
To tal lean muscle mass (g) 966 43 117.88 ± 9565. 1 807 4495 1.25 ± 10597.7 0.000 Med 
Total Bone Minera l Compositio n 966 25 10.60 ± 41 4.6 807 2672.99 ± 487.3 0.000 Med 
L2-L4 (Z-Score) 684 0 .24 ± 1.3 527 0.20 ± 1.2 NS 
L2-L4 BMC 689 52.92 ± 11.0 534 54.63 ± I I. I 0.007 Med 
Femoral Neck (Z-Score) 664 0.05 ± 0.9 5 15 0. 15 ± 1.0 NS 
N eck BMC 671 4 .75 ± 0.8 527 5.03 ± 1.0 0 .000 Med 
P-values at the end of table indicate if there is a significant di fference between all individuals in the cohort who were taking medications and all those that were not on any 
medications. The last column indicates which group is greater in value for that measurement (e.g. average glucose level for individuals not on any medications is significantly 
higher than that of individuals taking medications). No-Med refers to subjects who were not taking any medications, whereas Med refers to subjects taking any type of medication. 
n and n' refer to the total number subjects not taking medication and taking medication respectively. NS- Not significant ifp-value is less than 0.5. 
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Table 12. The baseline descriptive characteristics for the male subjects on medications versus those who were not taking any 
medications. 
No Medication Taking medication 
n Mean SD n' Mean SD p 
Age 158 48.93 ± 12.2 229 36.43 ± 12.7 0.000 Non-Med 
We ig ht (kg) 158 86 .98 ± 14 .8 227 83 .2 1 ± 13.4 0 .010 Non-Med 
He ig ht (em) 158 174.46 ± 6 .2 227 175 .83 ± 6. 1 0.03 2 Med 
Wa ist (em) 156 I 0 1.26 ± 12 .8 223 95 .75 ± II. I 0 .000 Non-Med 
Hip (em) 156 102.98 ± 9.7 223 100.09 ± 8.6 0.002 N on-Med 
Total % Body Fat 158 27.52 ± 7.0 226 24 .12 ± 7.5 0 .000 Non-Med 
Total %Trunk Fat 158 32.98 ± 7.8 226 28 .55 ± 9.0 0.000 Non-Med 
Total BMD (g/cm~) 158 1.25 ± 0. 1 226 1.27 ± 0. 1 NS 
Spine BMD 150 1.25 ± 0.2 207 1.26 ± 0.2 NS 
Left Hip BMD 150 0 .99 ± 0. 1 207 1.07 ± 0. 1 0 .000 Med 
BMI 158 28.59 ± 4 .7 227 26.90 ± 4.0 0.000 Non-Med 
Wa ist-Hip Ratio 156 0 .98 ± 0 . 1 223 0.96 ± 0.1 0 .000 Non-Med 
P-values at the end of table indicate if there is a significant difference between all males in the cohort who were taking medications and all those that were not on any medications. 
The last column indicates which group is greater in value for that measurement (e.g. average glucose level for males not on any medications is significantly higher than that of 
males taking medications). Na-Med refers to subjects who were not taking any medications. whereas Med refers to subjects taking any type of medication. nand n' refer to the 
total number subjects not taking medication and taking medication respectively. NS- Not significant if p-value is less than 0.5. 
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Table 13 . The baseline laboratory values, HOMA-IR, and HOMA-P for male subjects comparing those on medications versus those 
not taking any medications. 
No Medicatio n Taking Medicat ion 
n Mean so n' Mean so p 
G lucose 157 5.66 ± 1.4 227 5.07 ± 0.7 0.000 Non-Med 
Phosphate 15 1 1.10 ± 0.2 2 11 1. 15 ± 0.2 0.003 Med 
Calcium 151 2.36 ± 0.1 2 15 2.37 ± 0. 1 NS 
A lbumin 151 42 .17 ± 4.0 2 11 43.03 ± 3.9 0.044 Med 
C ho lesterol 157 5.00 ± 1.0 227 5. 13 ± 1.2 NS 
Trig lycerides 157 1.61 ± 0.9 227 1.42 ± 1.0 NS 
Magnesium 151 0.89 ± 0.1 21 1 0.90 ± 0.1 NS 
HOL 157 1.20 ± 0.3 227 1.27 ± 0.3 0.012 Med 
GGT 125 28.77 ± 23. 1 161 23.55 ± 19.2 0.038 Non-Med 
LOL 157 3.06 ± 0.8 227 3.19 ± 1.0 NS 
Risk Factor 157 4.30 ± 1.0 227 4.17 ± 1.2 NS 
B uche 112 10468.82 ± 25 11.5 172 9954.74 ± 2496.9 NS 
Corrected Buche (S I Units) 15 7839.65 ± 6992.6 30 4314.27 ± 5535.3 NS 
Insulin 148 93.04 ± 72.6 206 68.19 ± 44.5 0.000 Non-Med 
BMI 158 28.59 ± 4.7 227 26.90 ± 4.0 0.000 Non-Med 
HOMA-p 148 140.43 ± 105.9 205 139.84 ± 167.2 NS 
HOMA-IR 148 3.64 ± 5.3 206 2.25 ± 1.6 0.000 Non-M ed 
Triglyceride!HOL ratio 157 1.45 ± 0.9 227 1.24 ± 1.1 0.046 Non-Med 
Log Insulin 148 1.88 ± 0.3 206 1.77 ± 0.2 0.000 Non-Med 
Log HOMA-IR 148 0.44 ± 0.3 206 0.28 ± 0.2 0.000 Non-M ed 
LogHOMA-p 148 2.05 ± 0.3 205 2.04 ± 0.3 NS 
Log Triglyceride 157 0.14 ± 0.2 227 0.06 ± 0.3 0.004 Non-M ed 
P-values at the end of table indicate if there is a significant difference between all males in the cohort who were taking medications and all those that were not on any medications. 
The last column indicates which group is greater in value for that measurement (e.g. average glucose level for males not on any medications is significantly higher than that of 
males taking medications). No-Med refers to subjects who were not taking any medications, whereas Med refers to subjects taking any type of medication. nand n' re fer to the 
total number subjects not taking medication and taking medication respectively. NS- Not significant if p-value is less than 0.5. 
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Table 14. The baseline cohort bone density and body composition data comparing male subjects who were on medications against 
those that were not taking an~ medications. 
No Medication Taking Medication 
n Mean so n' Mean so p 
Total Arm BMO 158 1.06 ± 0.2 226 1.08 ± 0. 1 NS 
Total Leg BMO 158 1.41 ± 0. 1 226 1.45 ± 0. 1 0.003 Med 
Total T runk BMO 158 0.99 ± 0.1 226 1.00 ± 0.1 NS 
Total Rib BMO 72 0.75 ± 0.1 92 0 .76 ± 0. 1 NS 
Total Pelvis BMO 72 1.22 ± 0.1 92 1.26 ± 0. 1 NS 
Total BMO 158 1.25 ± 0. 1 226 1.27 ± 0. 1 NS 
Arm % Fat 158 22.93 ± 9.0 226 18.32 ± 8.3 0.000 Non-Med 
Arm tissue 158 9948. 15 ± 2968.6 226 9627.12 ± 231 1.5 NS 
Arm Fat weight(g) 158 2496.89 ± 1710.6 226 1971.38 ± 1431.7 0.00 1 Non-Med 
Arm Lean muscle mass (g) 158 7445 .60 ± 1620.3 226 7655.76 ± 1324.1 NS 
Arm Bone Mineral Composition 157 460.22 ± 80.0 226 473.83 ± 69. 1 NS 
Leg% Fat 158 22 .48 ± 6.9 226 2 1.40 ± 6.8 NS 
Leg Tissue weight(g) 158 25006.44 ± 4548.6 226 256 17.38 ± 4378.2 NS 
Leg Fat weight (g) 158 6085 .9 1 ± 2706.8 226 5928.77 ± 2728. 1 NS 
Leg lean muscle mass(g) 158 18853.20 ± 2945.7 226 19688.46 ± 262 1.9 0.004 Med 
Leg bone mineral composition 158 11 97.58 ± 171. 1 226 1254.49 ± 178.8 0.002 Med 
Trunk % Fat 158 33.00 ± 7.8 226 28.63 ± 8.9 0.000 Non-Med 
Trunk Tissue weight (g) 158 43948.82 ± 10423. 1 226 39938.62 ± 7259.8 0.000 Non-Med 
Trunk Fat weight (g) 158 151 18.35 ± 5446. 1 226 12 182.83 ± 5377.7 0.000 Non-Med 
Trunk lean muscle mass (g) 158 288 11 .46 ± 6706.3 226 27755 .7 1 ± 3376.6 0.043 Non-Med 
Trunk bone mineral composition 158 9 12.47 ± 225.4 226 990.38 ± 186.4 0.000 Med 
Andro id % fat mass 156 40. 19 ± 9.4 225 35 .16 ± 11.4 0.000 Non-Med 
Android tissue mass (g) 156 7028 .01 ± 1830.7 226 6 11 3 .05 ± 1606.9 0.000 Non-Med 
Andro id Fat mass (g) 156 2959 .49 ± 1248.9 226 231 1.62 ± 1240.5 0.000 Non-Med 
Andro id lean muscle mass (g) 156 4055 .70 ± 787.2 226 3805.8 1 ± 596.2 0.000 Non-Med 
Android BMC 156 57. 12 ± 13.1 226 60 .16 ± 12 .6 0.023 Med 
Gynecoid % Fat 156 29.88 ± 7.7 226 28.75 ± 8. 1 NS 
Gynecoid t issue mass (g) 156 12576.58 ± 2069.4 226 12476.08 ± 2 192.5 NS 
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Gynecoid fat mass (g) 156 3934.74 ± 1425 .9 226 3813.27 ± 1582.2 NS 
Gynecoid lean muscle mass (g) 156 8636.84 ± 1250.4 226 8676 .08 ± 1248.6 NS 
Gynecoid BMC 156 344 .54 ± 55.2 226 347.96 ± 60.5 NS 
Total % body fat 158 27.47 ± 7.0 226 24.1 4 ± 7.5 0.000 Non-Med 
Total tissue mass (g) 158 83664.0 1 ± 14428.6 226 79847.25 ± 13 123 .1 0.007 Non-Med 
Total fat mass (g) 158 24392.73 ± 8951.2 226 20702.66 ± 90 11.6 0.000 Non-Med 
Total lean muscle mass (g) 158 59271.32 ± 8257.4 226 59 144.72 ± 6999.5 NS 
Total Bone Mineral Composition 158 3035 .87 ± 418.0 226 3202.64 ± 415.4 0.000 Med 
L2-L4 (Z-Score) 125 0. 12 ± 1.4 154 0 .18 ± 1.3 NS 
L2-L4 BMC 127 63 .09 ± 11.5 159 62.68 ± ILl NS 
Femora l Neck (Z-Score) 122 -0.09 ± 0.8 147 0.07 ± 1.1 NS 
Neck BMC 125 5.59 ± 0.8 156 5.93 ± 1.0 0.00 1 Med 
P-values at the end of table indicate if there is a significant difference between all males in the cohort who were taking medications and all those that were not on any medications. 
The last column indicates which group is greater in value for that measurement (e.g. average total mass for all male subjects not on any medications is significantly higher than that 
of male subjects taking medications). No-Med refers to subjects who were not taking any medications. whereas Med refers to subj ects taking any type of medication. n and n' 
refer to the total number subjects not taking medication and taking medication respectively. NS- Not significant ifp-value is less than 0.5. 
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Table 15 . The baseline descriptive characteristics for the female subjects on medications versus those who were not taking any 
medications. 
No Med icatio n Taking Medication 
n Mean so n' Mean so p 
Age 805 45 .08 ± 12.1 582 43 .55 ± 9.3 0 .01 I Non-Med 
Weight (kg) 805 70.75 ± 15.0 581 68 .02 ± 12.8 0 .000 Non-M ed 
Heig ht (em) 805 161.97 ± 5.7 58 1 162.32 ± 5.9 NS 
Waist (em) 80 1 92.56 ± 15.5 578 88.60 ± 12.3 0.000 Non-M ed 
Hip (em) 800 103.47 ± I 2.4 578 100.99 ± 10.4 0.000 Non-M ed 
Total %Bo dy Fat 805 38.32 ± 7.4 580 36.72 ± 7.4 0.000 Non-Med 
Total %Trunk Fat 804 39.64 ± 8.5 579 37.72 ± 8.6 0.000 Non-Med 
Total BMO (g/cm~) 805 1.15 ± 0. 1 580 1.16 ± 0.1 N S 
Spine BMO 775 1.20 ± 0.2 556 1.21 ± 0. 1 NS 
Left Hip BMO 774 0.95 ± 0. I 557 0.97 ± 0. I 0.003 Med 
Right H ip BMO 109 0.02 ± 0.1 80 0.00 ± 0.0 N S 
BMI 805 26.98 ± 5.6 581 25.82 ± 4.7 0.000 Non-Med 
Waist-Hi~ Ratio 800 0.89 ± 0. 1 578 0.88 ± 0. 1 0.000 Non-Med 
P-values at the end of table indicate if there is a significant difference between all females in the cohort who were taking medications and all those that were not on any 
medications. The last column indicates which group is greater in value for that measurement (e.g. average age for all females not on any medications is significantly higher than 
that of femal es taking medications). No-Med refers to subjects who were not taking any medications. whereas Med refers to subjects taking any type of medication. nand n' refer 
to the total number subjects not taking medication and taking medication respectively. NS- Not significant ifp-value is less than 0.5 . 
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Table 16. The baseline laboratory values, HOMA-IR, and HOMA-P for female subjects comparing those on medications versus those 
not taking any medications. 
n 
Glucose 799 
Phosphate 765 
Calcium 764 
Albumin 764 
Cho lesterol 799 
Triglycerides 799 
Magnesium 765 
HOL 800 
GGT 540 
LOL 799 
Risk Factor 799 
Buche 580 
Corrected Buche (SI Units) 118 
Insul in 75 1 
BMI 805 
HOMA-~ 750 
HOMA-IR 750 
Triglyceride/ HOL rat io 799 
Log Insulin 751 
Log HOMA-IR 750 
No Medication 
Mean so 
5.14 ± 1.1 
1.20 ± 0.2 
2.34 ± 0.1 
40.45 ± 3.8 
5.23 ± 1.0 
1.24 ± 0.7 
0.87 ± 0.1 
1.55 ± 0.4 
18.46 ± 22.8 
3. 11 ± 0.9 
3.52 ± 1.0 
92 11 .83 ± 2594.4 
5867.05 ± 5343.5 
76.23 ± 83.6 
26.98 ± 5.6 
148.4 1 ± 323.4 
2.63 ± 3.7 
0.88 ± 0.6 
n' 
575 
562 
562 
562 
575 
575 
562 
575 
367 
575 
575 
449 
127 
541 
581 
540 
54 1 
575 
Taking Medication 
Mean SO 
4.99 ± 0.7 
1.21 ± 0.2 
2.34 ± 0. 1 
41.52 ± 3.6 
5. 17 ± 1.0 
1.03 ± 0.7 
0.89 ± 0. 1 
1.59 ± 0.4 
17.37 ± 27.6 
3.12 ± 0.9 
3.40 ± 0.9 
8627.76 ± 281 0.7 
5594.73 ± 5248.3 
62.31 ± 39.2 
25.82 ± 4.7 
128.79 ± 120.0 
2.06 ± 1.6 
0.72 ± 0.6 
p 
0.004 
NS 
N S 
0.000 
N S 
0.000 
0.002 
NS 
NS 
NS 
0.027 
0.00 1 
NS 
0.000 
0.000 
NS 
0.00 1 
0.000 
Non-Med 
M ed 
Non-Med 
Med 
Non-Med 
Non-Med 
Non-Med 
Non-Med 
Non-Med 
Non-Med 
I. 79 ± 0.3 54 1 I. 73 ± 0.2 0.000 Non-Med 
0.3 1 ± 0.3 541 0.23 ± 0.3 0.000 Non-Med 
Log HOMA-~ 749 2.09 ± 0.3 539 2.04 ± 0.2 0.00 1 Non-Med 
Log Triglyceride 799 0.04 ± 0.2 575 -0 .06 ± 0.2 0.000 Non-Med 
P-values at the end of table indicate if there is a significant di fference between all females in the cohort who were taking medications and all those that were not on any 
medications. The last column indicates which group is greater in value for that measurement (e.g. average glucose level for females not on any medications is significantly higher 
than that of females taking medications). No-Med refe rs to subjects who were not taking any medications. whereas Med re fers to subjects taking any type of medication. n and n' 
refer to the total number subjects not taking medication and taking medication respectively. NS- Not significant if p-value is less than 0.5. 
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Table 17. The baseline cohort bone dens ity and body composition data comparing female subjects who were on medications against 
those that were not taking an~ medications 
No Medication Taking Medication 
n Mean SD n' Mean SD p 
Total Arm BMD 804 0.88 ± 0. 1 580 0.89 ± 0. 1 NS 
Total Leg BMD 804 1.23 ± 0.1 580 1.25 ± 0. 1 0.000 Med 
Total Trunk BMD 804 0.92 ± 0. 1 580 0.92 ± 0. 1 NS 
Total Rib BMD 278 0.65 ± 0.1 197 0.65 ± 0. 1 NS 
Total Pel vis BMD 278 1.13 ± 0. 1 197 1.13 ± 0. 1 N S 
Total BMD 802 1.15 ± 0.1 579 1.1 6 ± 0. 1 NS 
Arm% Fat 803 39.89 ± 9.4 580 38.11 ± 9.3 0.00 1 Non-Med 
Arm tissue 804 7646.69 ± 2790.5 580 7278.25 ± 2597.1 0.013 Non-Med 
Arm Fat weight(g) 804 335 1.09 ± 19 17.9 580 3057.88 ± 1856.1 0.005 Non-Med 
Arm Lean muscle mass (g) 804 4303 .09 ± 1044. 1 580 4220.38 ± 9 13.0 NS 
Arm Bone Mineral Composition 804 304.28 ± 56.9 580 3 12.43 ± 51.3 0.006 Med 
Leg% Fat 804 38.9 1 ± 7.0 580 37.98 ± 6.8 0.014 Non-Med 
Leg Tissue weight(g) 804 21778.05 ± 4434.4 580 2 1405.18 ± 3899.4 NS 
Leg Fat weight (g) 804 9025.01 ± 3 162.6 580 8628.93 ± 2794.3 0.016 Non-Med 
Leg lean muscle mass(g) 803 12755.96 ± 193 1.6 580 1278 1.58 ± 1885.9 NS 
Leg bone mineral composition 804 895.45 ± 136.3 579 9 11.96 ± 135 .6 0.026 Med 
Trunk% Fat 804 39.64 ± 8.5 579 37.71 ± 8.6 0.000 Non-Med 
Trunk Tissue weight (g) 804 34 164.86 ± 8979.3 580 32229.33 ± 6877.9 0.000 Non-Med 
Trunk Fat weight (g) 804 14354.22 ± 6 186.9 580 12856.38 ± 513 1.4 0.000 Non-Med 
Trunk Jean muscle mass (g) 804 19873 .27 ± 4 135.2 580 19355.70 ± 2777.9 0.009 Non-Med 
Trunk bone mineral composition 804 735.87 ± 148.5 580 756.63 ± 147.7 0.0 10 Med 
Android % fat mass 799 44.74 ± 10.3 580 42 .63 ± 10.5 0.000 Non-Med 
Andro id tissue mass (g) 799 5287.65 ± 1672.7 580 4923.59 ± 142 1.6 0.000 Non-Med 
Android Fat mass (g) 799 2520.64 ± 1264.9 580 2229.11 ± 1098.6 0.000 Non-Med 
Android lean muscle mass (g) 799 2769. 10 ± 5 J7. 1 580 2694.33 ± 470.6 0.006 Non-Med 
Android BMC 799 51.36 ± 10.7 580 51.63 ± 10.7 NS 
Gynecoid% Fat 799 45.07 ± 6.4 580 44.39 ± 6.6 NS 
Gynecoid tissue mass (g) 799 11 070.3 1 ± 2 175.8 580 10855.11 ± 2033 .5 NS 
Gynecoid fat mass (g) 799 5 186.82 ± 1594.1 580 5007.55 ± 1507.5 0.035 Non-Med 
G~necoid Jean muscle mass (g) 799 5881.19 ± 904.3 580 5845 .13 ± 898.7 N S 
-----~--- -----~------ ----------
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Gynecoid BMC 799 255.80 ± 46.6 580 257.39 ± 45 .9 NS 
Total % body fat 805 38.30 ± 7.4 580 36.7 1 ± 7.4 0.000 Non-Med 
Total tissue mass (g) 805 68075.52 ± 21662.1 580 64722.13 ± 12582.0 0.00 1 Non-Med 
Total fat mass (g) 805 27566.99 ± 10558.5 580 25305.07 ± 9 137.6 0.000 Non-Med 
Total lean muscle mass (g) 805 39935.64 ± 5891.0 580 39432.47 ± 5299. 1 NS 
Total Bone M ineral Composition 805 2405.08 ± 324.0 580 2466.70 ± 333.8 0.00 1 Med 
L2-L4 (Z-Score) 559 0.26 ± 1.3 373 0.2 1 ± 1.1 NS 
L2-L4 BMC 562 50.62 ± 9.5 375 51.22 ± 9.2 NS 
Femoral Neck (Z-Score) 542 0.09 ± 0 .9 368 0 .19 ± 0.9 NS 
NeckBMC 546 4 .56 ± 0.7 371 4 .65 ± 0.6 NS 
P-values at the end of table indicate if there is a significant difference between all females in the cohort who were taking medications and all those that were not on any 
medications. The last column indicates which group is greater in value for that measurement (e.g. average total bone mineral composition for female subjects not on any 
medications is significantly higher than that of females taking medications). No-Med refers to subjects who were not taking any medications, whereas Med refers to subjects 
taking any type of medication. n and n' refer to the total number subjects not taking medication and taking medication respectively. NS- Not significant ifp-value is less than 0.5. 
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Table 18. The baseline descriptive characteristics for all subjects that were smokers versus those that were non-smokers. 
No n-smokers Smokers 
n Mean so n ' M ean so p 
Age 1573 43.99 ± 11.9 222 41.79 ± 10.9 0.009 Non-SMO 
Weight (kg) 1570 73.01 ± 15 .3 222 72.42 ± 16.1 NS 
Heig ht (em) 1570 165 .1 8 ± 8.0 222 164.17 ± 8.4 NS 
Waist (em) 1557 92.35 ± 14.3 2 19 92.8 1 ± 13 .1 NS 
Hip (em) 1555 102.20 ± 11.2 219 102.29 ± 10.6 NS 
Tota l % Bo dy Fat 1568 34.96 ± 9.1 222 34.98 ± 8.8 NS 
Total % Trunk Fat 1566 36.89 ± 9.4 222 37.34 ± 9.2 NS 
Total BMO (g/em1) 1568 1.1 8 ± 0.1 222 1.1 7 ± 0. 1 O.Q25 Non-SMO 
Spine BMO 1489 1.22 ± 0.2 209 1.1 9 ± 0.2 0.0 18 Non-SMO 
Left Hip BMO 1489 0.98 ± 0.1 209 0.95 ± 0. 1 0.0 11 Non-SMO 
Wais t-Hi12 Ratio 1555 0.90 ± 0. 1 219 0.91 ± 0. 1 N S 
P-values at the end of table indicate if there is a significant difference between all non-smoking subjects and smokers. The last column indicates which group is greater in value for 
that measurement (e.g. average age for non-smokers is significantly higher than that of smokers). Non-SMO refers to non-smokers. SMO refers to smokers. n and n ' refer to the 
total number of non-smoking and smoking subjects respectively. NS- Not significan t ifp-value is less than 0.5. 
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Table 19. The baseline laboratory values, HOMA-IR, and HOMA-P for the ent ire cohort comparing those who smoke with those who 
do not smoke. 
Non-smokers Smoker 
n Mean so n' Mean so p 
Glucose 1558 5. 14 ± 1.0 220 5.01 ± 0.7 NS 
Phosphate 1493 1.19 ± 0.2 209 1.20 ± 0.2 NS 
Calcium 1494 2.35 ± 0. 1 2 10 2.34 ± 0. 1 NS 
Albumin 1492 41.33 ± 3.9 209 41.04 ± 3.9 NS 
Cholesterol 1558 5. 18 ± 1.0 220 5. 13 ± 1.1 NS 
Triglycerides 1558 1.21 ± 0.8 220 1.37 ± 0.8 0.004 SMO 
Magnesium 1493 0.88 ± 0. 1 209 0.88 ± 0. 1 NS 
HOL 1559 1.50 ± 0.4 220 1.43 ± 0.4 0.006 Non-SMO 
GGT 1049 19.95 ± 25 .3 149 19.64 ± 13.3 NS 
LOL 1558 3. 13 ± 0.9 220 3.07 ± 0.9 NS 
Risk Factor 1558 3.61 ± 1.0 220 3.78 ± 1.1 0.023 SMO 
Buche 11 54 9255. 12 ± 2696.6 175 8960. 11 ± 2854.9 NS 
Corrected Buche (SJ Units) 267 5720. 11 ± 5430.8 25 5156.03 ± 5382.3 NS 
Insul in 1449 72.44 ± 69.7 209 70.44 ± 41.4 NS 
BMI 1570 26.72 ± 5.1 222 26.76 ± 4.9 NS 
HOMA-~ 1447 137.68 ± 245.4 208 157.11 ± 176.8 NS 
HOMA-JR 1448 2.51 ± 3.3 209 2.3 1 ± 1.5 NS 
Triglyceride!HOL ratio 1558 0.91 ± 0.7 220 1.07 ± 0.9 0.002 SMO 
Log Insulin 1449 1.78 ± 0.3 209 1.78 ± 0.2 NS 
Log HOMA-IR 1448 0.29 ± 0.3 209 0.29 ± 0.3 NS 
Log HOMA-~ 1445 2.06 ± 0.3 208 2.09 ± 0.3 NS 
Log Triglyceride 1558 0.01 ± 0.2 220 0.07 ± 0.2 0.00 1 SMO 
Waist-Hip Ratio 1555 0.90 ± 0. 1 2 19 0.91 ± 0. 1 NS 
P-values at the end of table indicate if there is a significant difference bel:\veen all non-smoking subjects and smokers. The last column indicates which group is greater in value for 
that measurement (e.g. average 1-IDL level for non-smokers is significantly higher than that of smokers ). Non-SMO refers to non-smokers. SMO refers to smokers. n and n· refer 
to the total number of non-smoking and smoking subjects respectively. NS- Not significant if p-value is less than 0.5. 
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Table 20. The baseline cohort bone density and body composition data comparing all subjects who were smokers against those that 
who were non-smokers. 
Non-smoker Smoker 
n Mean so n' Mean so p 
Total Arm BMO 1567 0.92 ± 0. 1 222 0.92 ± 0. 1 NS 
Tota l Leg BMO 1567 1.28 ± 0.1 222 1.27 ± 0.2 NS 
Tota l Trunk BMO 1567 0.94 ± 0. 1 222 0.93 ± 0. 1 NS 
Total Rib BMO 572 0.68 ± 0.1 78 0.70 ± 0.1 0.026 SMO 
Total Pe lv is BMO 572 1.1 6 ± 0. 1 78 1.1 7 ± 0.2 NS 
Total BMO 1565 1.1 8 ± 0.1 22 1 1.1 7 ± 0. 1 0.023 Non-SMO 
Arm % Fat 1566 34.98 ± 12.3 222 34.8 1 ± 11.6 NS 
Arm ti ssue 1567 7992. 12 ± 28 19.3 222 8023.85 ± 2990.2 NS 
Arm Fat weight(g) 1567 3000.63 ± 1893.3 222 2988.60 ± 1768.5 NS 
Arm Lean muscle mass (g) 1567 4992.78 ± 1745.8 222 5049.3 1 ± 1882.6 NS 
Arm Bone Minera l Composition 1566 343.38 ± 88.6 222 342.00 ± 93 .8 NS 
Leg% Fat 1567 34.93 ± 9.9 222 34.30 ± 9.4 NS 
Leg Tissue weight(g) 1567 22491.00 ± 4447.8 222 222 19.86 ± 5184.2 NS 
Leg Fat weight (g) 1567 8258.5 1 ± 3 176.2 222 8043.97 ± 3256.0 NS 
Leg lean muscle mass(g) 1567 14229.55 ± 3451.0 22 1 14179.43 ± 3658.0 NS 
Leg bone mineral composition 1567 977.23 ± 197.2 22 1 960.88 ± 230.9 NS 
Trunk % Fat 1566 36.90 ± 9.4 222 37.34 ± 9.2 NS 
Trunk T issue weight (g) 1567 35 147.13 ± 9090.2 222 351 81.00 ± 8390.9 NS 
Trunk Fat weight (g) 1567 13622.3 1 ± 5824.1 222 13734.10 ± 5322.9 NS 
Trunk lean muscle mass (g) 1567 2 1548.64 ± 5374.4 222 2 1446.90 ± 4975. 1 NS 
Trunk bone minera l composit ion 1567 793 .97 ± 185.8 222 78 1.67 ± 188.9 NS 
Android % fat mass 1559 42.3 1 ± 11.0 222 42.73 ± 11.0 NS 
Android ti ssue mass (g) 1560 5423. 14 ± 17 14.2 222 5463.14 ± 1694.8 NS 
Android Fat mass (g) 1560 2430.74 ± 1232.6 222 2457.3 1 ± 1171. 1 NS 
Android lean muscle mass (g) 1560 2994.76 ± 724.4 222 3005.35 ± 777.2 NS 
Android BMC 1560 53 .35 ± 11.7 222 52.23 ± 12 .0 NS 
G~necoid % Fat 1560 41.38 ± 9.5 222 4 1.1 5 ± 9. 1 NS 
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Gynecoid tissue mass (g) 1560 11 346.60 ± 2 184.7 222 11144.01 ± 2386.9 NS 
Gynecoid fat mass (g) 1560 4851.39 ± 1640.5 222 4733.90 ± 1593.9 NS 
Gynecoid lean muscle mass (g) 1560 6494.81 ± 1517.1 222 6408.30 ± 1591.2 NS 
Gynecoid BMC 1560 277. 16 ± 60.8 222 272.25 ± 69.9 NS 
To tal % body fat 1567 34.97 ± 9.0 222 34.96 ± 8.8 NS 
Total tissue mass (g) 1567 69984.92 ± 18886.9 222 69405.30 ± 15788.4 NS 
Total fat mass (g) 1567 25663.42 ± 10093.2 222 25539.60 ± 9509. 1 NS 
Total lean muscle mass (g) 1567 44027.23 ± 10065.3 222 43905.84 ± 10652.8 NS 
Total Bone Mineral Composition 1567 2592.05 ± 452.0 222 2551.9 1 ± 505.0 NS 
L2-L4 (Z-Score) 1063 0.27 ± 1.2 153 -0.09 ± 1.3 0.00 1 Non-SMO 
L2-L4 BMC 1074 53.94 ± 11.0 154 51.71 ± 11.4 0.019 Non-SMO 
Femoral Neck (Z-Sco re) 1035 0. 13 ± 0.9 149 -0.09 ± 0.9 0.008 Non-SMO 
Neck BMC 1053 4.88 ± 0.9 150 4.77 ± 0.9 NS 
P-values at the end of table indicate if there is a significant difference between all non-smoking subjects and smokers. The last column indicates which group is greater in value for 
that measurement (e.g. average total bone mineral density for non-smokers is significantly higher than that of smokers). Non-SMO refers to non-smokers. SMO refers to 
smokers. nand n' refer to the total number of non-smoking and smoking subjects respectively. NS- Not significant if p-value is less than 0.5. 
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Table 21. The baseline descriptive characteristics for all male subjects that were smokers versus those that were non-smokers. 
Male 
Non-Smoker Smoker 
n Mean SD Mean SD p 
Age 350 41.49 ± 14.19 39.06 ± 12.52 NS 
Weight (kg) 348 84.35 ± 13.59 87.61 ± 16.63 NS 
Heig ht (em) 348 175.36 ± 6.4 1 175.73 ± 5.54 NS 
Waist (em) 342 97.66 ± 12.04 100.47 ± 12.69 NS 
Hip (em) 34 1 I 01.09 ± 9.15 103.29 ± 9 .22 NS 
Total %Body Fat 347 25.37 ± 7.60 25 .70 ± 7.39 NS 
Total %Trunk Fat 347 30. 18 ± 8.94 30.35 ± 8.36 NS 
Total BMD (g/cm2) 347 1.26 ± 0.10 1.29 ± 0.10 0 .05 Smo 
Spine BMD 3 18 1.25 ± 0. 16 1.29 ± 0.18 NS 
Left Hip BMD 318 1.03 ± 0.14 1.05 ± 0 .16 NS 
BMI 348 27.45 ± 4.33 28.28 ± 4.68 NS 
Waist-Hip Ratio 34 1 0.97 ± 0.06 0.97 ± 0.06 NS 
P-values at the end of table indicate if there is a significant difference between all male non-smoking subjects and male smokers. The last column indicates which group is greater 
in value for that measurement (e.g. average total bone mineral density of male smokers is significantly higher than that of non-smokers. NS- Not significant ifp-value is less than 
0.5. 
,--------------------------------------------------------------------------------------------------------------------------~-----
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Table 22. The baseline laboratory values, HOMA-IR, and HOMA-P for all male subjects comparing those who smoke w ith those who 
do not smoke. 
Male 
Non-Smoker Smoker 
N Mean so Mean SD p 
G lucose 347 5.30 ± 1.05 5.31 ± 1.1 8 NS 
Phosphate 323 1. 13 ± 0.18 1.13 ± 0. 15 NS 
Calcium 325 2.36 ± 0.12 2.35 ± 0.10 NS 
Albumin 323 42.64 ± 4.05 42.98 ± 3.63 NS 
Cho lestero l 347 5.08 ± I. 11 4.92 ± 1.08 NS 
Trig lycerides 347 1.47 ± 0.95 1.69 ± 1.11 NS 
Magnesium 323 0.89 ± 0. 11 0.88 ± 0.14 NS 
HDL 347 1.25 ± 0.26 1.18 ± 0.26 NS 
GGT 253 25.80 ± 2 1.57 26.40 ± 17.13 NS 
LDL 347 3. 15 ± 0.94 2.92 ± 0.88 NS 
Risk Factor 347 4. 19 ± 1.09 4.34 ± 1.33 NS 
Buche 256 10190.1 4 ± 2587.77 9706. 14 ± 24 14.46 NS 
Corrected Buche (SJ U nits) 4 1 563 1.58 ± 6370.22 403 1.95 ± 4649.71 NS 
Insulin 3 15 77.98 ± 59.09 83 .05 ± 57.52 NS 
HOMA-p 3 14 134.61 ± 116.1 9 180. 15 ± 273.09 NS 
HOMA-IR 3 15 2.83 ± 3.83 2.85 ± 2.07 NS 
Trig lyceride!HDL ratio 347 1.28 ± 0.98 1.56 ± 1.20 NS 
Log Insulin 3 15 1.81 ± 0.25 1.84 ± 0.26 NS 
Log HOMA-IR 3 15 0.34 ± 0.28 0.36 ± 0.28 NS 
Log HOMA-p 3 14 2.04 ± 0.26 2.09 ± 0.33 NS 
Log Triglyceride 347 0.09 ± 0.26 0. 14 ± 0.28 
1P-values at the end of table indicate if there is a significant difference between all male non-smoking subjects and male smokers. 
NS 
NS- Not significant if p-value is less than 0.5 
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Table 23. The baseline cohort bone density and body composition data comparing male subjects who were smokers against those who 
were non-smokers. 
Male 
Non-Smoker Smoker 
N Mean SD Mean SD p 
Total Arm BMD 347 1.06 ± 0.15 1.09 ± 0.14 NS 
Total Leg BMD 347 1.43 ± 0.13 1.46 ± 0.13 NS 
Total Trunk BMD 347 0.99 ± 0.09 1.0 I ± 0.09 NS 
Total Rib BMD 143 0.75 ± 0.09 0.76 ± 0.08 NS 
Total Pelvis BMD 143 1.24 ± 0.14 1.26 ± 0.14 NS 
Total BMD 347 1.26 ± 0.10 1.29 ± 0.10 0.05 Smo 
Arm% Fat 347 20.02 ± 9.04 20.50 ± 8.57 NS 
Arm tissue 347 9667.50 ± 2389.17 10428.39 ± 3724.51 NS 
Arm Fat weight(g) 347 2133 .05 ± 1486.25 2472.59 ± 2082.53 NS 
Arm Lean muscle mass (g) 347 7531.87 ± 1384.56 7955.9 1 ± 1853.77 NS 
Arm Bone Mineral Composition 346 465.50 ± 73 .81 490.07 ± 72.08 0.03 Smo 
Leg% Fat 347 21.77 ± 6.86 22.23 ± 7.28 NS 
Leg Tissue weight(g) 347 25293. 13 ± 4266.78 26 159.9 1 ± 5638.82 NS 
Leg Fat weight (g) 347 5940.56 ± 2647.65 6394.67 ± 3251 .28 NS 
Leg lean muscle mass(g) 347 1932 1.80 ± 2740.54 19765 .30 ± 3 173.64 NS 
Leg bone mineral composition 347 1226.74 ± 174.94 1284.39 ± 204.64 0.04 Smo 
Trunk% Fat 347 30.25 ± 8.95 30.35 ± 8.36 NS 
Trunk Tissue weight (g) 347 41354.17 ± 8938.77 42867.83 ± 8296. 14 NS 
Trunk Fat weight (g) 347 13247.18 ± 5647.12 13773.26 ± 5436.03 NS 
Trunk lean muscle mass (g) 347 28098.27 ± 5106.25 29094.65 ± 4126. 11 NS 
Trunk bone mineral composition 347 959.33 ± 205.14 963 .74 ± 231.38 NS 
Android % fat mass 344 36.93 ± 11.08 37.42 ± 11.20 NS 
Android tissue mass (g) 345 6428.23 ± 1734.56 6768.04 ± 1968.06 NS 
Android Fat mass (g) 345 2540. 19 ± 1277.60 2697.72 ± 1385.69 NS 
Android lean muscle mass (g) 345 3890.91 ± 667.83 4070.24 ± 812.66 N S 
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Android BMC 345 58.74 ± 12.94 61. 17 ± 13.65 NS 
Gynecoid % Fat 345 29.04 ± 7.87 29.84 ± 8.85 NS 
Gynecoid tissue mass (g) 345 12479.90 ± 2066.97 12848.39 ± 2582.78 NS 
Gynecoid fat mass (g) 345 3825.99 ± 1483.57 4073.00 ± 1758.20 NS 
Gynecoid lean muscle mass (g) 345 8660.34 ± 1229.79 8775.33 ± 1399.47 NS 
Gynecoid BMC 345 345.4 1 ± 57.39 360.37 ± 68.88 NS 
Total % body fat 346 25.39 ± 7.55 25.70 ± 7.39 NS 
Total tissue mass (g) 346 81044.43 ± 13332. 11 84173.26 ± 16411.87 NS 
Total fat mass (g) 346 22006.09 ± 9 100.46 23288.41 ± 9795.87 NS 
Total lean muscle mass (g) 346 59038.43 ± 7352.03 60884.85 ± 8737.25 NS 
Total Bone Mineral Composition 346 3 126.38 ± 424.95 3223.89 ± 449.46 NS 
TMASS 346 84. 17 ± 13 .48 87.40 ± 16.60 NS 
L2-L4 (Z-Score) 247 0. 16 ± 1.32 0. 14 ± 1.52 NS 
L2-L4 BMC 253 62.96 ± 11.32 62.29 ± 10.71 NS 
Femoral Neck (Z-Score) 238 -0.0 1 ± 0.93 0.05 ± 1.0 I NS 
NeckBMC 249 5.76 ± 0.90 5.89 ± 0.89 NS 
P-values at the end of table indicate if there is a signi ficant difference between all male non-smoking subjects and male smokers. The last column indicates which group is greater 
in value for that parameter (e.g. average total bone mineral density of male smokers is significantly higher than that of non-smokers). Non-SMO reters to non-smokers. SMO 
refers to smokers. NS- Not significant ifp-value is less than 0.5 
Page 100 of 167 
Table 24. The baseline descriptive characteristics for all female subjects that were smokers versus those that were non-smokers. 
Age 
Weight (kg) 
Height (em) 
Waist (em) 
Hip (em) 
Total % Body Fat 
Total %Trunk Fat 
Total BMD (g/cm~) 
Female 
Non-Smoker Smoker 
Mean SD 
42.50 ± I 0.36 
68.45 ± 13.35 
161. 15 ± 6.04 
90.94 ± 12.52 
I 02.05 ± I 0.87 
37.4 1 ± 7.37 
39. 16 ± 8.5 1 
1.1 3 ± 0.09 
p 
0.01 
NS 
0.02 
NS 
NS 
NS 
NS 
0.00 
Non-Smo 
Non-Smo 
Non-Smo 
Non-Smo 
Non-Smo 
P-values at the end of table indicate if there is a significant di fference between all female non-smoking subjects and female smokers. The last column indicates which group is 
greater in value for that measurement (e.g. average weight for female non-smokers was significantly higher than that of female smokers). Non-SMO refers to non-smokers. 
SMO refers to smokers. NS- Not significant if p-value is less than 0.5 
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Table 25. The baseline laboratory values, HOMA-IR, and HOMA-P for all female subjects comparing those who smoke with those 
who do not smoke. 
n 
Glucose 1207 
Phosphate 11 66 
Calcium 11 65 
Albumin 1165 
Cholesterol 1207 
Triglycerides 1207 
Magnesium 11 66 
HOL 1208 
GGT 796 
LOL 1207 
Risk Factor 1207 
Buche 894 
Corrected Buche (Sl Units) 225 
Insulin 1130 
HOMA-p 1129 
HOMA-IR 1129 
Triglyceride/HOL ratio 1207 
Log Insulin 1130 
Log HOMA-IR 11 29 
Log HOMA-p 11 27 
Non-Smoker 
Mean so 
5.10 ± 0.96 
1.20 ± 0.18 
2.34 ± 0.12 
40.97 ± 3.73 
5.21 ± 1.03 
1.13 ± 0.70 
0.88 ± 0.08 
1.58 ± 0.37 
18.09 ± 26.15 
3. 12 ± 0.88 
3.45 ± 0.93 
8989.56 ± 2674.28 
5761.62 ± 5256.29 
70.84 ± 72.41 
Female 
Smoker 
Mean so 
4.93 ± 0.53 
1.22 ± 0.18 
2.34 ± 0. 14 
40.56 ± 3.80 
5.19 ± 1.08 
1.29 ± 0.73 
0.88 ± 0. 11 
1.49 ± 0.38 
17.57 ± 11 .21 
3.1 1 ± 0.92 
3.63 ± 1.02 
8780.2 1 ± 2930.57 
5370.14 ± 5587.41 
67.27 ± 35 .81 
p 
0.03 Non-Smo 
NS 
NS 
NS 
NS 
0.01 Smo 
NS 
0.0 I Non-Smo 
NS 
NS 
0.02 
NS 
NS 
NS 
Smo 
138.44 ± 270.94 15 1.28 ± 143. 16 NS 
2.43 ± 3.20 2. 17 ± 1.25 NS 
0.80 ± 0.63 0.95 ± 0.69 0.00 Smo 
1.77 ± 0.25 1.77 ± 0.23 NS 
0.27 ± 0.28 0.27 ± 0.25 NS 
2.06 ± 0.26 2.10 ± 0.24 NS 
Log Triglyceride 1207 -0.01 ± 0.23 0.05 ± 0.22 0.00 Smo 
P-values at the end of table indicate if there is a significant difTerence between all female non-smoking subjects and female smokers. The last column indicates which group is 
greater in value for that measurement (e.g. average glucose for female non-smokers was sign ificantly higher than that of female smokers). Non-SMO refers to non-smokers. SMO 
refers to smokers. NS- Not significant ifp-value is less than 0.5. 
-- -----------------------
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Table 26. The baseline cohort bone density and body composition data comparing female subjects who were smokers against those 
who were non-smokers. 
Female 
Non-Smoker Smoker 
n Mean SD Mean SD p 
Total Arm BMD 12 16 0.88 ± 0.10 0.87 ± 0.09 NS 
Total Leg BMD 1216 1.24 ± 0. 10 1.2 1 ± 0.11 0 .00 Non-Smo 
Total Trunk BMD 12 16 0.92 ± 0.09 0.9 1 ± 0.09 0 .03 Non-Smo 
Total Rib BMD 429 0.65 ± 0.05 0.66 ± 0.07 NS 
Total Pelvis BMD 429 1.13 ± 0.11 1. 12 ± 0 .14 NS 
Total BMD 12 14 1.1 6 ± 0.09 1.1 3 ± 0 .09 0.00 Non-Smo 
Arm % Fat 12 15 39.23 ± 9.43 38.55 ± 9.09 NS 
Arm tissue 121 6 7508.64 ± 2751.7 1 7395.39 ± 2409.93 NS 
Arm Fat weight(g) 121 6 3244.0 1 ± 1925.35 3 123.47 ± 1657. 10 NS 
Arm Lean muscle mass (g) 12 16 4267.02 ± 1004.63 4289.63 ± 889.44 NS 
Arm Bone M ineral Composition 12 16 308.47 ± 55.46 303.30 ± 50.07 NS 
Leg% Fat 12 16 38.67 ± 6.94 37.45 ± 7.07 0.03 Non-Smo 
Leg Tissue weight(g) 12 16 2 1675. 13 ± 4 151.68 2 11 90.08 ± 4540.58 NS 
Leg Fat weight (g) 12 16 8907.02 ± 2984.00 8475.03 ± 3 125.43 NS 
Leg lean muscle mass(g) 12 16 12773 .11 ± 1906.77 127 11.1 4 ± 1973.99 NS 
Leg bone mineral composition 12 16 905.57 ± 135.17 875.85 ± 147.05 0.01 Non-Smo 
Trunk % Fat 12 15 38.78 ± 8.60 39. 17 ± 8.51 NS 
Trunk Ti ssue weight (g) 12 16 33368.66 ± 8338.74 33 171.94 ± 7 185.04 NS 
Trunk Fat weight (g) 12 16 13718.72 ± 5876.44 13723.86 ± 5308.60 NS 
Trunk lean muscle mass (g) 12 16 19683. 13 ± 3741 .39 19448.06 ± 2736.39 NS 
Trunk bone mineral composition 12 16 745.98 ± 148.73 734.08 ± 142.58 NS 
Android % fat mass 12 11 43 .80 ± 10.48 44. 11 ± 10.50 NS 
Android tissue mass (g) 12 11 51 35.03 ± 1599.34 5122.08 ± 1437.70 NS 
Android Fat mass (g) 12 11 2397.33 ± 12 19.47 2394.47 ± 1104.06 NS 
Android lean muscle mass (g) 12 11 2739.9 1 ± 503 .82 2727.02 ± 465.94 NS 
Android BMC 12 11 51.71 ± 10.72 49.89 ± 10.30 0.04 Non-Smo 
G~necoid % Fat 12 11 44.87 ± 6.49 44. 10 ± 6.42 NS 
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Gynecoid tissue mass (g) 12 ll 11017.44 ± 2 108.49 10698.55 ± 2125.23 NS 
Gynecoid fat mass (g) 12 11 5137.30 ± 1559.27 4906.63 ± 1506.20 NS 
Gynecoid lean muscle mass (g) 12 11 5877.79 ± 900.09 5789.64 ± 914.39 NS 
Gynecoid BMC 12 11 257.46 ± 45.72 249.22 ± 48.81 0.03 Non-Smo 
Total% body fat 12 17 37.66 ± 7.40 37.38 ± 7.37 NS 
Total tissue mass (g) 1217 668 12.87 ± 19073.46 65545.49 ± 13161.56 NS 
Total fat mass (g) 1217 26675.16 ± 10119.51 26127.98 ± 9372.13 NS 
Total lean muscle mass (g) 1217 39758.78 ± 5702.25 39468.14 ± 5300.81 NS 
Total Bone Mineral Composition 1217 2438.7 1 ± 325.84 2376.27 ± 346.97 0.02 Non-Smo 
L2-L4 (Z-Score) 816 0.30 ± 1.21 -0. 16 ± 1.28 0.00 Non-Smo 
L2-L4 BMC 821 51.17 ± 9.26 48.71 ± 9.71 0.01 Non-Smo 
Femoral Neck (Z-Score) 797 0.17 ± 0.94 -0.13 ± 0.8 1 0.00 Non-Smo 
Neck BMC 804 4.6 1 ± 0.67 4.46 ± 0.68 0.02 Non-Smo 
P-values at the end of table indicate if there is a significant difference bel\veen all female non-smoking subjects and female smokers. The last column indicates which group is 
greater in value for that parameter (e.g. average total BMC for female non-smokers was significantly higher than that of female smokers). Non-SMO refers to non-smokers. 
SMO refers to smokers. NS- Not significant ifp-value is less than 0.5. 
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Table 27. One-way ANOVA analysis comparing descriptive characteristics of the entire cohort factoring for Bray Percentage body fat 
categories of lean/normal individuals, overweight individuals and obese individuals. 
Entire Cohort 
Normal/Lean Overweight 
8 1 587 78 544 
Age 1'2 41.25 ± 12.45 45.34 ± 10.92 
Weight (kg) ' ·2,3 63. 18 ± 10.41 70. 18 ± 10.78 
Height (em) •.2 166.03 ± 8.1 1 164.33 ± 7.84 
Waist (em) 1' 2'3 81.93 ± 8.99 90.54 ± 9.42 
Hip (em) 1'2.3 93.52 ± 6.19 100.72 ± 6.32 
Total %Body Fat1' 2'3 26.51 ± 6.90 35.42 ± 5.28 
Total %Trunk Fat1'2 '3 27.32 ± 7.02 37.79 ± 4 .72 
Total BMD (g/em2) 2.3 1. 17 ± 0.10 1.1 7 ± 0 .10 
Spine BMD2,3 1.20 ± 0.16 1.20 ± 0.15 
Left Hip BMD3 0 .97 ± 0.14 0.96 ± 0.12 
BMI 1'2'3 22.84 ± 2.74 25 .91 ± 2.9 1 
Waist-Hip Ratio '·2,3 0 .88 ± 0.07 0.90 ± 0.07 
P-values less than 0.5 
NS- Not significant values are less than 0.5 
1 Normal/Underweight individuals are significantly different as compared with overweight individuals 
2 Normal/Underweight individuals are significantly different as compared with obese individuals 
3 Overweight individuals are significantly different as compared with only obese individuals 
Obese 
87 668 
44.44 ± 11.35 
83.93 ± 15.58 
164 .79 ± 8.36 
103 .27 ± 13 .63 
111.25 ± 10.88 
42 .12 ± 6.23 
44.77 ± 5.56 
1.2 1 ± 0. 10 
1.24 ± 0.1 6 
0.99 ± 0.13 
30.87 ± 5.03 
0 .93 ± 0.08 
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Table 28. O ne-way ANOV A analysis comparing laboratory values, HOMA-p, and HOMA-IR for all cohort subjects factoring for 
Bray Percentage body fat categories of lean/normal individuals, overweight individuals and obese individuals. 
Entire Cohort 
Normal/Lean Overweight 
8 I 587 78 544 
G lucose1' 1'3 4 .9 1 ± 0.69 5.1 2 ± 0.9 1 
Phosphate1,J 1.2 I ± 0. 18 1. 19 ± 0.18 
Calc ium 2.35 ± 0.12 2.34 ± 0. 13 
A lbumin'.J 41 .95 ± 3.80 4 1.55 ± 3.96 
C ho lestero l1"1 4.97 ± 1.0 1 5.29 ± 1.07 
T rig lycerides1•1,J 1.00 ± 0.6 1 1.22 ± 0.78 
Magnesium 0.88 ± 0. 10 0.89 ± 0.09 
HDL'·l,J 1.59 ± 0.40 1.50 ± 0.36 
GGT2 17.72 ± 21.48 18.97 ± 16.04 
LDL'·1 2 .92 ± 0.88 3.23 ± 0.92 
Risk Facto r1'1' 3 3.27 ± 0.9 1 3.67 ± 1.03 
Buc he 1' 1'3 8453.92 ± 2745.59 9207.80 ± 2453.22 
Corrected Buc he (S I U nits ) 1 4638.03 ± 4825.42 7074.40 ± 5159.52 
Insulin •.z.J 52.87 ± 33 .73 67.62 ± 77.6 1 
HOMA -P1•3 I 19.12 ± 185.77 124.69 ± 294.12 
HOM A-IR1'1'3 1.72 ± 1.43 2.30 ± 3.82 
T rig lyceride/HDL ratio 1•1,J 0 .70 ± 0.57 0.91 ± 0.75 
Log Jnsulin1'1"3 1.66 ± 0.22 1.75 ± 0.23 
Log HOMA-fR 1"1"3 0 .16 ± 0.24 0.26 ± 0 .25 
Log H OMA-f3 '·1.3 1.99 ± 0.24 2.05 ± 0 .25 
Log T rig lyceride1•1.3 -0 .06 ± 0.22 0.02 ± 0.24 
P-values less than 0.5 
NS- Not significant values are Jess than 0 .5 
1 Normal/Underweight individuals are significantly different as compared with overweight individuals 
1 Normai/Underweight individuals are signi ficantly different as compared with obese individuals 
3 Overweight individuals are significantly different as compared with only obese individuals 
Obese 
87 668 
5.32 ± I. I 2 
1.1 6 ± 0.1 8 
2.34 ± 0.12 
40.54 ± 3.66 
5.26 ± 1.04 
1.44 ± 0.87 
0.88 ± 0.09 
1.40 ± 0.35 
22.27 ± 30.44 
3.20 ± 0.87 
3.92 ± 1.04 
9948.12 ± 27 19.64 
5669.19 ± 6 172.78 
9 I. I 5 ± 7 1.74 
168.69 ± 2 19.832.3 
3.24 ± 3.40 
1. 14 ± 0.86 
1.89 ± 0.24 
0.4 1 ± 0.27 
2.13 ± 0.26 
0.09 ± 0.24 
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Table 29. One-way ANOVA analysis comparing bone density and body composition data comparing al l cohort subjects factor ing for 
Bray percentage body fat categories of lean/normal indiv iduals, overweight and obese individuals. 
Total Arm BMD1•3 
Total Leg BMD3 
Total T runk BMD1•3 
Total Rib BMD1•3 
Total Pelvis BMD1•3 
Total BMD 1.J 
Arm % Fat1'2'3 
Arm tissue 1.l.J 
Arm Fat weight(g) 1'2'3 
Arm Lean muscle mass (g) IJ 
Arm Bone Mineral Composition 
Leg% Fat1'2J 
Leg Tissue weight(g) 1'2'3 
Leg Fat weight (g) 1'2'3 
Leg lean muscle mass(g) 3 
Leg bo ne minera l composition 1•3 
T runk% Fat1'2'3 
T runk T issue weight (g) 1•2J 
Trunk Fat weight (g) 1•2•3 
Trunk lean muscle mass (g) I .J 
Trunk bone mineral composition 2 
Android% fat mass1•2.J 
Andro id tissue mass (g ) 1•2.3 
Android Fat mass (g) 1.2.3 
Andro id lean muscle mass (g ) I.J 
Android BMC 1'3 
Gynecoid% Fat 1'2J 
Normal/Lean 
81 587 
0.90 ± 0.13 
1.28 ± 0.14 
0.92 ± 0.09 
0.66 ± 0.08 
1.14 ± 0. 13 
1.17 ± 0. 10 
25.68 ± 10.24 
6529.74 ± 1725.72 
1702.94 ± 745.78 
4825. 14 ± 1765.29 
342.67 ± 87. 19 
27.93 ± 8.43 
19969.64 ± 3 185.90 
5744.40 ± 1725. 16 
14224.95 ± 3464.48 
956.4 1 ± 199.95 
27.33 ± 7.02 
29662.71 ± 6650.4 7 
8333.69 ± 2937.65 
21329.24 ± 5 195.10 
776.48 ± 182.98 
31.57 ± 9.30 
4294.84 ± 11 37.1 8 
14 13.76 ± 720.95 
2882.37 ± 672.53 
51.65 ± 10.88 
35 .06 ± 8.96 
Entire Cohort 
Overweight 
78 544 
0.9 1 ± 0.13 
1.27 ± 0.13 
0.93 ± 0.09 
0.67 ± 0.08 
1.1 5 ± 0. 13 
1.1 7 ± 0. 10 
35.47 ± 9.03 
7504.79 ± 166 1.1 6 
2720.50 ± 803. 14 
4789.79 ± 1585 .63 
339.90 ± 82.80 
34.96 ± 7.72 
21581.43 ± 3399.5 1 
7778.74 ± 1822.75 
13789.86 ± 3399.91 
947.74 ± 200.12 
37.83 ± 4.64 
33828. 17 ± 6 189.72 
13066.08 ± 2708.24 
20835.74 ± 5015.93 
796.25 ± 170.1 2 
43.41 ± 6.0 1 
51 69.92 ± 11 29.92 
2281.76 ± 632 .73 
289 1.53 ± 66 1.47 
5 1.95 ± I 1. 18 
4 1.7 1 ± 7.57 
Obese 
87 668 
0.96 ± 0. 15 
1.29 ± 0. 13 
0.96 ± 0.09 
0.69 ± 0.08 
1.1 9 ± 0. 13 
1.21 ± 0. 10 
42.80 ± 10.22 
9703 .25 ± 3433 .69 
4376.67 ± 2238.68 
533 1.26 ± 1848.53 
347.1 1 ± 96.49 
40.95 ± 8.29 
25408.23 ± 4756.08 
10827.97 ± 31 16.14 
14584.73 ± 3504.63 
1013.89 ± 197.65 
44.84 ± 5.35 
41 186.06 ± 9268. 12 
18848.83 ± 4906.23 
22332.93 ± 5627.83 
803.4 1 ± 200.95 
51.1 8 ± 6. 15 
6669.00 ± 1749.80 
348 1.33 ± 1128.94 
3 189.17 ± 794.38 
55.56 ± 12.41 
46.72 ± 7.6 1 
Gynecoid tissue mass (g) •.u 
Gynecoid fat mass (g) 1'2.3 
Gynecoid lean muscle mass (g) 1•3 
Gynecoid BMC 1'2,J 
Total% body fat 1'2.3 
Total tissue mass (g) 1'2.3 
Total fat mass (g) 1'2.3 
Total lean muscle mass (g) J,J 
Total Bone Minera l Composition 1.3 
L2-L4 (Z-Score) 2 
L2-L4 BMC,J 
Fe moral Neck (Z-Score) 2 
Neck BMC3 
P-values less than 0.5 
NS- Not significant values are less than 0.5 
9999.27 ± 
3572.34 ± 
6426.25 ± 
260.28 ± 
26.52 ± 
60035.1 9 ± 
16368.56 ± 
43665 .57 ± 
2547.76 ± 
0.36 ± 
53 .02 ± 
0 .21 ± 
4 .88 ± 
1569.53 109 12.80 ± 
1017.09 4621.92 ± 
1563.39 6287.82 ± 
60.30 269.96 ± 
6.88 35.42 ± 
10266.83 67712.67 ± 
4380.5 1 24295.86 ± 
I 0039.22 42569.74 ± 
473.73 2564.79 ± 
1.25 0.20 ± 
10.51 52.36 ± 
1.0 I 0.10 ± 
0.98 4 .75 ± 
1 Normal/Underweight individuals are significantly different as compared with overweight individuals 
2 Normal!Underweight individuals are significantly different as compared with obese individuals 
3 Overweight individuals are significantly different as compared with only obese individuals 
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1494.39 12866.2 1 ± 2285.87 
90 1.45 6 158.80 ± 1570.41 
1467.24 6708.95 ± 1515.35 
60.69 296.44 ± 59.07 
5.26 42. 10 ± 6.2 1 
21841.82 80550.52 ± 155 18.30 
3907.63 350 18.28 ± 8741.91 
9626.79 45546.01 ± 10442.37 
454.04 2639.99 ± 444.00 
1.20 0. 14 ± 1.30 
11.12 55.12 ± 11.1 7 
0.87 0.02 ± 0.92 
0.83 4.95 ± 0.85 
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Table 30. One-way ANOV A analysis comparing descriptive characteristics of all male subjects factoring for Bray Percentage body 
fat categories of lean/normal individuals, overweight individuals and obese individuals. 
M ale 
Normal/Lean Overwei oht 
19 138 13 104 
Age1 38.08 ± 14.70 44.2 1 ± 13.10 
Weight (kg) t .z.J 75.66 ± 9.23 84.10 ± 9. 12 
Height (em) 176.37 ± 6.47 175.24 ± 5.87 
Waist (em) t.z.J 88.25 ± 7.41 97.21 ± 6.54 
Hip (em) 1.2.3 94.87 ± 6.09 100.66 ± 5.45 
Total %Body Fae·2•3 17.40 ± 4.33 25.44 ± 2.06 
Total %Trunk Fat1•2•3 20.90 ± 6.14 31 .04 ± 3.57 
Total BMD (g/em~) 2 1.24 ± 0.10 1.26 ± 0.09 
Spine BMD 1.24 ± 0.1 7 1.25 ± 0.1 6 
Left Hip BMD 1.04 ± 0.17 1.02 ± 0. 12 
BMJI,Z,J 24.33 ± 2.72 27.39 ± 2.72 
Waist-Hip Ratio 1'2.J 0 .93 ± 0.07 0.97 ± 0.04 
P-values less than 0.5 
NS- Not significant values are less than 0.5 
1 Nom1al/Underweight individuals are significantly different as compared with overweight individuals 
2 Normai/Underweight individuals are signiticantly different as compared with obese individuals 
3 Overweight individuals are significantly different as compared with only obese individuals 
Obese 
14 154 
41.40 ± 13.12 
93.35 ± 14.72 
174.99 ± 6.63 
107.04 ± 11.37 
107.6 1 ± 8.96 
32.66 ± 3.80 
38.07 ± 3.98 
1.28 ± 0.1 0 
1.27 ± 0.1 6 
1.04 ± 0.13 
30.46 ± 4.36 
0.99 ± 0.05 
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Table 31. One-way ANOV A analysis comparing laboratory values, HOMA-~, and HOMA-IR for all male subjects factoring for Bray 
Percentage body fat categories of lean/normal individuals, overweight individuals and obese individuals. 
Male 
Normal/Lean Overweight 
19 138 13 104 
Glucose2 5.08 ± 0.782 5.39 ± 0.83 
Phosphate 1.15 ± 0.17 1.13 ± 0.18 
Calc ium 2.37 ± 0. 14 2.36 ± 0. 10 
A lbumin 43 .03 ± 3.95 42.83 ± 3.68 
Cho lesterol' ·2 4.73 ± 1.02 1•2 5.32 ± 1.1 2 
Triglycerides1'2 1.1 6 ± 0.74 1•2 1.55 ± 0.99 
Magnesium' 0.88 ± 0. 10 1 0.9 1 ± 0.12 
Hoe 1.31 ± 0.272 1.25 ± 0.27 
GGT',z 19. 19 ± 10.00 12 29.25 ± 21.49 
LDL1'2 2.87 ± 0.93 1'2 3.35 ± 0.98 
Risk Factor1'2 3.74 ± 1.02 1•2 4.37 ± 1.15 
Buche1' 2 8956.3 8 ± 2968.32 12 10419.8 1 ± 1844.09 
Corrected Buche (S l Units) 1 2 173.02 ± 4388.43 1 9203.20 ± 5692.65 
Insulin •.z 54.27 ± 35.25'·2 76. 12 ± 44.77 
HOMA-P'J 10 1.2 1 ± 80.94 125.49 ± 89.83 
HOMA-lR2 1.79 ± 1.1 42 2.67 ± 1.66 
T rig lyceride/HDL ratio 1'2 0.97 ± 0.7612 1.36 ± 1.03 
Log lns ulin' ·2•3 1.68 ± 0.21 1,2 1.82 ± 0.223 
Log HOMA-lR 1' 2'3 0.19 ± 0.22 1•2 0.36 ± 0.253 
Log HOMA-P1'2J 1.93 ± 0.23 12 2.03 ± 0.233 
Log Trig lyceride 1'2 -0.01 ± 0.2412 0.11 ± 0.25 
Waist-H ip Ratio 1•2•3 0.93 ± 0.07 12 0.97 ± 0.043 
P-values less than 0.5 
NS- Not significant values are less than 0.5 
1 Nom1ai/Underweight individuals are significantly different as compared with overweight individuals 
2 Normal/Underweight individuals are significantly different as compared with obese individuals 
3 Overweight individuals are significantly different as compared with only obese individuals 
Obese 
14 154 
5.43 ± 1.33 
I. II ± 0.18 
2.36 ± 0.11 
42.33 ± 4 .06 
5.18 ± 1.1 0 
1.76 ± 1.07 
0.89 ± 0.1 1 
1.18 ± 0.24 
28.9 1 ± 25 .93 
3.18 ± 0.89 
4.50 ± 1.06 
10978.93 ± 2246.65 
6936.48 ± 664 9.55 
99.52 ± 73. 12 
180.38 ± 195.17 13 
3.76 ± 5.39 
1.60 ± 1.09 
1.92 ± 0 .24 
0.46 ± 0 .28 
2. 15 ± 0.28 
0. 17 ± 0.26 
0.99 ± 0.05 
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Table 32. One-way ANOV A analysis comparing bone density and body composition data comparing all male subjects factoring for 
Bray Percentage body fat categories of lean/normal individuals, overweight and obese indiv iduals. 
Male 
Normal/Lean Overweight Obese 
19 138 13 104 14 154 
Total Arm BMD2 1.04 ± 0.15 1.07 ± 0.14 1.09 ± 0. 15 
Total Leg BMD 1.44 ± 0. 13 1.43 ± 0.12 1.44 ± 0. 14 
Total Trunk BMD 0.98 ± 0. 10 1.00 ± 0.09 1.0 I ± 0.09 
Total Rib BMD 0.74 ± 0.09 0.76 ± 0.07 0.77 ± 0. 10 
Total Pelvis BMD 1•2 1.20 ± 0. 14 1.27 ± 0.13 1.27 ± 0.14 
Total BMD2 1.24 ± 0. 10 1.26 ± 0.09 1.28 ± 0. 10 
Arm % Fat1•2.J 11 .87 ± 4.59 19.42 ± 3.46 27.94 ± 7.44 
Arm tissue 1,z'3 8699.95 ± 1569.65 951 6. 17 ± 1493 .79 10863 .14 ± 3329.31 
Arm Fat weight(g) 1'2'3 I 091.99 ± 450.01 1947.84 ± 5 12.42 3292.69 ± 1891.48 
Arm Lean muscle mass (g) 760 1.46 ± 1360.47 7568.33 ± 11 82. 18 7570.5 1 ± 1669.57 
Arm Bone Mineral Composi tion 470.26 ± 70.32 472.97 ± 62.97 464.47 ± 82.84 
Leg% Fat1'2,J 15.38 ± 3.38 20.83 ± 2.65 28.41 ± 4.96 
Leg Tissue weight(g) 1'2'3 23 171.30 ± 334 1.92 25042.81 ± 3207.53 2766 1.52 ± 490 1.53 
Leg Fat weight (g) 1.2•3 3782.80 ± 1058.30 5492. 18 ± 1078. 12 8349.99 ± 2640.43 
Leg lean muscle mass(g) 19388.46 ± 27 13.80 19448.34 ± 27 10.60 1931 1.53 ± 292 1.90 
Leg bone minera l compos ition 1220.25 ± 180.37 1231.88 ± 17 1.30 1246.07 ± 184.09 
Trunk % Fat1•2•3 20.90 ± 6.14 3 1.20 ± 3.33 38.09 ± 4.08 
Trunk Tissue weight (g) 1•2 ,3 36 139.76 ± 683 1.1 8 4 1432.40 ± 53 13.07 46384.27 ± 9446.53 
Trunk Fat weight (g) 1'2'3 7938.99 ± 3 160.62 13305.9 1 ± 2595. 19 181 07.39 ± 4178.68 
Trunk lean muscle mass (g) 28200.70 ± 4771.24 28 126.41 ± 3283.26 28257.37 ± 6068.0 1 
Trunk bone mineral composition 976.57 ± 186.57 987.34 ± 172.55 929.90 ± 244.20 
Android % fat mass 1•2.J 26.55 ± 9.78 38.25 ± 5.9 1 45.57 ± 5.38 
Android tissue mass (g) 1•2,3 5286.37 ± 1159.95 6362.77 ± 1126.89 7599.6 1 ± 1821.37 
Android Fat mass (g) 1'2'3 15 11.36 ± 9 11.66 2483 .70 ± 656.63 3550. 17 ± 11 09.29 
Android lean muscle mass (g) 2 3782.26 ± 537.80 3878.97 ± 625.69 4049.43 ± 81 1.1 0 
Android BMC 58.97 ± 12.20 57.76 ± 12.65 60.26 ± 14.2 1 
Gynecoid % Fat1'2'3 22.74 ± 7.35 28.58 ± 4.65 35.45 ± 4.66 
-------------------
Gynecoid t issue mass (g) 1•2,3 
Gynecoid fat mass (g) 1' 2,3 
Gynecoid lean muscle mass (g) 
Gynecoid BMC2 
Total % body fat 1'2'3 
Tota l tissue mass (g) 1'2,3 
Tota l fat mass (g) 1'2,3 
Tota l lean muscle mass (g) 
Total Bone Minera l Composition 
L2-L4 (Z-Score) 
L2-L4 BMC2 
Femoral Neck (Z-Score) 
Neck BMC 
P-values less than 0.5 
NS- Not significant values are less than 0.5 
11 422.44 
2770.93 
8673 .33 
335.24 
17.41 
72525 .26 
13326.88 
59198.47 
3131.92 
0 .14 
59.80 
0 .06 
5 .80 
± 1648.74 
± 1266.53 
± 1220.05 
± 55.182 
± 4.3 1 
± 9082.39 
± 4068.20 
± 6829.57 
± 440.48 
± 1.33 
± 11.09 
± 1. 12 
± 1.0 I 
12251. 14 ± 1502.41 
3590.45 ± 659.75 
8652.94 ± 1248.52 
348.28 ± 57. 10 
25.48 ± 2.07 
80701.2 1 ± 8898.20 
2 1390.89 ± 3093.87 
593 10.50 ± 6539.28 
3 179.77 ± 388.32 
0.20 ± 1.34 
63.82 ± 11 .05 
0.00 ± 0.74 
5.70 ± 0.78 
1 Normal/Underweight individuals are significantly different as compared with overweight individuals 
2 Normal/Underweight individuals are significantly different as compared with obese individuals 
3 Overweight individuals are significantly different as compared wi th only obese individuals 
1373 1.95 ± 2251.86 
5037. 11 ± 1280.0 I 
8694.93 ± 1276.53 
357.50 ± 62. 17 
32.63 ± 3.7 1 
89787.93 ± 14492.4 1 
30550.55 ± 7144.35 
59237.39 ± 8697.89 
3119.46 ± 447.33 
0. 13 ± 1.36 
64.78 ± 10 .84 
-0.06 ± 0.9 1 
5 .8 1 ± 0.90 
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Table 33. One-way ANOV A analysis comparing descriptive characteristics for al l female subjects factoring for Bray Percentage body 
fat categories of lean/normal individuals, overweight individuals and obese individuals. 
Female 
Normal/Lean Overweight 
56 449 59 440 
Agel,2 42 .22 ± 11 .52 45.61 ± 10.33 
Weight (kg) 1.2..1 59.35 ± 7.28 66.89 ± 8.22 
Height (em) 1"2 162.86 ± 5.49 161.75 ± 5.75 
Waist (em) 1"2'3 80.03 ± 8.55 89.03 ± 9.32 
Hip (em) 1,2,3 93. 11 ± 6.1 8 100.73 ± 6.51 
Total% Body Fat1'2..J 29.32 ± 4.79 37.78 ± 2.08 
Total %Trunk Fat1·2..J 29.30 ± 6.03 39.39 ± 3.34 
Total BMD (g/em2) I..J 1.14 ± 0.08 1.15 ± 0.08 
Spine BM01..J 1.19 ± 0.16 1.19 ± 0. 15 
Left Hip BMD1..J 0.95 ± 0. 12 0.94 ± 0. 12 
BMI1'2..J 22.39 ± 2.58 25.57 ± 2.85 
Waist-Hip Ratio1'2..J 0.86 ± 0.07 0.88 ± 0.07 
P-values less than 0.5 
NS- Not significant values are less than 0.5 
1 Normal/Underweight individuals are significantly different as compared with overweight individuals 
2 Normal/Underweight individuals are significantly different as compared with obese individuals 
3 Overweight individuals are significantly different as compared with only obese individuals 
Obese 
73 5 14 
45.34 ± 10.6 1 
81.10 ± 14.71 
161.74 ± 6 .10 
I 02.15 ± 14.05 
11 2.32 ± 11.17 
44.96 ± 3.35 
46.78 ± 4.23 
1.18 ± 0.09 
1.23 ± 0.16 
0.97 ± 0.12 
30.99 ± 5.21 
0.91 ± 0.07 
--------------------------------------- - - --- -----------------------
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Table 34. One-way ANOV A analysis comparing laboratory values, HOMA-p, and HOMA-IR for a ll female subjects factoring for 
Bray Percentage body fat categories of lean/normal individuals, overweight individuals and obese individuals. 
Female 
Normal/Lean O verweight 
56 449 59 440 
G lucose1'2.J 4.86 ± 0.65 1,2 5.06 ± 0.923 
Phosphate I.J 1.23 ± 0. 17 1.21 ± 0. 17 
Calcium 2.35 ± 0. 12 2.34 ± 0. 13 
A lbumin1'3 4 1.64 ± 3.70 4 1.24 ± 3.97 
C holesteroll.2 5.05 ± 1.00 1·2 5.28 ± 1.06 
T rig lycerides 1'2.3 0.95 ± 0.56 1,2 1.1 4 ± 0.703 
Magnesium 0.89 ± 0.09 0.88 ± 0.08 
HDL 1'2.J 1.68 ± 0.39 12 1.56 ± 0.353 
GGT 17. 19 ± 24.3 1 16.20 ± 12.93 
LDL1'2 2.94 ± 0.86 1,2 3.20 ± 0.90 
Risk Factor1'2'3 3. 13 ± 0.82 1•2 3.51 ± 0.933 
Buche 1'2.J 8304.98 ± 2662.521.2 8903.00 ± 2494.983 
Corrected Buche (SI Uni ts) 5079.87 ± 4785.40 6684.62 ± 5001.34 
Insulin 1'2'3 52.46 ± 33.3 11.2 65.53 ± 83.653 
HOMA-~ 124.32 ± 206.24 124.50 ± 325.49 
HOMA-IR 1'2 ..l 1.70 ± 1.511.2 2.21 ± 4. 193 
T rig lyceride!HD L ratio 1•2.J 0.62 ± 0.47 12 0.81 ± 0.633 
Log Insulin 1.2.J 1.66 ± 0.22 1'2 1.74 ± 0.233 
Log HOMA-IR 1'2'3 0.15 ± 0.24 1•2 0.24 ± 0.253 
Log HOMA-~ 1.3 2.0 1 ± 0.24 2.05 ± 0.26 
Log T riglyceride1'u -0.07 ± 0.2 11.2 0.00 ± 0.233 
P-values less than 0.5 
NS- Not s ignificant values are less than 0.5 
1 Normal/Underweight individuals are significantly different as compared with overweight individuals 
2 Normai/Unden.veight individuals are signi ficantly different as compared with obese ind ividuals 
3 Overweight individuals are signi fican tly different as compared with only obese individuals 
Obese 
73 514 
5.29 ± 1.04 
1.1 7 ± 0. 171,3 
2.34 ± 0. 12 
40.03 ± 3.381.3 
5.29 ± 1.02 
1.34 ± 0.78 
0.87 ± 0.08 
1.47 ± 0.35 
20. 16 ± 31.47 
3.20 ± 0.87 
3.74 ± 0.97 
9639.7 1 ± 2775.00 
5426.15 ± 6095.61 
88.75 ± 7 1.24 
165.34 ± 226.47 
3.09 ± 2.56 
1.00 ± 0.72 
1.88 ± 0.24 
0.40 ± 0.27 
2. 13 ± 0.25 1.3 
0.06 ± 0.23 
----------- --------------
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Table 35 . One-way ANOVA analys is comparing bone density and body composition data comparing for all female subjects factoring 
for Bray Percentage body fat categories of lean/normal individuals, overweight and obese individuals. 
Female 
Norma l/Lean Overweight Obese 
56 449 59 440 73 514 
Total Arm BMD1'3 0.85 ± 0.08 0.87 ± 0.09 0.92 ± 0.12 
Total Leg BMD 1.J 1.23 ± 0.11 1.23 ± 0. 10 1.25 ± 0.10 
Total Trunk BMD1'3 0.90 ± 0.08 0.91 ± 0.08 0.95 ± 0.09 
Total Rib BMD1•3 0 .63 ± 0.05 0.65 ± 0.06 0.67 ± 0.05 
Total Pelvis BMD 1'3 I. I I ± 0. 11 1.11 ± 0. 10 1.1 6 ± 0.1 1 
Total BMD 1.J 1.1 4 ± 0.08 1.15 ± 0.08 1.18 ± 0.09 
Arm% Fat1' 2'3 29.93 ± 7.34 39.26 ± 4.75 47.27 ± 5.74 
Arm tissue1' 2.J 5862.73 ± 11 15.95 7029.37 ± 1305.63 9354.38 ± 3390.76 
Arm Fat weight(g) 1'2'3 I 890.72 ± 71 7.83 2903 .13 ± 749.25 4702.7 1 ± 2233 .88 
Arm Lean muscle mass (g) 1•2.3 3971.84 ± 637.26 41 33.05 ± 72 1.60 4657.73 ± I283 .I9 
Arm Bone Mineral Composition 303.74 ± 43.91 308.45 ± 48.62 3 11.81 ± 68.29 
Leg% Fae·2 31.79 ± 5.11 38.30 ± 3.69 44.71 ± 4.54 
Leg Tissue weight(g) 1'1 '3 18985.6 1 ± 2394.39 20763.28 ± 2893.33 24731.80 ± 4501.0 1 
Leg Fat weight (g) 1'2.3 6347.29 ± 1414.52 8319.20 ± 1518.36 11 57 1.84 ± 2854.17 
Leg lean muscle mass(g) u 12637.94 ± 1646.42 12449.36 ± 178 1.2 1 13165.77 ± 2 165.15 
Leg bone mineral composition1.J 875 .32 ± I I9.63 880.58 ± 137.85 944.05 ± 139.85 
T runk % Fat1'1'3 29.3 1 ± 6.03 39.40 ± 3.33 46.87 ± 3.79 
T runk Tissue weight (g) 1•2.3 27672.00 ± 5 166.03 32030.80 ± 4881.5 I 39625.58 ± 8631.37 
T runk Fat weight (g) 1'2 '3 8455.0 1 ± 2858.41 13009.40 ± 2734.07 1907 1.40 ± 5087.07 
Trunk lean muscle mass (g) I.J 192 17.29 ± 3053.91 19 11 2.49 ± 3608.6 1 20554.45 ± 4058.28 
Trunk bone mineral composition 1'2 7 14 .98 ± 130.49 75 1.08 ± 134.59 765.44 ± 168.67 
Android% fat mass1•2.J 33. 11 ± 8.58 44.63 ± 5.35 52.85 ± 5.31 
Android tissue mass (g) 1•2.3 3990. 10 ± 940.30 4887.33 ± 929. 16 6390.56 ± 1629.23 
Android Fat mass (g) 1'3 1383.77 ± 649.52 2233 .92 ± 618.09 3460.74 ± I I 35.02 
Android lean muscle mass (g) 2605.78 ± 420.78 2657.60 ± 403.75 293 1.76 ± 579.68 
A ndroid BMC1.J 49.40 ± 9.37 50.58 ± 10.36 54. 15 ± 11 .46 
Gynecoid % Fat 1'2.J 38.84 ± 5.22 44.82 ± 3 .9 1 50.09 ± 4 .39 
--------------------------------------
Gynecoid tissue mass (g) 1•2.3 
Gynecoid fat mass (g) 1' 2.3 
Gynecoid lean muscle mass (g) I.J 
Gynecoid BMC1'2.J 
Total % body fat1'2.J 
Total t issue mass (g) 1'2.J 
Total fat mass (g) 1'1 '3 
Total lean muscle mass (g) I.J 
Tota l Bone Mineral Composition 1.J 
L2-L4 (Z-Score) 2 
L2-L4 BMC3 
Femoral Neck (Z-Score) 2 
Neck BMC1'3 
P-values less than 0.5 
NS- Not significant values are less than 0.5 
956 1.85 ± 1255. 12 
38 18.65 ± 777. 15 
5735.6 1 ± 841.70 
237.23 ± 39.5 1 
29 .3 1 ± 4.79 
56224.19 ± 7094.96 
17296.65 ± 4042.30 
38926.14 ± 4599.27 
2369.51 ± 3 12.98 
0.44 ± 1.22 
50.74 ± 9.27 
0 .26 ± 0.96 
4 .56 ± 0.74 
10595 .75 ± 1306.37 
4866 .27 ± 768.59 
5727.5 1 ± 809.04 
25 1.40 ± 44.6 1 
37.77 ± 2.08 
64642.65 ± 22849.36 
24982.49 ± 3764.23 
38612.83 ± 4744.63 
24 19.44 ± 329.90 
0. 19 ± 1.1 6 
49.38 ± 9.01 
0. 12 ± 0.90 
4.50 ± 0.64 
1 Normal/Underweight individuals are significantly different as compared with overweight individuals 
2 Normal/Underweight individuals are significantly different as compared with obese individuals 
3 Overweight individuals are significantly different as compared with only obese individuals 
---------------- ----- - ---------
12607. 17 ± 2233.72 
6494.43 ± 1492.48 
6 114.7 1 ± 981 .39 
278. 17 ± 43.95 
44.94 ± 3.32 
77782.89 ± 14737.00 
36356.87 ± 8737.95 
41443 .93 ± 6788 .34 
2496.33 ± 327.03 
0. 14 ± 1.29 
52.20 ± 9.5 1 
0.04 ± 0.93 
4.70 ± 0.65 
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Table 36. One-way ANOV A analysis comparing descriptive data for al l subjects factoring for WHO BMI categories of lean/normal 
individuals, overweight and obese individuals. 
Entire Cohort 
Norma l/Lean Overweight 
ll 2 807 91 648 
Age1,2 41.65 ± 12.37 45 .00 ± 11.27 
Weight (kg) 1'2'3 6 1.59 ± 7.44 75.60 ± 8.39 
Height (em) 164.87 ± 7.63 165.51 ± 8.53 
Waist (em) 1.1'3 81.98 ± 7.94 94.99 ± 7.82 
Hip (em) 1'2,3 94.35 ± 6. 10 103.90 ± 5.78 
Total %Body Fat1'2'3 30.39 ± 7.88 36.68 ± 7.86 
Total %Trunk Fat1'2'3 3 1.14 ± 8.34 39.73 ± 7.32 
Total BMD (g/em2) 1'2,3 1.14 ± 0.08 1.19 ± 0.10 
Spine BMD1·2 1.18 ± 0. 15 1.24 ± 0 .16 
Left Hip BMD1'2,3 0.94 ± 0.13 0.98 ± 0.13 
BMJ1 ,2,3 22.62 ± 1.84 27.54 ± 1.48 
Waist-Hip Ratio1'2,3 0.87 ± 0.07 0.92 ± 0.07 
P-values less than 0.5 
NS- Not significant values are less than 0.5 
1 Normal/Underweight individuals are significantly different as compared with overweight individuals 
2 Normal/Underweight individuals are significantly different as compared with obese individuals 
3 Overweight individuals are significantly different as compared with only obese individuals 
Obese 
37 352 
45 .70 ± 11 .09 
94.05 ± 14.23 
164.79 ± 8 .52 
11 1.49 ± 12.01 
11 7. 17 ± 10.67 
42.26 ± 7.46 
45.0 1 ± 6 .19 
1.26 ± 0 .10 
1.26 ± 0.15 
1.03 ± 0 .13 
34.58 ± 4 .14 
0.95 ± 0.07 
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Table 37. One-way ANOVA analysis comparing laboratory, HOMA-~ and HOMA-IR data for all subjects factoring for WHO BMI 
categories of lean/normal individuals, overweight and obese individuals. 
Glucose1'2'3 
Phosphate1'2 
Calcium 
Albumin 1•2.J 
Cholesterol 1'2 
Triglycerides '·2 
Magnesium 
HDLI.2,3 
GGT1'2 
LDL1'2 
Risk Factor•.u 
Buche•.u 
Corrected Buche (SI Units) 
Insulin1'2'3 
HOMA-p2 
HOMA-IR1'2'3 
Triglyceride/HDL ratio 1•2.J 
Log lnsulin 1'2'3 
Log HOMA-IR 1'2'3 
Log HOMA-P1'2'3 
Log Triglyceride1'u 
P-values less than 0.5 
NS- Not significant values are less than 0.5 
Normal/Lean 
I 12 807 
4.87 ± 0.56 
1.21 ± 0.18 
2.35 ± 0. 13 
41.75 ± 3.88 
5.05 ± 1.02 
0.97 ± 0.53 
0.88 ± 0.09 
1.62 ± 0.37 
16.67 ± 19.24 
2.98 ± 0.88 
3.2 1 ± 0.80 
8543.13 ± 2599.1 6 
4887.44 ± 4745.27 
51.68 ± 28.67 
123.57 ± 169.35 
1.64 ± 1.04 
0.65 ± 0.46 
1.66 ± 0.20 
0. 16 ± 0.22 
2.01 ± 0.24 
-0.06 ± 0.2 1 
Entire Cohort 
Overweight 
9 1 648 
5.18 ± 0.93 
1.1 8 ± 0. 17 
2.35 ± 0. 12 
4 1.23 ± 3.77 
5.30 ± 1.05 
1.35 ± 0.89 
0.88 ± 0.08 
1.44 ± 0.36 
22.75 ± 32.39 
3.24 ± 0.91 
3.86 ± 1.09 
95 12.07 ± 2743.74 
6339. 19 ± 5847.78 
70.64 ± 40.35 
14 1.55 ± 139.78 
2.38 ± 1.50 
1.05 ± 0.86 
1.79 ± 0.22 
0.31 ± 0.24 
2.06 ± 0.25 
0.05 ± 0.25 
1 Normal/Underweight individuals are significantly different as compared with overweight individuals 
2 Normal/Underweight individuals are significantly different as compared with obese individuals 
3 Overweight individuals are significantly different as compared with only obese individuals 
Obese 
37 352 
5.62 ± 1.39 
1.1 5 ± 0.19 
2.34 ± 0. 12 
40.43 ± 3.77 
5.24 ± 1.07 
1.60 ± 0.86 
0.88 ± 0.11 
1.3 1 ± 0.31 
21.46 ± 12.64 
3.20 ± 0.89 
4.16 ± 1.02 
10399.85 ± 2426.79 
6557.08 ± 6450.26 
11 8.84 ± 119.52 
171.46 ± 425.60 
4.5 1 ± 6. 14 
1.34 ± 0.89 
1.99 ± 0.24 
0.54 ± 0.28 
2. 18 ± 0.26 
0. 15 ± 0.22 
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Table 38. One-way ANOVA analys is comparing percentage body fat and bone-mineral composition for all subjects facto ring for 
WHO BMI categories of lean/normal individuals, overweight and obese individuals. 
Entire Cohort 
Normal/Lean Overweight Obese 
11 2 807 9 1 648 37 352 
Total Arm BMD 1•2.3 0.87 ± 0.09 0.94 ± 0.14 1.02 ± 0.16 
Total Leg BMD1'2.3 1.24 ± 0. 12 1.30 ± 0.14 1.34 ± 0.13 
Total Trunk BMD1•2.3 0.90 ± 0.08 0.96 ± 0.09 1.00 ± 0.09 
Total Rib BMD1'2.3 0.64 ± 0.06 0.70 ± 0.08 0.72 ± 0.09 
Total Pelvis BMD1'2.3 1.1 I ± 0. 11 1.1 8 ± 0. 13 1.23 ± 0.13 
Total BMD1'2' 3 1.1 4 ± 0.08 1. 19 ± 0. 10 1.26 ± 0.10 
Arm % Fae ·2•3 30.24 ± 10.74 35.9 1 ± 11.43 43.90 ± 11.40 
Arm tissue 1'2.3 6280.25 ± 127 1.45 8260.80 ± 1458. 19 11478.64 ± 3824.78 
Arm Fat weight(g) 1'2.3 1979.06 ± 824.20 30 16.53 ± 1009. 10 5304.78 ± 263 1.70 
Arm Lean muscle mass (g) 1•2.3 4303.82 ± 1283.50 5248.92 ± 1682.3 1 6173.85 ± 2093.88 
Arm Bone Mineral Composition 1'2 320.20 ± 69.82 359.13 ± 9 1.26 369.46 ± 11 1.06 
Leg% Fat1'2.3 32. 11 ± 8.76 35.40 ± 9.86 40.04 ± 9.91 
Leg Tissue weight(g) 1'2'3 19625.44 ± 2722.39 23 128.98 ± 3067.86 27772.60 ± 4920.53 
Leg Fat weight (g) l,u 6559.47 ± 1985.21 8473.47 ± 248 1.59 11618.47 ± 3725.22 
Leg lean muscle mass(g) 1'2'3 13065.65 ± 2822.04 14660.11 ± 3469.9 1 16132.33 ± 3847.26 
Leg bone mineral composi tion1•2.3 905.48 ± 169.43 10 10.00 ± 208.95 1073.79 ± 200.25 
T runk % Fat1'2 '3 31. 15 ± 8.33 39.8 1 ± 7.15 45.05 ± 6.23 
Trunk T issue weight (g) 1' 2'3 28735. 19 ± 3952.2 1 36774.53 ± 4722.32 46869.61 ± 9910.64 
T runk Fat weight (g) 1'2'3 9229.55 ± 2936.52 149 16.09 ± 3022.83 2 1365.74 ± 5027.77 
Trunk lean muscle mass (g) 1•2.3 19493.47 ± 35 18.26 21858.66 ± 4317.85 25637.79 ± 7475.18 
Trunk bone mineral composition 1•2.3 747.86 ± 153 .96 852. 17 ± 181.86 79 1.75 ± 226.6 1 
Android% fat mass 1'2.3 35.42 ± 10.14 45.7 1 ± 7.86 52. 19 ± 6.58 
Android tissue mass (g) 1•2.3 4207.27 ± 846.49 5708.13 ± 939. 13 7743.59 ± 1663 .94 
Android Fat mass (g) 1.2.3 1546.54 ± 665.87 2646.70 ± 660.95 4093.94 ± 1092.02 
Android lean muscle mass (g) 1•2•3 2664.19 ± 5 11. 18 306 1.0 1 ± 625.91 3652.85 ± 858.01 
Android BMC 1' 2 
Gynecoid% Fae·2,.1 
Gynecoid tissue mass (g) 1'2'3 
Gynecoid fat mass (g) 1' 2.1 
Gynecoid lean muscle mass (g) 1•2•3 
Gynecoid BMC 1' 2.1 
Total % body fae'2'3 
Total tissue mass (g) 1'2,3 
Total fat mass (g) 1'2'3 
Total lean muscle mass (g) •.z,J 
Total Bone Mineral Composition 1'2 
L2-L4 (Z-Score) 
L2-L4 BMC1'2'3 
Femoral Neck (Z-Score) 
Neck BMC·2,3 
P-values less than 0.5 
NS- Not significant values are less than 0.5 
50.33 ± 
39.05 ± 
9902.99 ± 
3970.35 ± 
10. 17 
8.99 
1332.68 
11 00.76 
5930.92 ± 1243.03 
247.23 ± 49.65 
30.38 ± 7.85 
58987.97 ± 17559.30 
18421.37 ± 5156.29 
40005.15 ± 7704.82 
2445.10 ± 396.19 
0.24 ± 1.18 
50.74 ± 9.73 
0 .10 ± 0.95 
4.63 ± 0.81 
55.30 ± 11 .84 
41.81 ± 9.41 
11657.44 ± 
4978.53 ± 
6677.92 ± 
291.24 ± 
36.68 ± 
72237.12 ± 
27174.21 ± 
45063.38 ± 
139 1.26 
1243.02 
1488.663 
59.963 
7.85 
8 180.48 
5451 .30 
9690.49 
2697.95 ± 475 .28 
0.28 ± 1.31 
54.61 ± I 1.43 
0.05 ± 0.88 
4 .95 ± 0.9 1 
1 Normal/Underweight individuals are significantly different as compared with overweight individuals 
2 Normal/Underweight individuals are significantly different as compared with obese individuals 
3 Overweight individuals are significantly different as compared with only obese individuals 
56.31 ± 
45.76 ± 
14028. 17 ± 
6590.74 ± 
7440.27 ± 
13.58 
8.95 
2317.63 
1822.18 
1650.5 1 
3 18.45 ± 58.41 
42.23 ± 7.44 
90672.72 ± 14267.45 
39324.99 ± 9270.84 
51347.75 ± 11 253 .87 
27 19.88 ± 468.91 
0.12 ± 1.31 
57.90 ± 11.22 
0.19 ± 0.97 
5.21 ± 0 .86 
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Table 39. One-way ANOVA analysis comparing descriptive data for all male subjects factoring for WHO BMI categories of 
lean/normal individuals, overweight and obese individuals. 
Male 
Normal/Lean Overweight 
15 124 25 184 
Agel,2 36.5 1 ± 15.13 42.55 ± 13.2 1 
Weight (kg) 1'2.J 71.73 ± 6.95 84.49 ± 7.00 
Height (em) 2 176.36 ± 6.68 175.55 ± 6.36 
Waist (em) 1'2'3 87.28 ± 8.83 97.65 ± 6.88 
Hip (em) I.2.J 94.03 ± 7.58 101.05 ± 5.34 
Total %Body Fat1'2.J 18.70 ± 6.48 26.49 ± 5.45 
Total %Trunk Fat1•2.J 21 .99 ± 8.0 1 32.01 ± 6.51 
Total BMD (g/em2 ) 1'2.J 1.20 ± 0.09 1.27 ± 0.09 
Spine BMD 1'2 1.20 ± 0.14 1.28 ± 0.1 7 
Left Hip BMD1'2 1.00 ± 0. 16 1.04 ± 0. 14 
BMII,2,3 23.05 ± 1.70 27.39 ± 1.33 
Waist-Hip Ratio1'2'3 0.93 ± 0.07 0.97 ± 0.05 
P-values less than 0.5 
NS- Not significant values are less than 0.5 
1 Normal/Underweight individuals are significantly different as compared with overweight individuals 
2 Normal/Underweight individuals are significantly different as compared with obese individuals 
3 Overweight individuals are significantly different as compared with only obese individuals 
Obese 
6 92 
43.53 ± 13.13 
102.43 ± 12.07 
174. 17 ± 5.89 
112.40 ± 8.95 
111.44 ± 7.44 
32. 11 ± 4.92 
37.43 ± 4.54 
1.33 ± 0.09 
1.28 ± 0. 15 
1.08 ± 0. 12 
33.73 ± 3. 19 
1.0 1 ± 0.05 
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Table 40. One-way ANOV A analysis comparing laboratory, HOMA-P and HOMA-IR data for all male subjects factoring fo r WHO 
BMI categories of lean/normal individuals, overweight and obese individuals. 
Normal/Lean 
15 124 
Glucose1' 2 5.02 ± 0.70 
Phosphate1,z 1.18 ± 0.18 
Calcium 2.36 ± 0.15 
Albumin 42 .87 ± 4.03 
Cho lestero l1'2 4.75 ± 1.04 
Triglycerides 1' 2,J 1.12 ± 0.71 
Magnesium 0.88 ± 0. 11 
HDL1' 2,J 1.34 ± 0.27 
GGT 22 .75 ± 19.57 
LDL' 2.87 ± 0.92 
Risk Factor1'2 3 .63 ± 0.92 
Buche 1' 2 9239.51 ± 2850.01 
Corrected Buche (S l Units) 389 1.23 ± 5050.08 
Insulin 1'2'3 57.15 ± 43. 16 
HOMA-P2 11 6.2 1 ± 99.44 
HOMA-IR 1.88 ± 1.49 
Triglyceride/HDL ratio 1'2,J 0 .90 ± 0.69 
Log Insulin1'2'3 1.70 ± 0.20 
Log HOMA-IR 1'2'3 0.21 ± 0.22 
Log HOMA-P 1.98 ± 0.24 
Log Triglyceride 1'u -0.02 ± 0.24 
P-values less than 0.5 
NS- Not significant values are less than 0.5 
Male 
Overweight 
25 184 
5.34 ± 1.02 
1.12 ± 0 .16 
2.37 ± 0.10 
42.81 ± 3.95 
5 .2 1 ± 1.10 
1.55 ± 1.03 
0.89 ± 0.08 
1.23 ± 0.25 
28.29 ± 24.6 1 
3.25 ± 0.96 
4.36 ± 1. 14 
I 03 10.09 ± 2505.82 
5563.67 ± 6078.65 
73.59 ± 48.1 6 
137.94 ± 181.10 
2.53 ± 1.64 
1.37 ± 1.06 
1.80 ± 0.24 
0.33 ± 0.26 
2.02 ± 0.28 
0. 11 ± 0.27 
1 Normal/Underweight individuals are significantly different as compared with overweight individuals 
2 Normal/Underweight individuals are significantly different as compared with obese individuals 
3 Overweight individuals are signi ficantly different as compared with only obese individuals 
Obese 
6 92 
5.62 ± 1.40 
1.09 ± 0.18 
2.36 ± 0.10 
42.44 ± 3 .82 
5.13 ± 1. 13 
1.89 ± 1.00 
0.90 ± 0.16 
1.13 ± 0.23 
24.96 ± 13.78 
3. 14 ± 0.9 1 
4.64 ± 1.02 
11044.03 ± 1754.12 
10096.55 ± 7978.38 
11 2.92 ± 75.79 
168.68 ± 87.09 
4 .53 ± 6.59 
1.78 ± 1.08 
1.99 ± 0.22 
0.54 ± 0.27 
2.17 ± 0.232 
0.22 ± 0.22 
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Table 41. One-way ANOV A analysis comparing body fat and bone-mineral composition all male subjects factoring for WHO BMI 
categories of Jean/normal indiv iduals, overweight and obese indiv iduals. 
Total Arm BMD1'2,.J 
Total Leg BMD 1'2 
Total Trunk BMD 1•2 
Total Rib BMD 1' 2 
Tota l Pelvis BMD1•2,.J 
Total BMD 1' 2'3 
Arm % Fat1'2'3 
Arm tissue1•2•3 
Arm Fat weight(g) I.Z..J 
Arm Lean muscle mass (g) 1•2 J 
Arm Bone Mineral Composition 1•2 
Leg% Fat1'2..J 
Leg Tissue weight(g) 1"2'3 
Leg Fat weight (g) 1'2J 
Leg lean muscle mass(g) 1"2"3 
Leg bone mineral composition 1' 2 
Trunk % Fat 1'2'3 
Trunk Tissue weight (g) 1•2J 
Trunk Fat weight (g) 1•2•3 
Trunk lean muscle mass (g) 1•2J 
Trunk bone mineral composition•..J 
Android % fat mass1•2,.J 
Android tissue mass (g) 1"2.3 
Android Fat mass (g) 1"2.3 
Android lean muscle mass (g) 1•2•3 
Android BMC1 
Gynecoid % Fat1"2J 
Normal/Lean 
IS 124 
0.97 ± 0.10 
1.39 ± 0.13 
0.94 ± 0.09 
0.70 ± 0.05 
1.1 6 ± 0.11 
1.20 ± 0.09 
13.00 ± 6.06 
8017.69 ± 12 15 .76 
11 08.94 ± 602.98 
690 1.48 ± 1069.22 
435.37 ± 71.68 
17.09 ± 5.63 
22322.70 ± 2758.82 
4036.05 ± 1446.14 
18286.45 ± 2414.2 1 
11 60.4 1 ± 168.40 
22.02 ± 8. 12 
33928.49 ± 3790.51 
7826.85 ± 3369.93 
26 101.55 ± 2929.48 
909.25 ± 171.70 
27.7 1 ± 11.26 
5053.93 ± 1081.29 
1517.41 ± 974.75 
3544.55 ± 472.78 
56.3 I ± II. 18 
24.27 ± 8.47 
Male 
Overweight 
25 184 
1.08 ± 0.13 
1.44 ± 0.12 
1.0 I ± 0.08 
0.77 ± 0.06 
1.27 ± 0. 12 
1.27 ± 0.09 
20.44 ± 6.74 
9627.86 ± 1174.76 
2041.47 ± 666.38 
7586.42 ± 1167.76 
478.76 ± 63.51 
22.29 ± 5.43 
25286.35 ± 2943 .34 
5954.52 ± 1780.34 
1933 1.80 ± 2367.88 
125 1.54 ± 162.8 1 
32.1 0 ± 6.43 
4 1425.63 ± 4300.85 
13739.68 ± 3536.20 
27685.89 ± 2923.87 
1017.09 ± 179.49 
38.36 ± 8.00 
6380.99 ± 1032.67 
2523 .73 ± 809.66 
3857.27 ± 473.40 
60.59 ± 13.29 
29.40 ± 5.72 
Obese 
6 92 
1.16 ± 0. 16 
1.47 ± 0. 14 
1.03 ± 0.09 
0.80 ± 0. 13 
1.33 ± 0. 15 
1.33 ± 0.09 
28.7 1 ± 8.1 3 
12283.04 ± 3693 .87 
3829.85 ± 2215.40 
8453.28 ± 1866.74 
491.64 ± 80.78 
27.20 ± 6.75 
29712.40 ± 5195.79 
8682.17 ± 3240.89 
20914.55 ± 33 18.91 
1293.27 ± 193.77 
37.44 ± 4.57 
5 1705 .23 ± 10 138.70 
19642.96 ± 3900.78 
32029.65 ± 7694.28 
917.52 ± 27 1.32 
46.28 ± 5.57 
8485 .09 ± 1738.39 
3985.45 ± 1062.26 
4499.65 ± 882.62 
59.86 ± 14.62 
35.09 ± 6.82 
Gynecoid tissue mass (g) 1'1'3 11011.88 ± 1555.65 12429.35 ± 1344.63 
Gynecoid fat mass (g) '·1,3 2863.57 ± 1384.58 3770.49 ± 904.16 
Gynecoid lean muscle mass (g) 1•1•3 8172.81 ± 1104.92 8654.52 ± 1070.04 
Gynecoid BMC 1' 1.J 314.78 ± 50.24 355 .59 ± 53.40 
Total %body fat 1•1.J 18.69 ± 6 .37 26.52 ± 5.45 
Total tissue mass (g) ' ·1,3 68707.16 ± 6802.73 80988.91 ± 6798.51 
Total fat mass (g) 1'1,3 135 16.45 ± 5023 .62 22391.27 ± 5285.41 
Total lean muscle mass (g) 1•1,3 55190.83 ± 6093 .14 58597.72 ± 6030.06 
Total Bone M ineral Composition 1'1 2966.17 ± 420.03 3223.26 ± 405.37 
L2-L4 (Z-Score) -0 .07 ± 1.15 0.3 1 ± 1.46 
L2-L4 BMC'·1 57.30 ± 9.44 64 .34 ± 11 .60 
Femoral Neck (Z-Score) -0.16 ± 1. 11 0.01 ± 0.86 
Neck BMC'·1 5.46 ± 0 .90 5 .82 ± 0.90 
P-values less than 0.5 
NS- Not significant values are less than 0.5 
1 Normal/Underweight individuals are significantly different as compared with overweight individuals 
2 Normal!Underweight individuals are significantly different as compared with obese individuals 
3 Overweight individuals are significantly different as compared with only obese individuals 
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14734.36 ± 2232.27 
5342.04 ± 1489.38 
9392.35 ± 1427.44 
372.92 ± 62.46 
32.10 ± 4.89 
98833 .64 ± 11927.88 
32971 .78 ± 75 11.57 
6586 1.9 1 ± 7671.97 
3195.86 ± 426.92 
0.11 ± 1.31 
66.89 ± 10.0 1 
0.15 ± 0.85 
6 .09 ± 0.76 
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Table 42. One-way ANOV A analysis comparing descriptive data for all female subjects factoring for WHO BMI categories of 
lean/normal individuals, overweight and obese individuals. 
Female 
Norma l/Lean O verweight 
92 683 56 461 
Age1'2 42.58 ± 11 .57 46.02 ± 10.23 
Weight (kg) 1'2..1 59.75 ± 5.88 72.02 ± 5.90 
Height (em) 1'2 162.78 ± 5.69 161.48 ± 5.41 
Waist (em) 1'2..1 81 .05 ± 7.40 93.97 ± 7.94 
Hip (em) 1'2..1 94.40 ± 5.81 104.98 ± 5.54 
Total % Bo dy Fat1'2'3 32.51 ± 6.04 40.72 ± 4.03 
Total% Trunk Fat1'2..1 32.81 ± 7.25 42.78 ± 4.97 
Total BMD (g/cm2) •.2..1 1.1 3 ± 0.08 1.16 ± 0.08 
Spine BMD 1'2'3 1.18 ± 0. 15 1.22 ± 0.1 5 
Left Hip BMD1'2.J 0 .94 ± 0.12 0.95 ± 0.1 1 
BMII,2,3 22.55 ± 1.85 27.60 ± 1.53 
Waist-Hip Ratio1'2..1 0.86 ± 0.07 0.90 ± 0.07 
P-values less than 0.5 
NS- Not significant values are less than 0.5 
1 Normal/Underweight individuals are significantly different as compared with overweight individuals 
2 Normai!Underweight individuals are significantly different as compared with obese individuals 
3 Overweight individuals are signi ficantly different as compared with only obese individuals 
Obese 
31 259 
46.55 ± 10. 12 
91. 10 ± 13.79 
161.46 ± 6.64 
11 1.23 ± 12.90 
11 9. 18 ± 10.94 
45 .84 ± 4.19 
47.71 ± 4.12 
1.23 ± 0.09 
1.25 ± 0.15 
1.0 I ± 0.12 
34.89 ± 4.40 
0.93 ± 0 .07 
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Table 43. One-way ANOVA analysis comparing laboratory, HOMA-~ and HOMA-IR data for all female subjects factoring for WHO 
BMI categories of lean/normal individua ls, overweight and obese individuals. 
Normal/Lean 
92 683 
G lucose1'2.J 4 .84 ± 0.53 
Phosphate2 1.22 ± 0.1 7 
Calc ium 2.35 ± 0. 12 
Albumin'·2.J 4 1.56 ± 3.82 
Cho I estero 11 5. 10 ± 1.0 I 
T rig lycerides 1•2.J 0 .95 ± 0.49 
Magnesium 0.89 ± 0.09 
HDL'·u 1.67 ± 0.37 
GGT' 15.38 ± 18.95 
LDL1'2 3.00 ± 0.87 
Risk Factor1'2'3 3 .14 ± 0.75 
Buche '·2.J 842 1.96 ± 2536.47 
Corrected Buche (S1 Uni ts) 4994 .94 ± 47 17.88 
1nsulin 1•2•3 50.77 ± 25 .40 
HOMA-P2 124.80 ± 178.45 
HOMA-IR 1'2.J 1.60 ± 0.94 
Trig lyceride!HDL ratio '·2.J 0.60 ± 0.38 
Log 1nsul in1'2'3 1.66 ± 0.20 
Log HOMA-IR'-2'3 0. 15 ± 0.2 1 
Log HOMA-p'·u 2.0 1 ± 0.24 
Lo<> Trio!yceride 1'2.J -0.07 ± 0.20 
P-values less than 0.5 
NS- Not significant values are less than 0.5 
Female 
Overweight 
56 461 
5. 12 ± 0.89 
1.20 ± 0. 17 
2.34 ± 0.12 
40.64 ± 3 .54 
5.33 ± 1.04 
1.27 ± 0.82 
0.88 ± 0.08 
1.52 ± 0.36 
20.40 ± 34.95 
3.24 ± 0.89 
3.66 ± 1.00 
9 193 .07 ± 2783.85 
6660.67 ± 5781.3 1 
69.3 1 ± 36.88 
142.73 ± 120.80 
2.3 1 ± 1.44 
0.92 ± 0.74 
1.79 ± 0.2 1 
0.30 ± 0.23 
2.08 ± 0.24 
0.03 ± 0.24 
1 Normal/Underweight individuals are signi ficantly diffe rent as compared with overweight individuals 
2 Normal/Underweight individuals are significantly different as compared with obese individuals 
3 Overweight individuals are significantly difterent as compared with only obese individuals 
Obese 
3 1 259 
5.62 ± 1.39 
1. 18 ± 0. 18 
2 .34 ± 0. 13 
39.74 ± 3.50 
5 .28 ± 1.05 
1.50 ± 0.79 
0.87 ± 0.09 
1.37 ± 0.31 
20.14 ± 11 .96 
3.22 ± 0.89 
3.99 ± 0.97 
10174.45 ± 2598.53 
5872.02 ± 6027.23 
12 1.1 9 ± 131.72 
172.55 ± 493 .23 
4.52 ± 5.99 
1. 18 ± 0.76 
1.99 ± 0.25 
0 .54 ± 0.28 
2 .18 ± 0.28 
0 .12 ± 0.22 
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Table 44. One-way ANOV A analys is comparing body fat and bone-mineral composition a ll female subjects factoring for WHO BMI 
categories of lean/normal indiv iduals, overweight and obese individuals. 
Total Arm BMD1'2.J 
Total Leg BMD 1' 2.J 
Total Trunk BMD 1'2.J 
Total Rib BMD 1' 2.J 
Total Pelvis BMD 1' 2.J 
Total BMD 1' 2' 3 
Arm % Fat1' 2' 3 
Arm tissue 1'2.J 
Arm Fat weight(g) 1'2,3 
Arm Lean muscle mass (g) 1•2.3 
Arm Bone Mineral Composition 1•2,.J 
Leg% Fat1'2.J 
Leg Tissue weight(g) I .2.J 
Leg Fat weight (g) 1' 2.3 
Leg lean muscle mass(g) 1'2'3 
Leg bone mineral composition1'2'3 
Trunk % Fat1'2'3 
Trunk T issue weight (g) 1•2.3 
Trunk Fat weight (g) 1'2'3 
Trunk lean muscle mass (g) 1'2.3 
Trunk bone mineral composition 1•2•3 
Android % fat mass1•2.J 
Andro id tissue mass (g) 1•2.3 
Android Fat mass (g) 1' 2'3 
Android lean muscle mass (g) 1•2.3 
Android BMC1' 2 
Gynecoid % Fat1'2,.J 
Gynecoid tissue mass (g) 1' 2'3 
Normal/Lean 
92 683 
0 .85 ± 0.08 
1.2 I ± 0. I 0 
0.89 ± 0.07 
0.63 ± 0.05 
1.09 ± 0.10 
1.1 3 ± 0.08 
33 .37 ± 8. 10 
5964.81 ± 997.72 
2137.03 ± 758.01 
3832.20 ± 539.53 
299.29 ± 44.55 
34.84 ± 6.05 
19135.75 ± 2413.15 
7017.61 ± I 706.60 
12 11 6.41 ± 1579.83 
859.20 ± I 2 1.86 
32.80 ± 7.22 
27792.34 ± 3 174.06 
9484.22 ± 2778.5 I 
18293.76 ± 1923 .57 
718.56 ± 130.76 
36.80 ± 9.28 
4054.58 ± 695.47 
I 55 1.80 ± 594. 19 
2505.4 1 ± 32 1.29 
49.25 ± 9.60 
41.7 1 ± 5.99 
9703 .00 ± 1183.69 
Female 
Overweight 
56 461 
0.89 ± 0. 10 
1.24 ± 0. 10 
0.93 ± 0.08 
0.66 ± 0.06 
1. 13 ± 0.1 1 
1. 16 ± 0.08 
42.05 ± 5.58 
7709.38 ± I 176. 1 I 
3400.22 ± 845.83 
4315.69 ± 606.90 
3 11. 16 ± 45.04 
40.6 1 ± 5.25 
22258.09 ± 2669.04 
9470.25 ± 1937.00 
I 2794.33 ± I 540.90 
9 12.97 ± 132.75 
42 .86 ± 4.65 
34906.52 ± 3434.23 
15371.10 ± 265 I .68 
19535.76 ± 19 16.82 
784.73 ± 133 .10 
48.62 ± 5.55 
5437.13 ± 747.90 
2693 .23 ± 586.51 
2743.28 ± 322.54 
53.05 ± 10.34 
46.74 ± 4.90 
11 340.72 ± 1283.62 
Obese 
31 259 
0.97 ± 0.12 
1.29 ± 0.09 
0.98 ± 0.09 
0.69 ± 0.05 
1.20 ± 0. 11 
1.23 ± 0.09 
49.3 I ± 6.44 
111 93.32 ± 3844.14 
5829.90 ± 2576.52 
5363.39 ± 1488.67 
326.33 ± 85.5 I 
44.57 ± 6.12 
27049.76 ± 46 I 4.27 
12635.43 ± 3289.48 
14425.93 ± 2268.69 
994.96 ± 133.24 
47.75 ± 4. 17 
45196.34 ± 9247.14 
22000.92 ± 5240.02 
23389.23 ± 5932.19 
746.66 ± 190. 12 
54.29 ± 5.55 
7485.42 ± I 554.42 
4 136.09 ± 11 02.88 
3353.68 ± 608.69 
54.82 ± 12.56 
49.54 ± 6.04 
13774.02 ± 2303.87 
Gynecoid fat mass (g) 1'2'3 
Gynecoid lean muscle mass (g) 1•2•3 
Gynecoid BMC 1'2'3 
Total % body fat 1' 2.J 
Total tissue mass (g) 1' 2,3 
Total fat mass (g) 1' 2,3 
Total lean muscle mass (g) •.u 
Total Bone Mineral Composition 1'2.J 
L2-L4 (Z-Score) 
L2-L4 BMC2•3 
Femoral Neck (Z-Score) 
Neck BMC'·2 
P-values less than 0.5 
NS- Not significant values are less than 0.5 
4169.96 ± 
5526.59 ± 
235.05 ± 
32.49 ± 
57237.66 ± 
19304.69 ± 
37270.39 ± 
2351.26 ± 
0.29 ± 
49.46 ± 
0.15 ± 
4.47 ± 
908.8 1 
730.74 
38.55 
6.03 
183 18 .13 
4663.43 
3788.07 
309.72 
1.18 
9.26 
0.91 
0.69 
5453.28 ± 997.23 
5887.80 ± 676.35 
265.16 ± 39.34 
40.72 ± 4.03 
687 16.33 ± 5702.59 
29054.00 ± 4176.32 
39662.96 ± 3797.46 
2485.71 ± 308.23 
0.26 ± 1.25 
50.66 ± 8.67 
0.07 ± 0.89 
4.59 ± 0.62 
1 Normal/ Underweight individuals are significantly different as compared with overweight individuals 
2 Normal/Underweight individuals are significantly different as compared with obese individuals 
3 Overweight individuals are significantly different as compared wi th only obese individuals 
7032.05 ± 
6745.83 ± 
1722.25 
1056.30 
298.65 ± 42.29 
45.80 ± 4.15 
87798.58 ± 13948.25 
41572.18 ± 8805.81 
46226.42 ± 7056.0 1 
2550.39 ± 353.80 
0.12 ± 1.3 1 
54.57 ± 9.73 
0.20 ± 1.02 
4.90 ± 0.65 
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Table 45. Summary of single nucleotide polymorphisms, allele frequencies, and Hardy-Weinberg equilibrium (HWE). HWE was 
estimated using chi-squared analysis with one-degree of freedom . 
Position (Base Pair RS number Variant Location MAF/Minor a llele HWE (P-value) 
Number) count 
188043476 rs 182052 A/G Intron 0.412/902 l 
188054508 rs3774262 A/G Intron 0.142/321 0.01 1 
188056399 rs6773957 AIG 3' UTR 0.489/ 1070 0.877 
188056769 rsl 063537 CIT 3'UTR 0.142/311 0.007 
188058086 rs I 063539 C/G 3'UTR 0.146/320 0.021 
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Table 46. Linkage disequilibrium analysis for the 5 SNPS assessed on the adiponectin gene. These are the measures of linkage 
disequilibrium (D' and R2) among the five SNPs in adiponectin. 
SNPl x SNP2 D D' r R"2 n 
rs1063537 x rs1063537 0.08427 0 .999192 0.999192 0.998384 1796 
rs1063537 x rs3774262 0.083679 0.994929 0.980436 0.961255 1706 
rs1063537 x rs182052 -0.0193 0 .625157 -0.14113 0.019919 1705 
rs1063537 x rs1063539 0.080878 0.968486 0.920604 0.847512 1634 
rs1063537 x rs6773957 0.058224 0.998831 0.414554 0.171855 1706 
rs3774262 x rs3774262 0.086301 0.99919 0 .99919 0.99838 1707 
rs3774262 x rs182052 -0.01945 0.613495 -0 .14055 0.019754 1705 
rs3774262 x rs1063539 0.082408 0 .960927 0 .92692 0.859181 1633 
rs3774262 x rs6773957 0.059793 0.998831 0.420681 0.176973 1705 
rs182052 x rs182052 0.221745 0.999764 0.999764 0.999529 1706 
rs182052 x rs1063539 -0.01548 0.457365 -0.10862 0.011799 1634 
rs182052 x rs6773957 -0.071 0.573115 -0.31174 0.097182 1704 
rs1063539 x rs1063539 0 .091439 0.999184 0.999184 0.998368 1634 
rs1063539 x rs6773957 0 .055524 0 .869198 0 .379514 0.144031 1634 
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Table 47. A multivariate regression analysis of total bone mineral density for each SNP frequency, factoring for 4 specific 
confounding variables. The values listed are the p-values for each regression. 
SNP No confounders Gender Age Medication Status Smoking Status 
rsl 063537 0.3936 0.4602 0.2655 0.6576 0.831 25 
rs3774262 0.4905 0.8213 0.4598 0.8969 0.55384 
rs 182052 0.7817 0.1589 0.9134 0.5447 0.20145 
rsl 063539 0.8648 0.3016 0.6531 0.29 0.1 3557 
rs6773957 0.6446 0.3812 0.04078* 0.5075 0.7464 
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Table 48. A multivariate regression analysis of spine bone mineral density between discs L2-L4 for each SNP frequency, factoring for 
4 specific confounding variables. The values listed are the p-values for each regression. 
SNP No confounders Gender Age Medication Status Smoking Status 
rsl063537 0.4053 0.2378 0.5428 0.45211 0.835004 
rs3774262 0.701 0.5171 0.8097 0.56177 0.89 
rs 182052 0.5128 0.8618 0.858 0.50072 0.74536 
rsl063539 0.5259 0.1339 0.593 0.08479 0.6365 
rs6773957 0.4268 0.8832 0.513 0.56067 0.6071 
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Table 49. A multivariate regression analysis of left hip-femoral neck bone mineral density for each SNP frequency, factoring for 4 
specific confounding variables. The values listed are the p-values for each regression . 
SNP No confounders Gender Age Medication Status Smoking Status 
rsl063537 0.9671 0.3241 0.5186 0.9922 0.820159 
rs3774262 0.7457 0.4231 0.5274 0.6941 0.515642 
rsl82052 0.7272 0.1801 0.6292 0.3146 0.103945 
rsl063539 0.2219 0.1152 0.9731 0.7782 0.335048 
rs6773957 0.8978 0.8844 0.0863 0.5421 0.258928 
,----------------------------------------------------
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Table 50. A multivariate regression analysis of total percentage body fat measured by DEXA for each SNP frequency, factoring for 4 
specific confounding variables. The values listed are the p-values for each regression. The significant values are bolded. 
SNP No confounders Gender Age Medication Status Smoking Status 
rsl063537 0.8309 0.577 0.08669 0.7474 0.4357 
rs3774262 0.3624 0.6629 0.06179 0.8522 0.6245 
rs 182052 0.2 103 0.95496 0.1347 0.7434 0.1837 
rsl063539 0.8978 0.9001 0.01256 0.571 9 0.7156 
rs6773957 0.6297 0.5078 0.3079 0.9649 0.5824 
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Table 51. A multivariate regression analysis of total percentage trunk fat measured by DEXA for each SNP frequency, factor ing for 4 
specific confounding variables. The values listed are the p-values for each regression. The significant values are bolded. 
SNP No confounders Gender Age Medication Status Smoking Status 
rsl063537 0.9926 0.5444 0.1581 0.6729 0.709 
rs3774262 0.5287 0.6884 0.1185 0.7963 0.92 14 
rs 182052 0.112 0.95179 0.1974 0.68655 0.2302 
rs l 063539 0.9451 0.99 0.03455 0.47 1 0.7846 
rs6773957 0.6704 0.8219 0.4482 0.8987 0.7748 
0 
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Figure 4 . Power calculation fo r total sample size used for the data. 
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3.0.2 Overfeeding study results 
The results rrom the overfeeding study are displayed in tables 52 through to 55. Table 52 
displays the physical and biochemical characteristics of the 64 males overfed a positive energy 
balance of30% greater than their baseline intake. The study cohort was divided into 3 groups-
normal weight, overweight and obese. Percentage body, android and trunk fat were significantly 
increased after 7 days of overfeeding. There was also a significant increase was also noted in 
HDL and LDL cholesterol after 7 days of overfeeding. There was also a significant increase in 
triglycerides and insulin all groups after 7 days of overfeeding in all groups. Insulin resistance 
and ~-cell function significantly increased in all three groups after 7 days of overfeeding. 
Adiponectin increased significantly after 7 days of overfeeding. 
Partial correlations of baseline variables that were related to baseline fasting serum 
adiponectin, after controlling for age are located in Table 53. Significant partial correlations are 
labeled . Only HDL in all subjects was found to be negatively correlated significantly after 
correcting for age. Table 54 shows the partial correlations of changes in variables due to 
overfeeding related to baseline fasting serum adiponectin, after control for age. No significant 
results were found . Table 55 shows partial correlations of changes in variables due to 
overfeeding related to changes in fasting serum adiponectin, after control for age. Again, no 
significance was found between any of the variables assessed. 
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Table 52. Physical and biochemical characteristics of subjects at baseline and in response to 7-days of overfeeding1 
Normal Weight2 Overweight2 Obese2 
(n = 23- 25) (n = 13-14) (n = 22- 25) 
Before After Before After Before After 
Age (y) 23.87 ± 3.7 NA 21.97 ± 3.1 NA 23.16 ± 2.4 NA 
Height (em) 178.89 ± 6.6 NA 179.62 ± 4.8 NA 179.55 ± 7.1 NA 
Weight(kg) 4•6.7 72.26±9.6 74.42±9.6 77.81 ±4.3 79.39±4.3 91.39± 15.4 93 .93± 16.0 
BMI (kg/m2) 4 ·6·7 22.58 ± 2.7 23.26 ± 2.9 24.13 ± 1.3 24.63 ± 1.5 28.23 ± 4.2 29.103 ± 4.3 
Percent Body Fat(%) 3·6•7·8 14.82 ± 3.4 15.60 ± 3.4 9 22.54 ± 0.8 22.82 ± 1.1 9 31.15 ± 4.9 31 .0 I ± 4.8 
PercentTrunkFat(%) 3·6•7•8 16.78 ± 3.7 17.78 ± 3.8 9 25.39±1.9 25.79±2.2 9 35.07 ± 5.4 34.97 ± 5.3 
Percent Android Fat(%) 3•6•7 19.38 ± 4.4 20.16 ± 5.0 28.84 ± 2.6 29.45 ± 2.7 40.00 ± 7.2 40.77 ± 6.8 
Total Cholesterol (mmoi/L) 6 4.41 ± 0.9 4.68 ± 0.9 4.63 ± 0.9 4.72 ± 1.1 4.59 ± 0.7 4.86 ± 0.8 
HDL-Cholesterol (mmoi/L) 6 1.38 ± 0.3 1.48 ± 0.3 1.38 ± 0.3 1.43 ± 0.3 1.12 ± 0.2 1.34 ± 0.3 
LDL-Cholesterol (mmoi/L) 2.61 ± 0.7 2.64 ± 0.7 2.82 ± 0.7 2.83 ± 0.9 2.81 ± 0.7 2.83 ± 0.6 
Triacylglycerol (mmoi/L) 6•7 0.94 ± 0.3 1.22 ± 0.8 0.92 ± 0.3 1.00 ± 0.5 1.35 ± 0.7 1.57 ± 0.9 
Glucose (mmoi/L) 4.98 ± 0.4 5.03 ± 0.5 5.03 ± 0.4 5.09 ± 0.6 5.24 ± 0.7 5.11 ± 0.5 
Insulin (pmoi/L) 4•6•7 44.22 ± 23.8 64.02 ± 23.7 51.54 ± 17.03 68.69 ± 43.6 80.19 ± 53.3 I 08.22 ± 76.7 
HOMA-IR 4•6.7 1.43 ± 0.8 2.09 ± 0.9 2.35 ± 2.68 2.95 ± 2.9 2.80 ± 2.3 3.67 ± 2.8 
HOMA-p 4•6·7 85.45 ± 39.38 126.34 ± 49.9 101.49 ± 25. 1 140.84 ± 101.7 134.95 ± 63.0 190.28 ± I 07.3 
Adiponectin (11g/mL) 6 11.60 ± 6.3 13 .96 ± 4.5 12.84 ± 4.6 14.81 ± 4.05 I 0.69 ± 6.3 12.82 ± 6.1 
1 All values are means± SDs. HOMA - IR, Homeostasis model assessment of insulin resistance; HOMA -~ of ~ cell function: NA, not applicable. Adiposity 
status and response to overfeeding analyzed by 2 - factor mix model AN OVA (SPSS, version 17.0 Chicago, IL, USA) for repeated measures. 
2 Subjects were classified on the basis of%BF as either normal weight (8- 20.9%), overwe ight (2 1 - 25.9%) or obese(> 26%) according to criteria recommended by Bray {Bray. 
2003 #48} . 
3 Significant difference between normal weight, overweight and obese subjects at baseline ( I - Way ANOVA, followed by a Bonferroni corrected test, P < 0.05). 
4 S ignificant difference between normal weight vs obese subjects at baseline ( I -Way ANOVA, followed by a Bonferroni corrected test, P < 0.05). 
5 S ignificant difference between obese vs normal weight and obese vs overweight subjects at baseline ( I -Way A NOVA, followed by a Bonferroni corrected test, P < 0.05). 
G Significant difference due to overfeeding (2- Way mixed model ANOVA, P < 0.05). 
7 S ignificant difference due to adiposity status (2 - Way mixed model ANOVA, P < 0.05). 
8 S ignificant overfeeding by ad iposity status interaction (2- Way mixed model A NOVA, followed by a Bonferroni corrected test when significant, P < 0.05). 
9 Significant difference within group (paired /-test. P < 0.05). 
- - - - ----- - -
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Table 53 . Partial correlations of baseline variables related to baseline fasting serum adiponectin, after control for age 1 
All Subjects Normal weight2 Overweight2 Obese2 
(n = 59 - 64) (n = 23 - 25) (n = 14) (n = 22 - 25) 
r r r r 
Weight - 0.246 0 .050~ -0.284 NS -0.425 NS -0.177 NS 
BMI - 0.289 0.0233 -0.322 NS -0.188 NS -0.296 NS 
Percent Body Fat - 0.127 NS -0.094 NS 0.338 NS -0.309 NS 
Percent Trunk Fat - 0.155 NS -0.096 NS 0.235 NS -0.403 0.041 3 
Percent Android Fat - 0.140 NS 0.064 NS 0.066 NS -0.343 NS 
Total Cholesterol 0.057 NS 0.340 NS 0.050 NS -0.313 NS 
HDL-Cholesterol 0.401 0.001 0.178 NS 0.222 NS 0.357 NS 
LDL-Cholesterol 0.020 NS 0.328 NS -0.039 NS -0.242 NS 
Triacylglycerols -0.175 NS 0.089 NS 0.167 NS -0.339 NS 
Glucose -0.225 NS 0.196 NS 0.026 NS -0.427 0.0423 
Insulin -0.225 NS 0.126 NS -0. 192 NS -0.499 0.0153 
HOMA-IR -0.229 NS 0.141 NS -0.170 NS -0.505 0.0143 
HOMA-P -0.204 NS 0.042 NS -0.292 NS -0.399 NS 
1 HOMA-IR, Homeostasis model assessment of insulin resistance; HOMA-P of p cell function. Partial correlation analysis after control for age was used to 
screen for potential factors related to fasting adiponectin. 
2 Subjects were classified on the basis of%BF as either nom1al weight (8- 20.9%), overweight (2 1- 25.9%) or obese(> 26%) according to criteria recommended by Bray {Bray, 
2003 #48} . 
3 Not significant after Bonferroni correction to adjust for the multiple variables tested. 
- - --------·------- - --- ------------ ------------- -
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Table 54. Partial correlations of changes in variables due to overfeeding related to basel ine fasting serum adiponectin, after control for 
age 1 
All Subjects Normal weight2 Overweight2 Obese2 
(n =59- 64) (n = 23 - 25) (n = 14) (n = 22 - 25) 
r p r p r p r p 
Weight -0.043 NS 0.0 15 NS -0. 103 NS -0.049 NS 
BMI -0.045 NS 0.01 1 NS -0.1 03 NS -0.050 NS 
Percent Body Fat 0.066 NS 0. 155 NS -0.415 NS -0.027 NS 
Percent Trunk Fat 0.10 1 NS 0. 158 NS -0.248 NS 0.183 NS 
Percent Android Fat -0.123 NS -0.1 9 1 NS -0.244 NS -0.057 NS 
Total Cholesterol 0.053 NS 0.146 NS 0.326 NS -0.069 NS 
HDL-Cholesterol -0.086 NS 0.050 NS -0.073 NS -0.115 NS 
LDL-Cholesterol 0. 168 NS 0.241 NS 0.439 NS -0.040 NS 
Triacylglycerols -0. 142 NS -0.035 NS -0.430 NS -0.435 0.0383 
G lucose -0.045 NS -0.264 NS 0.095 NS 0.002 NS 
Insulin -0.1 25 NS -0.438 0.0323 0.3 13 NS 0.1 12 NS 
HOMA-IR -0.084 NS -0.1 75 NS 0.059 NS 0.230 NS 
HOMA-~ -0 081 NS -0 228 NS 0 2 10 NS 0 022 NS 
1 HOMA-IR, Homeostasis model assessment of insulin resistance; HOMA-~ of~ cell function . Partial correlation analysis after control for age was used to 
screen for the potential changes in factors due to overfeeding re lated to fasting adiponectin. 
2 Subjects were c lassified on the basis of%BF as either normal weight (8- 20.9%), overweight (21 - 25.9%) or obese(> 26%) according to criteria recommended by Bray {Bray, 
2003 #48). 
3 Not significant after Bonferroni correction to adjust for the multiple variables tested. 
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Table 55 . Partial correlations of changes in variables due to overfeeding related to changes in fasting serum adiponectin, after control 
for age 1 
Weight 
BMI 
Percent Body Fat 
Percent Trunk Fat 
Percent Android Fat 
Total Cholesterol 
HDL-Cholesterol 
LDL-Cholesterol 
Triacylglycerols 
Glucose 
Insulin 
HOMA-IR 
All Subjects 
(n =59- 64) 
r p 
-0.098 NS 
-0.097 NS 
0.005 NS 
0.027 NS 
0.208 NS 
0.113 NS 
0.258 NS 
0.001 NS 
0.018 NS 
0.201 NS 
0.193 NS 
0.084 NS 
0.076 NS 
Normal weight2 
(n = 23- 25) 
r p 
-0.125 NS 
-0 .124 NS 
-0.040 NS 
0.036 NS 
0.286 NS 
-0.010 NS 
0.197 NS 
-0 .149 NS 
-0.10 1 NS 
0.298 NS 
0.316 NS 
0.141 NS 
0.152 NS 
Overweighe 
(n = 14) 
r p 
-0.022 NS 
-0.021 NS 
0.347 NS 
0.074 NS 
0.200 NS 
-0.336 NS 
0.2 12 NS 
-0.452 NS 
0.078 NS 
-0.055 NS 
-0.440 NS 
-0.189 NS 
-0.354 NS 
Obese2 
(n = 22 - 25) 
r p 
-0. 159 NS 
-0.157 NS 
0.067 NS 
-0.061 NS 
0.072 NS 
0.436 0.0383 
0 .296 NS 
0.409 0.0503 
0.27 1 NS 
0.239 NS 
0.165 NS 
-0.040 NS 
0.029 NS HOMA-~ 
1 HOMA-IR, Homeostasis model assessment of insulin resistance; HOMA-~ of~ cell function. Partial correlation analysis after control for age was used to 
screen for potential changes in factors due to overfeeding related to the potential changes in adiponectin due to overfeeding. 
2 Subjects were classified on the basis of%BF as either normal weight (8- 20.9%), overweight (21- 25.9%) or obese(> 26%) according to criteria recommended by Bray {Bray, 
2003 #48 }. 
3 Not s ignificant after Bon ferroni correction to adjust for the multiple variables tested. 
Page 141 of 167 
4.0 Discussion 
4.0.1 Adiponectin and Bone Mineral Density 
Adiponectin, since its initial discovery as an adiopkine released by fat cells, has been 
shown to be involved in insulin regulation, body fat composition, and has an anti-inflammatory 
role. Most recently, adiponectin has been suggested as having a direct role in bone mineral 
density regulation and in bone metabolism, but this relationship has not been completely 
understood. This study aimed to further validate this relationship and to show whether specific 
genotypes of adiponectin were associated with differences in bone mineral density. 
Previous studies (Lenchik eta!., 2003; Ji.irimae et al. , 2007; Kontogianni eta!. , 2004) 
suggested an association of serum adiponectin with bone mineral density. However, few studies 
to date have explored the effect of genetic variations in the adiponectin gene on the variations of 
bone density at the population level. This genetic association study shows no association of any 
SNP genotype or haplotype with any phenotype of bone mineral density. Although mouse 
models showed knock out and transgenic mice of adiponectin that may have a significant 
influence of adiponectin on BMD, this does not support that any genetic variations in the 
adiponectin gene play an important ro le in determining bone mineral density in the 
Newfound land population. 
There were a total of 1811 subjects in this study, with 403 males and 1408 females. The 
power calculation, shown in Figure 4, demonstrates this study had adequate power to show a 
direct effect from adiponectin on bone mineral density. It is possible, given the lack of variation 
in SNPs within the cohort, that a larger sample-size is needed to see a potential genotypic effect. 
However, according to the calculation, there were sufficient subjects obtained for the analysis. 
Page 142 of 167 
In addition, although three ofthe five single nucleotide polymorphisms were not in HWE, these 
were still used in the analysis as it was difficult to select ideal tagging SNPs with reasonable 
allele frequencies. Moreover, although these SNPs were not in HWE, they could still provide 
valuable information with the two tagging SNPs in HWE with the other three. 
The findings are similar to an analysis of SNP polymorph isms in the Chinese population. 
Zhang et al. (2007) found no significant association of adiponectin genotypes with peak BMD in 
Chinese men and women. However, a significant within-family association with peak femoral 
BMD was noted in the Thr394Thr polymorphism in the PPGAGC l gene. 
A study in 249 Korean women and 80 Korean men looked at two polymorphisms using 
the Taqman probe (Lee et al, 2006). Genotyping of the T45G polymorphism in exon 2 and the 
G276T polymorphisms in intron 2 in the adiponectin gene was performed. Within the female 
cohort, subjects with G alleles at the T45G locus had significantly lower lumbar spine BMD than 
those subjects with the TT genotype (Lee et a/. , 2006). However, no association was found with 
the other polymorphism. The results do not support this finding as in this study no association 
was found. Their small sample size does not provide adequate power to properly assert an 
association. 
In another study of 1329 postmenopausal Korean women, the two genes for the 
adiponectin receptors ADIPORI and ADIPOR2 were assessed (Kim eta/., 2012). ADIPORI 
rs 16850799 and rs340 I 0966 polymorph isms were significantly associated with femur neck BMD 
(Kim eta/., 2012). ADIPOR2 SNPs and haplotypes were not associated with BMD at any site. 
Our study did not assess the adiponectin receptor gene; however, this may be focus for further 
research. 
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There is the possibility that a subgroup in the general population may have its BMD 
phenotype be affected by the genetic variations in the adiponectin gene. In order find such a 
relationship, there needs to be a much larger sample size with homogeneous conditions, both 
genetic and environmental factors. This is often difficult to obtain but highly recommended if 
possible. 
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4.0.2 Adiponectin and its response to Positive Energy Challenge 
This study displayed a new major finding that over short-term positive energy challenge, 
there is a significant initial increase in serum adiponectin levels. This was found in all categories 
of normal and underweight individuals, overweight and obese individuals, as measured by 
DEXA. To our knowledge, this is the first study to present this finding. This is an especially 
interesting finding since several cross-sectional studies have shown that circulating adiponectin 
is decreased in individuals with increasing adiposity phenotypes (Kumada et al., 2003, Vilarrassa 
et al. 2005). 
One study has shown a negative correlation between adiposity or obesity with 
adiponectin when overfeed for longer periods of time. Ukkola et al. (2008) in a I 00 day study of 
24-sedentary young males, 12 identical twin pairs, each overfed 84,000 kcal over basel in e. 
Serum adiponectin concentration correlated positively with body weight at baseline, but not with 
other indicators of ad ioposity. Serum adiponectin levels, however, decreased significantly over 
I 00-day period of overfeeding (Ukkola el al. 2008). Another study by Astrand el a!. (20 I 0) also 
helps support our findings that there is a difference in adiponectin secretion with long-term and 
short-term overfeeding. In a four week positive energy challenge on 18 young normal-weight 
adu lts (12 male and 6 female), there was no significant increase in circulating adiponectin 
(Astrand et al., 20 I 0). This lack of difference may be explained by the relatively small sample 
size and not controlling for gender (Astrand et al. 20 10) 
Interestingly, in a study of prepubertal obese children from Warsaw, Poland, circulating 
adiponectin levels were 25% lower in obese children as compared with controls (Gajewksa eta!. 
20 II). However, after implementation of a three-month lifestyle modification program aimed at 
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· weight reduction in these children, serum adiponectin levels substantially increased (Gajewksa et 
a!., 20 II). A similar finding was reported by Medina-Bravo eta!. (20 II) when assessing the 
relationship between adipocity and visceral adipose tissue measured by CT in children and 
adolescents. An inverse correlation was associated with visceral adipose tissue and adiponectin 
levels in this group (Medina-Bravo eta!., 20 II). There has been some recent evidence that 
shows adiponectin is also released by myocytes, as well as adipocytes, and there has been some 
suggestion that its regulation may be related to PPAR-y (Amin eta!. 2010). This evidence may 
partly explain the increase of serum adiponectin both short-term overfeeding, as well as with 
exercise and weight reduction. However, the mechanism of the changes in adiponectin levels is 
not known at present. 
There were other studies that explored the relationship of overfeeding with adiponectin. 
Bmns eta!. (2009) conducted 5-day high-fat diet (60% fat, 32.5% carbohydrates and 7.5% 
protein) on 26 normal-weight young men with daily overfeeding set to 50% greater than their 
baseline intake. Although the group used a different macronutrient composition as part of their 
study as compared with ours, they still observed a significant increase in adiponectin 
concentration (Bmns eta!. 2009). Age and gender of the Bmns eta!. (2009) subjects were 
comparable to the normal-weight subgroup in our cohort. These findings, along with our own, 
provide strong evidence that the increase of adiponectin concentration is driven by the increase 
in caloric intake irrespective of macronutrient composition. In addition, our results show for the 
first time in the short-term, that the ability of increased synthesis and secretion of adiponectin is 
preserved in subjects spanning all obesity categories. 
In this cohort, adiponectin concentrations significantly increased within the entire cohort 
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across normal-weight, overweight and obese subject phenotypes. However, when comparing 
between each group, no significant difference was found in serum adiponectin pre- and post 
overfeeding within the obese group. This finding would indicate that adiposity is not a 
significant factor in serum adiponectin ' s response to short-term overfeeding. In addition, further 
stratification of the adiponectin serum levels in low, medium and high serum adiponectin 
concentrations did not reveal any significant difference in pre- and post-overfeeding serum 
adiponectin groups. This gave further support to the notion that adiponectin levels during short-
term overfeeding are not affected by adiposity status. 
Despite the evidence showing long-term positive energy challenge being associated with 
decreased levels of adiponectin, our results indicate that there may be a difference in action and 
regulation of adiponectin with short-term overfeeding when compared with long-term 
overfeeding. No studies in humans have been published yet addressing the biochemical role of 
adiponectin during metabolism. 
Many overweight and most obese individuals have insulin resistance. To counteract the 
high insulin resistance, the synthesis and secretion of adiponectin from the body may increase 
physiologically, such as in obesity. However, as can be seen with the findings and this study of 
Ukkola eta/. (2007), there seems to be a paradox that has still yet not been properly explained. 
The low adiponectin level in obese and type 2 diabetic patients suggest that their ability for 
adiponectin secretion is low. However, the data does not show that adiposity status is a 
contributing factor to adiponectin concentration. Circulating adiponectin levels were, however, 
inversely correlated with BMI and weight for the entire cohort along with percentage trunk fat, 
fasting g lucose, fasting insulin and HOMA-IR in obese subjects. Some studies advocate that the 
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inverse relationship between adiponectin and adiposity phenotypes is likely solely dependent 
upon the development of insulin resistance (Pellme, 2003; Cnop, 2003). To address this concern 
the presented data was controlled for fasting insulin and/or HOMA-lR. After this control, no 
negative partial correlations between adiponectin and adiposity-related phenotypes were found. 
This finding also supports the belief that the inverse relationship between adiposity and 
circulating adiponectin is likely dependent on changes in insulin resistance rather than solely the 
change in obesity status (Cnop, 2003; Pellme, 2003). These findings provide a key stepping-
stone for future study in the elements involved in adiponectin secretion. 
4.0.3 Study Limitations 
It is important to identify the limitations in this study. This study only assessed young 
males aged 19-29. Females, nor those males later in age were not included. This limits the 
ability to extrapolate the results to other groups. In addition, this genetic analysis, although it 
had 1800 subjects, was likely still not large enough to establish any genotypic associations. 
Furthermore, only total circulating adiponectin was measured in this investigation. Wang et al., 
(2008) suggested that high molecular weight adiponectin is the main physiologically active 
isoform of adiponectin, but other isoforms do exist. Low, medium and high molecular weight 
adiponectin also may respond to nutritional regulation and exercise in the same manner as total 
circulating adiponectin (Christiansen, 20 I 0). 
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4. 0.4 Conclusion 
Our CODING study cohort revealed no significant association with bone-mineral density 
and adiponectin genotypes. Although this finding was supported by other studies, it is 
acknowledged that this sample size may not have been large enough to show any link. 
However, the overfeeding cohort does demonstrate that endogenous adiponectin concentration 
significantly increases within the entire cohort and all three adiposity groups in response to short-
term overfeeding. Results further show this occurs despite the macronutrient feeding regime 
used . These novel findings suggest adiponectin may act as a protective mechanism during 
periods of weight gain and insulin resistance independent of adiposity status and diet 
com position. 
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